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Desmoglein 3 (Dsg3) belongs to the desmoglein subfamily and functions as an 
adhesion molecule in desmosomes. Two pools of Dsg3 have been identified, detergent 
soluble and insoluble proteins. Recent studies show that DSG3 is upregulated in 
squamous cell carcinoma (SCC). However, its biological function in cancer remains 
poorly understood. The aim of this study was to investigate the extra-junctional 
functions of Dsg3, in particular its roles in signalling that regulates cell morphology and 
locomotion in cancer cells. This study adopted a unique cancer cell model with Dsg3 
gain-of-function and has discovered two novel regulatory signal pathways that may 
play a crucial role in the control of cell invasion and metastasis in Dsg3 associated 
cancers. Firstly, Dsg3 regulates the phosphorylation of Ezrin at Thr567 in a PKC-
dependent manner that is crucial for its activation and regulation of actin based 
membrane projections and accelerated cell locomotion in SCC. Secondly, Dsg3 
modulates the transcriptional activity of cJun:AP1 that is responsible for regulating a 
cohort of genes to confer an invasive phenotype. It is likely that these two pathways 
are closely linked in that the Dsg3-mediated activation of cJun:AP1 elicits PKC-
dependent Ezrin activation that in turn enable it to form a complex with Dsg3 at the 
plasma membrane to promote membrane projection and cell locomotion. Several lines 
of evidence support these conclusions: Dsg3 forms a complex with Ezrin at the plasma 
membrane and induces phosphorylation of Ezrin resulting in augmented membrane 
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protrusions and cell migration. Dsg3 silencing inhibits junction formation concomitant 
with collapse of membrane protrusion. Furthermore, Dsg3 regulates the activity of 
cJun:AP1. Collectively, these findings provide new insight regarding Dsg3 in cancer, 
suggesting it acts as a key regulator of cell invasion and metastasis in SCC. Therefore, 
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1.1  Metastatic cancer: the clinical perspective 
In 2012 there were an estimated 32.6 million peoples living with cancer and 8.2 million 
cancer deaths worldwide (Globocan 2012 International Agency for research on cancer, 
WHO). The most common causes of cancer deaths being attributed to lung (1.59 
million deaths), Liver (745 000 deaths), stomach (723 000 deaths), colorectal (694 000 
deaths) breast (521 000 deaths) and oesophageal cancer (400 000 deaths) (Globocan 
2012 International Agency for research on cancer, WHO). More than 90% of cancer 
related deaths are attributed to metastasis rather than the primary malignancy itself 
(Gupta and Massagué, 2006), underscoring the importance in tackling this aspect of 
cancer cell behaviour. 
Desmoglein 3 has been shown to be upregulated in squamous cell carcinoma (SqCC) of 
the head and neck (HNSqCC) (Chen, et al., 2007, Chung, et al., 2004, Huang, et al., 
2010), oesophagus (ESSqCC) (Fang, et al., 2014, Fang, et al., 2014, Savci-Heijink, et al., 
2009) and lung (Savci-Heijink, et al., 2009), specifically non-small cell lung cancer 
(NSCLSqCC). Squamous cell carcinoma describe cancers of epithelial linage occurring in 
organs covered with squamous epithelium such as the skin, mouth, oesophagus, 
prostate, lungs, prostate vagina and cervix. The majority of SqCC cases are attributed 
to the following anatomical sites (Yan, et al., 2011):  
23 | P a g e  
• Non-melanoma skin cancer (NMSCqCC),  
• Head and neck (HNSqCC)  
• Oesophageal (ESSqCC)  
• Non-small lung cancer (NSCLSqCC).  
Squamous cell carcinoma represent the most common cancer capable of metastasis 
worldwide (Marinkovich, 2007). The overall survival rate for these four SqCCs are 
among the lowest with a 5-year survival rate of <30%, 35% <10% and <14%, 
respectively, when systemic disease develops (Yan, et al., 2011) compared with the 4 
major cancers in the UK (2010-2011) breast, prostate, lung and bowel with a 5-year 
survival of 87%, 85% 10% and 59% respectively (Cancer Research UK 
http://www.cancerresearchuk.org/cancerinfo/cancerstats/survival/commoncancers/ 
#One July 2014). With the exception of NMSCC, which has it has the advantage of 
presenting on the skin surface and therefore greater chances of early detection, the 
overall survival among HNSCC, ESCC and NSCLC are among the lowest.  
Treatment of SqCC has seen many developments. Targeted therapies most relevant to 
SqCC are being investigated which are aimed at cell cycle regulation, growth factor 
receptors, angiogenesis and protein degradation (Reviewed by (Yan, et al., 2011) which 
should, if proven successful, enhance current first line management strategies namely 
involving a combination of surgery, radiotherapy and chemotherapy. Despite advances 
in diagnostic and treatment methods, these four SqCC have not seen a significant 
increase in survival rates in 30 years (Agada, et al., 2009), this is in part believed to be 
attributed to late diagnosis and a lack of clinical and biological markers, which is 
essential to prognosis, monitoring tumour response to therapy, the development of 
resistance and metastasis. As a result most patients present with metastatic disease at 
the time of diagnosis and additional primary tumours which confers poor survival rates 
in the four major SqCC (Agada, et al., 2009, Yan, et al., 2011).  
It is increasingly clear that the development of novel early detection strategies, 
prognostic markers and anti-metastatic therapies needs to be developed to increases 
the survival rate of patients that present with SqCC. In parallel, the understanding of 
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Figure 1.1 Invasion-metastasis cascade. Here tumour cells from the primary tumour site 
locally invade the surrounding tissues. Invasive tumour cells enter the blood stream or 
lymphatic system through intravasation. If the tumour cell survives in circulation they will 
arrest at a distant organ site and extravasate to enter the tissue. Tumour cells that survive at 
the secondary site form micrometastases which develop into clinically detectable macroscopic 
metastases. Figure adapted from (Valastyan and Weinberg, 2011)  
identified targets/markers, beyond their efficacy and clinical impact, in cancer cell 
biology is essential to tackle therapeutic resistance and relapse. (For a details review of 
SqCC epidemiology, pathology, risk factors, molecular characteristics, prognostic 
markers and therapies see (Yan, et al., 2011) 
1.2 Metastatic cancer: the cellular mechanisms  
Invasion-metastasis cascade 
Metastasis, by definition, describes the ability of a tumour cell to migrate and invade 
from the primary site. The process of metastasis is achieved through a complex series 
of cellular events termed the invasion-metastasis cascade. As summarised in Figure 
1.1, the process requires a primary tumour cell to locally break through the basal 
membrane and invade the surrounding stroma or extracellular matrix (ECM). The cell 
then needs to intravasate into the circulatory or lymphatic system for transport, 
survive in circulation and arrest at a distal site. Once arrested the tumour cell 
extravasates into the parenchyma of the distal tissue to survive and adapt to the new 
microenvironment. Finally, the tumour cell initiates the proliferative programme at the 
metastatic site resulting in the formation of clinically detectable metastatic colonies or  
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Figure 1.2 Cellular events of epithelial to mesenchymal transition. (A) Initiated by the loss of 
cell-cell adhesion through the disassembly of tight junctions, adheren junction, Desmosomes 
and gap junctions. Loss of cell-cell junctions in particular adheren and tight junctions disrupts 
polarity complex function resulting in a loss of apical basal polarity. Once EMT is initiated 
expression of junctional proteins and polarity complexes is repressed to maintain junctional 
and polarity loss concomitantly mesenchymal gene expression profiles are activated. (B) 
Progression of EMT sees actin re-organisation and the formation of pro-migratory and invasive 
membrane structures namely, lamellipodia, filopodia and invadopodia together with the 
expression of MMPs to degrade the ECM to facilitate motility and invasion. In the Reverse, 
mesenchymal to epithelial transition (MET) cells that have undergone EMT can revert back to 
an epithelial phenotype(Figure from (Lamouille, et al., 2014). 
macrometastases. (for a more detailed description of the cellular and molecular 
mechanism involved in the metastatic cascade see (Reymond, et al., 2013) 
Epithelial to mesenchymal transition 
The reversible process of epithelial to mesenchymal transition (EMT) describes the 
transition of polarised epithelial cells to assume a mesenchymal phenotype (Hay, 
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1995). As illustrated in Figure 1.2 this process can occur fully or partially involving 
cellular changes such as the loss of cell adhesion and apical-basal polarity; cytoskeleton 
reorganisation, changes in cell shape, development of pro migratory and invasive 
membrane structures; the acquisition of front-rear polarity and the expression of 
metrix degrading enzymes (Thiery, et al., 2009). Transcriptionally, epithelial gene 
expression signatures are down regulated and a mesenchymal gene profile is activated 
(Thiery, et al., 2009). All these events enable epithelial cell to assume a mesenchymal 
phenotype with enhanced migratory and invasive capacity, resistant to apoptosis and 
senescence (Thiery, et al., 2009). In the same way cells that have undergone this 
process can revert to an epithelial phenotype through the process of mesenchymal to 
epithelial transition (MET). The ability of cells to move back and forth between 
mesenchymal and epithelial states is essential during embryogenesis organ 
development and cancer progression specifically the establishment of secondary 
tumours, through the process of EMT and MET (Lee, et al., 2006). For more detail on 
the cellular and molecular events of EMT see (Kalluri and Weinberg, 2009, Lamouille, 
et al., 2014). 
The process of EMT occurs in 3 distinct biological settings and thus classified into three 
different subtypes. Type 1 EMT occurs during embryo formation, organ development 
to generate diverse cell types. Type 2 is associated with wound healing, tissue 
regeneration and inflammation. When Type 2 EMT is sustained due to persistent 
inflammation, tissue fibrosis can occur. Finally Type 3 EMT occurs in association with 
cancer progression and metastasis. Here neoplastic cells i.e. those that have already 
accumulate genetic and epigenetic changes which confer a proliferative advantage to 
form a localised tumour, enter in to EMT to acquire characteristic essential to cancer 
progression and metastatic spread (Thiery, 2002). Typically these cells are located at 
the invasive front of primary tumours (Thiery, 2002) and would eventually enter into 
the invasion-metastasis cascade to disseminate to distal sites. Once arrested at a distal 
site cancer cells would enter into the process of MET to establish a secondary 
epithelial tumour (Zeisberg, et al., 2005) (For a more detailed description of the three 
EMT Subtypes see (Kalluri and Weinberg, 2009, Thiery, et al., 2009). 
Epithelial to mesenchymal transition is regulated at transcriptional, translational and 
post-transcriptional levels. Key drivers of the EMT process are a variety of transcription  
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Figure 1.3 Role of EMT in cancer progression. As illustrated the EMT (C) occurs following the 
development of a carcinoma in situ (B) from normal epithelia (A). The EMT programme provids 
a mechanism for the acquisition of a malignant phenotype. The carcinoma cells that acquire a 
mesenchymal phenotype (green cell) which subsequently enter into steps on the migration-
invasion cascade to leave the primary site, disseminate through circulation (D) to ultimately 
colonise distal organs following the process of MET (E) (adapted from (Kalluri and Weinberg, 
2009)  
factors including SNAIL, zinc-finger E-box-binding, AP-1 (see section 1.7) and basic 
helix-loo-helix (Lamouille, et al., 2014) which are intricately regulated in a cooperative 
fashion to repress the epithelial phenotype and activate the mesenchymal phenotype. 
(for a full review of the molecular mechanism and regulation of EMT see (Lamouille, et 
al., 2014). 
1.3 Mechanism of tumour cell motility in metastasis 
1.3.1 Modes cancer cell migration 
To migrate and invade through surrounding tissue cancer cells must modify their shape 
and stiffness to interact with the surrounding microenvironment. How a cancer cells 
migrate and invade varies in both mode and strategy, disseminating as single cells or as 
a collective, in an amoeboid or mesenchymal fashion as illustrated in Figure 1.4. During 
individual cell migration cancer cells can adopt either a mesenchymal or amoeboid 
C D E
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Figure 1.4 Strategies of cancer cell migration. This diagram illustrates the main migratory 
strategies adopted by cancer cell to facilitate cancer progression. Migration strategy is 
determined by the molecular programmes activated. As indicated by the triangles, collective 
migration is Cell-cell and Cell-ECM dependent while Individual cell migration is independent of 
intercellular adhesion. (Adapted from (Friedl and Wolf, 2003)  
strategy. Amoeboid migration is characterised by cycles of morphological expansion 
and contraction, deformability and low substrate binding that is stress fibres- 
proteolysis- and integrin-independent (Friedl, et al., 2001). The force in this type of 
movement is generated by actomyosin which generates hypostatic pressure to 
essentially squeezing the cell body through interstitial gaps (Wolf, et al., 2003) (Figure 
1.5). A less adhesive strategy, amoeboid migration is commonly adopted by 
lymphomas and small-cell lung cancer (Rintoul and Sethi, 2001). 
Mesenchymal single cell migration requires a 5 step migration cycle predominantly 
found in cancers derived from connective tissue and epithelial origin (Brabletz, et al., 
2001, Friedl and Wolf, 2009, Sanz-Moreno, et al., 2008). This strategy is dependent on 
the presence of focal contacts, actomyosin contractility and focalised proteolysis, thus 
integrin- and Rho GTPases- dependent (Friedl, et al., 1998, Sanz-Moreno, et al., 2008).  
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Figure 1.5 Major steps of mesenchymal and amoeboid migrations strategies. In mesenchymal 
cell migration the protrusions (lamellipodia, filopodia and pseudopodia) extend out into the 
ECM at the leading edge of a polaried cell. Focal contacts between the Cell and ECM form at 
the leading edge and rear of the cell. (1,2). Next Actomyosin contraction create tension force 
between the front a rear focal adhesions (3) Finally focal adhesion at the rear disassemble and 
the trailing edge retracted resulting in cell-body translocation forward. In Amoeboid migration 
polarised blebs form due to local disassembly of the cell actin cortex (1,2). Actomyosin 
contraction generates hydrostatic pressure squeezes the cell mass through interstitial gap (3). 
Only once the nucleus has cleared will the cell body fully translocate through the interstitial 
gap (Adapted from http://www.ltnt.ethz.ch/research/interface/cell_migration and (Friedl and 
Wolf, 2010) 
As illustrated in Figure 1.5 mesenchymal migrations is achieved through the 
continuous cycle of interdependent steps. As shown the cell body changes shape to 
become polarized (front-rear) and elongated, forming extending membrane 
protrusions (pseudopodia) at the leading edge. Attachment of these protrusions to the 
surrounding ECM is then facilitated through focal adhesion. Once focal contacts at the 
leading edge and rear are established actomyosin contraction generates tension forces 
between the front and rear. Detachment of focal adhesions and retraction at the rear 
result in cell-body translocation forward (Friedl and Wolf, 2009). Rear focal contact 
then re-established and the cycle continues. The additional step of ECM proteolysis 
occurs in 3 dimensional rather than in two dimensions where cancer cell move over an 
organ surface for example. In a three dimension microenvironment focalised 
proteolysis at the leading edge is required to create a pathway for migration (Egeblad 
and Werb, 2002, Wolf and Friedl, 2011). 
Mesenchymal migration
Amoeboid migration
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An additional mode of individual cell mesenchymal is as a chain (chain migration) 
which describes the stream-like movement of cells one after the other. The tracks 
through which these cellular chains or strands migrate are generated by the first 
invading cell or ‘gureilla cell’ clearing a path for subsequent cells to (Friedl and Wolf, 
2008, Kulesa and Gammill, 2010). These chains of single cells are characteristic of 
epithelial carcinomas conferring high metastatic capacity and poor prognosis (Seftor, 
et al., 2002).  
The alternative mode of cancer cell migration and invasion is collective, here two 
morphological and functional variants have been described, the cluster/cohort 
strategy and the multi-cellular strand/sheet strategy (Figure 1.4). Cluster/cohort 
migration describes the migration of detached cell clusters from the primary site, 
which characteristically move through tissue gaps i.e. the path of least resistance seen 
in epithelial cancers. The multi-cellular strand/sheet strategy describes the protrusion 
of sheets and strands of tumour cells which maintain contact with the primary site 
seen in squamous cell carcinoma, mammary and colon cancers (Ilina and Friedl, 2009, 
Nabeshima, et al., 1999). 
The mode and strategy adopted by any cancer cell is dependent on the molecular 
programme utilised and surrounding microenviroment (Friedl, 2004, Friedl and Wolf, 
2010). Both of which are subject to change due to cancer cells migrating and invading 
into different microenvironments and ECM compositions; and changes in the cancer 
cell itself through processes including EMT, MET and the invasion-metastasis cascade 
which dramatically alter cell morphology, junction protein expression and proteolytic 
capacity all of which will provoke adaptive re-programming to engage in a migration 
strategy best suited to the new context (Hanahan and Weinberg, 2011, Polyak, et al., 
2009, Wolf and Friedl, 2011). This migrational plasticity means that cancer cells are 
able to shift from highly adhesive, proteolytic migration strategies (mesenchymal) to 
low adhesive, non-proteolytic migration (amoeboid); and from collective to detached 
and disseminated migration (EMT). For more detail on modes and strategies of cancer 
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Figure 1.6 Actin based membrane protrusions. There are 3 main types of actin based 
processes driven by localised actin polymerisation, exhibited by migrating and invading cells 
Lamellipodia, Filopodia and Invadapodai/Podosomes. Lamellipodia and filopodia are 
predominantly utilised by cell migrating on two dimensional substrates to facilitate motion. 
However on three dimensional ECM, migration requires the cell to degrade and remodel the 
surrounding ECM in order to progress, hence these cells require the formation of invadopodia 
eliciting their photolytic activity to invade and migrate (Figure from (Yamaguchi and Condeelis, 
2007). 
1.3.2 Molecular mechanisms and signalling pathways in cancer cell migration 
Actin cytoskeleton and actin based structures 
Cell migration is a highly integrated multistep process initiated by actin based 
processes, specifically membrane protrusions (Bailly and Condeelis, 2002) with the 
aberrant regulation of migration promoting disease and plays a pivotal role in cancer 
progression and metastasis (Sahai, 2005). The driving force behind the formation and 
maintenance of pro-invasive and -migratory membrane structures is the spatial and 
temporal regulation of the actin cytoskeleton, specifically, actin filament assembly, 
disassembly and contraction at specific sub-cellular domains such as the leading edge 
and rear of a polarised cells (Pollard and Borisy, 2003, Sahai, 2005). The protrusive 
membrane structures, lamellipodia, pseudopdia, filopodia and invadopodia, formed by 
migrating and invading cells are classified by their morphological, structural and 
functional characteristics (Figure 1.6). Lamellipodia are flat sheet like projections which 
form at the leading edge of migrating cells. Characterised by a dense network of 
branched actin filaments lamellipodia formation is driven by driven by Scar/WAVE and 
Arp2/3 complex activation (Pollard and Borisy, 2003, Svitkina and Borisy, 1999). They 
have a major role in driving cell migration as they extend and attached to the  
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Figure 1.7 Regulation of cell migration by Rho GTPases. Illustrated in a schematic 
demonstrating the Role of Rho GTPases in regulation of cell motility through their ability to 
modulation, filopodia, lamellipodia, actomyosin contraction and stress fibres. Cdc42 promotes 
filopodia formation through the activation of WASP/N-WASP proteins and Arp2/3 complex 
activation. Rac proteins promote lamellipodia formation through WAVE/Scar proteins and 
Arp2/3 complex activation. Together Cdc42 and Rac spacialy down regulate actomyosin  
assemble and contractility at the leading edge via the PAK/MLC (myosin light chain), while 
promoting actin polymerisation through PAK/LIM kinase. Rho protein promote cell-body 
translocation through modulating Actomyosin assembly, stabilisation and contractility through 
LIM kinase, formin protein activation, ROCK-dependent MLC phosphorylation and respectively 
(Adapted from (Frame and Brunton, 2002, Keely, et al., 1998) 
surrounding ECM via focal adhesion providing an anchor from which force can be 
generated through actomyosin contraction to pull the cell body forward (Condeelis 
and Segall, 2003). Pseudopodia are the functionally and compositionally equivalent to 
lamellipodia differing only in structure and context to form cylindrical, rounded or 
filopod- like protrusions in three- dimensional matrix, where as lamellipodia are 
associated with two dimensional migration (Sahai, 2005). Filopodia are transient thin 
finger-like projections that contain parallel bundles of crosslinked actin filaments 
which also form at the leading edge of migrating cells (Faix and Rottner, 2006). Their 
formation is driven by members of the formin family via WASP/N-WASP AND Arp2/3 
complex activation (Pellegrin and Mellor, 2005, Schirenbeck, et al., 2005). Filopodia are 
thought to sense external cues to determine migration direction rather than 
facilitating migration itself (Gupton and Gertler, 2007). Invadopodia/Podosomes are 
Formins
ROCK
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ventral membrane protrusions characterised by the presence of metrics degradation 
enzymes (Buccione, et al., 2004). These protrusions facilitate migration through dense 
ECM through the degradation and remodelling of ECM structures (Even-Ram and 
Yamada, 2005), thus formed by highly invasive cancer cells in three dimensional 
environments (Buccione, et al., 2004). Invadopodia formation is driven by N-WASP-
Arp2/3 and cofilin pathway activation (Yamaguchi, et al., 2005). 
Finally, actin cytoskeleton contractility is an essential element in the process of cell 
migration as the ability of cells to move requires the generation of force. This is 
achieved through the association of F-actin with the actin motor protein myosin II to 
form actomyosin. The process of contraction occurs through binding of ATP and its 
subsequent hydrolysis for Myosin II of actomyosin to generate contraction forces 
between the front and the rear of the cell to facilitate cell-body translocation in the 
direction of movement (Cramer, 1999, Kamm and Stull, 2001). 
Rho GTPases 
The driving force behind all actin-based strategies of migration and invasion is the actin 
cytoskeleton through it co-ordinated spatial and temporal reorganisation, assembly, 
disassembly and contractility (Pollard and Borisy, 2003). The Rho GTPase family 
consists of 20 small GTP-binding proteins of which Rho, Rac and Cdc42 subfamilies 
represent the most widely studied in cell migration (Noren, et al., 2001). Rho, Rac and 
Cdc42 family proteins have been shown to play an essential and pivotal role in 
regulation of pathways leading to changes in cell shape, formation of stress fibres, 
focal adhesion, membrane protrusions and cell migration as a whole (Raftopoulou and 
Hall, 2004, Sahai and Marshall, 2002). Rho GTPases exist in two interchangeable forms. 
GTP bound (active) and GDP bound (inactive). GDP/GTP-exchange proteins (GEPs) 
stimulate the exchange of GDP to GTP/GDP-dissociation inhibitors (GDIs) inhibit the 
exchange of GDP to GTP; and GTPases-activating proteins (GAPs) stimulate the 
exchange of GTP to GDP (Braga and Yap, 2005, Menke and Giehl, 2012). In their GTP 
bound state Rho GTPase interact with specific downstream effectors to provoke a 
cellular response. 
As illustrate in Figure 1.7 Rho GTPases play an essential role in cell migration through 
the regulation of filopodia and lamellipodia formation; focal adhesion and actomyosin 
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contraction. As shown both Cdc42 and Rac are required at the leading edge of 
migrating cells promoting the formation of filopodia and lamellipodia respectively. This 
achieved through the WASP/Scar/WAVE family proteins acting on Arp2/3 complex 
(Machesky and Hall, 1997, Nobes and Hall, 1995). The Arp2/3 complex nucleates actin 
polymerisation at sites of filopodia and lamelliapodia formation (Machesky and Insall, 
1998, Mullins, et al., 1998). Additionally Cdc42 and Rac down modulate actomyosin 
assemble and contraction at the leading edge (Sanders, et al., 1999) to facilitate it’s 
extension into the ECM to essentially co-ordinates cellular effort towards a net 
forward movement. These inhibitory affects are achieved through p21-activating 
kinase (PAK) activation (Daniels and Bokoch, 1999). PAK is a serine threonine kinase 
which phosphorylates and inactivates myosin light chain kinase (MLCK) to reduce 
actomyosin contraction at the leading edge. MLCK activates Myosin II, in its active 
state myosin II binds F-actin to generate actomyosin contraction (Verkhovsky, et al., 
1995). Similarly PAK can also phosphorylated and inactivate LIM kinase which 
phosphorylates and inactivates de-polymerisation protein cofilin to promote actin 
filament assembly (Frame and Brunton, 2002). Rho protein function in cell migration is 
primarily associated with actomyosin contractility, essential to cell body contraction 
and rear retraction (Burridge and Chrzanowska-Wodnicka, 1996, Chrzanowska-
Wodnicka and Burridge, 1996). This is achieved through its ability to, via ROCK, activate 
LIM kinase (Maekawa, et al., 1999, Sumi, et al., 2001); inactivate LIM phosphatases 
(Kawano, et al., 1999) which stabilises actin filaments and actomyosin bundles to 
collectively promote the generation of contractile forces. Rho proteins also activate 
formin proteins such as mDia1 and mDia2 which promote actin polymerisation 
through their association with actin monomer binding protein, profilin (Gotoda, et al., 
2000, Uehata, et al., 1997). (For comprehensive reviews on the role and regulation of 
Rho GTPases in cell migration and invasion see (Frame and Brunton, 2002, Raftopoulou 
and Hall, 2004, Sahai, 2005, Sahai and Marshall, 2002) 
1.4 The role of Intercellular junctions in tumour suppression 
Intercellular junctions mediate adhesion between adjacent cells. There are several 
types of intercellular junctions, anchoring, communicating and occluding junctions 
(Figure 1.8). Intercellular junctions are particularly abundant in the epidermis and 
confer characteristics critical to its function. Desmosomes and adherens junctions are  
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Figure 1.8 Cell-Cell Junctions. Tight junctions are occluding junctions located at the apical 
membrane providing a selectively impermeable barrier to seal the intercellular space. Tight 
junctions also play an essential role in the establishment of cell polarity through their 
association with polarity complexes. Adherens junctions located more basal than tight 
junctions they junction to link the actin cytoskeleton of neighbouring cells to sites of adhesion 
forming an adhesion belt which encircles the host cell or form spots of adhesion. Desmosomes 
form spots of adhesion linking the intermediate filaments of neighbouring cell to sites of 
adhesion which is essential to tissue architecture and integrity. Finally Gap junctions, form 
spots of adhesion, with gabs between them spanning ~2nm bridged by ion channels composed 
of connexions to directly link the cytoplasm of neighbouring cells. (Adapted from 
http://organelle-marker.com/intercellular-junctions/. August 2014) 
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both anchoring junctions and confer mechanical strength and integrity essential to the 
maintenance of tissue architecture. Gap junctions allow cell-cell communication by 
facilitating the movement of molecules and ion between adjacent cells, crucial to co-
ordinated differentiation and proliferation. Finally occluding Tight junctions, provide a 
selectively impermeable barrier to solutes and water between epithelial cells and 
provide essential barrier functions. 
Intercellular junctions are conventionally accepted to function as tumour suppressors 
by restricting cell growth through cell-adhesion-mediated contact inhibition (Okegawa, 
et al., 2002). In support the disruption of cell-cell adhesion has been shown to 
significantly contribute to uncontrolled cell proliferation and play a causal role in 
tumour dissemination. The tumour suppressor function of adhesion is exemplified by 
the function of E-cadherin which when disrupted is associated with tumour 
development (Pećina-Slaus, 2003). When expressed in cancer cell lines, E-cadherin 
inhibits growth and reduces invasiveness (Frixen, et al., 1991, Vleminckx, et al., 1991, 
Watabe, et al., 1994). Likewise the expression of desmosomal components in non-
adhesive fibroblasts (L929) generates adhesion, while the strongly invasive nature of 
these cells was inhibited when transfected with desmosomal components. 
Furthermore, the invasive phenotype of L929 fibroblasts was restored when 
desmosomal adhesion was inhibited (Tselepis, et al., 1998). Recent studies support this 
concept by identifying mutations in cell-cell adhesion genes encoding alpha-catenins 
(component of adheren junctions) in Head and Neck SqCC (Fanjul-Fernández, et al., 
2013). Further prognostic assessment to evaluate the impact of these alpha catenin 
mutations revealed four-fold increase in mortality if tumours harbour these lesions 
(Fanjul-Fernández, et al., 2013). Another study shows further support by 
demonstrating that loss of cell adhesion molecule, Echinoid, promotes tissue over 
growth i.e. loss of contact inhibition function (Yue, et al., 2012). Specific to 
Desmosomes, the loss or reduction of junction components including Dsg1-3, Pg, and 
Pkps has been observed in the development and/or progression of SqCCs of the skin 
head and neck and prostate, correlating with increased metastasis and poor prognosis. 
(Dusek and Attardi, 2011). For more detail on the role of cell adhesion in tumour 
suppression see (Dusek and Attardi, 2011, Moh and Shen, 2009). 
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1.5 Desmosomes 
Desmosomes are calcium dependent, highly organised multi-protein structures 
composed of cadherins, armadillo and plakin family proteins. They uniquely function as 
intercellular adhesive junctions which tether the intermediate filaments of 
neighbouring cells to the plasma membrane at sites of cell-cell contact to form the 
Desmosome-Intermediate Filament Complex (DIFC) (Delva, et al., 2009, Getsios, et al., 
2004, Saito, et al., 2012). Desmosomes provide mechanical and adhesive strength 
which is essential to the maintenance of tissue architecture and integrity, particularly 
to that of the skin, oral mucosa, simple epithelia and heart (Desai, et al., 2009, Green 
and Simpson, 2007) which are subjected to relatively high levels of mechanical stress.  
1.5.1 Desmosome structure and composition. 
As illustrated in Figure 1.9, a characteristic desmosome is composed of: 
transmembrane cadherins, desmogleins (Dsg) and desmocollins (Dsc), which mediate 
adhesion between adjacent cells; Aramdillo family proteins, plakoglobin (Pg) and 
plakophilin (Pkp), which associate with the cytoplasmic tail of cadherins; and plankin 
family protein, Desmoplakin (Dp), which associates with the stress-bearing 
intermediate filaments of the cytoskeleton. These components are arranged to form 
two symmetrical electron dense cytoplasmic plaques (DCP) from neighbouring cells, 
around a shared central extracellular core domain (ECD) which is bisected by a dense 
midline (Farquhar and Palade, 1963, Odland, 1958). The extracellular core domain (also 
known as desmoglea) spans 20-35nm and consists of the extracellular domains of 
desmosomal cadherins. Each DCP consists of an inner dense plaque (IDP) and an outer 
dense plaque (ODP) both approximately 15-20nm thick. The cytoplasmic tails of the 
desmosomal cadherins directly interact with Pg, also known as γ-catenin, which in turn 
associates with the N-terminal globular head of Dp and Pkps to form the ODP. The IDP 
consists of the C-terminal tail of Dp which interacts with the intermediate filaments of 
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Figure 1.9 Desmosome structure. The desmosome is a multi-protein adhesive complex 
composed of desmosomal cadherins, armadillo family proteins (plakoglobin and plakophilin) 
and plakin family proteins (Desmoplakin). They are arranged as two symmetrical electron 
dense plaques (inner dense plaque and outer dense plaque) which facilitate the association 
between the C-terminus of the desmosomal cadherin and the intermediate filaments of the 
cytoskeleton. Desmosomes function to link the intermediate filaments of neighbouring cells to 
sites of adhesion which is essential in the maintenance of tissue integrity. 
Desmosomal Cadherins 
Desmosomal cadherins are calcium binding, single pass transmembrane glycoproteins 
that belong to the cadherin superfamily. Their function is to provide the adhesive Dsc 
isoforms can exist in 2 spliced variants, a ’long’ (a) and ‘short’ (b) form, the latter of 
which lacks the ICS domain. The extracellular domain of desmosomal cadherins 
consists of four extracellular cadherins like domains (EC1-4), separated by calcium 
binding motifs, and an extracellular anchor (EA) domain followed by the 
transmembrane domain (TM). The intracellular domain consists of an intracellular 
anchor domain (IA), an intracellular cadherin-like domain (ICS) which provides a 
interface at the core of desmosomes. There are currently seven characterised human 
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Figure 1.10 Desmoglein and Desmocollin proteins structure. Both Dscs and Dsgs share a 
common extracellular structure consisting of four extracellular cadherin like domains (EC), 
followed by an extracellular anchor domain (EA). The transmembrane domain (TM) links the 
extracellular domain to the intracellular domain that contains an intracellular anchor domain 
(IA) followed by a intercellular cadherins-like domain (ICS). The ICS is shortened in Dsc (b) 
variant. Specific for Dsgs are the additional three domains, a proline-rich linker domain (IPL), 
repeating unit domain (RUD) and finally a desmoglein-specific terminal domain (DTD) that are 
located at the C-terminus of Dsgs.  
binding site for Pg, a proline-rich linker domain (IPL), repeating unit domain (RUD) and 
finally, a desmoglein-specific terminal domain (DTD) that is found only in Dsg proteins. 
The functions of IPL and RUD are currently unknown. For Desmosomal cadherins 
mediate adhesion through their Cell Adhesion Recognition (CAR) sites located in the 
EC1 domain (Tselepis, et al., 1998). Adhesion between the desmosomal cadherins was 
originally thought to occur in a homophilic manner like classical cadherins. However, 
later studies using blocking peptides corresponding to the CAR sites of both Dsgs and 
Dscs have shown that desmosomal adhesion was only perturbed when peptides to 
both Dsgs and Dscs were present (Runswick, et al., 2001), suggesting that desmosomal 
cadherins mediate heterophillic binding. A later report by the same group has shown 
that Dsc2/3 and Dsg2/3 also interact with each other in a homophilic and isoform 
specific fashion suggesting that both heterophilic and homophilic ligations can occur 
(Thomason, et al., 2010). For more detail on the structure of Desmosomal cadherins 
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Armadillo Family proteins 
Armadillo proteins form a large family characterised by the presence of a repeated ~42 
amino acid ARM motif, such proteins include β-catenin, Pg and Pkps. Plakoglobin, 
consists of an N- and C-terminal domain which flank a central right handed superhelix 
(Huber, et al., 1997) that associates and binds to the C-terminal tails of desmosomal 
cadherins. Plakoglobin is a homologue of β-catenin, exhibiting dual localisation in 
desmosomes and adherens junction through its association with desmosomal 
cadherins and E-cadherin. However, due to higher affinity, Pg tends to localise in the 
desmosome (Chitaev, et al., 1996). Plakoglobin has also been implicated in facilitating 
cross-talk between desmosomes and adherens junctions and in regulating desmosome 
size (Lewis, et al., 1997, Palka and Green, 1997, Ruiz, et al., 1996). 
Plakophilin exists as 3 isoforms (Pkp 1-3) expressed in a tissue- and cell differentiation-
specific manner (Hatzfeld, 2007). Plakophilin 1 and 2 have two variants, ‘a’ the shorter 
variant and ‘b’ the longer form. Structurally, Pkps consist of a central arm repeat 
domain with a flexible insert (Choi and Weis, 2005) flanked by C- and N-terminal 
domains. All Pkps exhibit dual localisations in desmosomes and the nucleus (Hatzfeld, 
2007), regulated by 14-3-3 protein which retains cytoplasmic localisation (Müller, et al., 
2003, Schmidt, et al., 1997). The N-termial head of Pkp mediates interactions with Dp, 
Pg and desmosomal cadherins as well as facilitating their transport to cell-cell contacts 
(Chen, et al., 2002, Hatzfeld, et al., 2000, Kowalczyk, et al., 1999). 
Desmoplakin 
Desmoplakin is the predominant plaque protein required for desmosome assembly, 
intermediate filament association and regulation of desmosomes and adherens 
junction localisation (Bornslaeger, et al., 1996, Bornslaeger, et al., 2001, Huber, 2003, 
Smith and Fuchs, 1998, Troyanovsky, et al., 1994). Desmoplakin consists of a globular 
head and tail domain which flank a central α-helical coiled-coil rod domain that 
mediates Dp dimerisation (Green, et al., 1988). The globular N-terminal head domain 
facilitates targeting to ODP and binding to Pg, while the C-terminal domain mediates 
attachment to intermediate filament (Bornslaeger, et al., 1996, Meng, et al., 1997, 
Stappenbeck and Green, 1992). There are two isoforms of Dp, DpI and DpII generated 
by alternative splicing, however they appear to be functionally redundant (McGrath, et 
al., 1997, Uzumcu, et al., 2006). 
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Figure 1.11. Expression of desmosome components in the epidermis. A schematic of the 
Basal, spinous, granular and cornified layers of the epidermis (right). The blue blocks on the 
left, illustrate the expression pattern of desmosomal cadherins (Dsg 1-4 and Dsc 1-3) and 
plaque proteins (Dp, Pg, and Pkp 1-4). The controlled levels of expression and localisation of 
the desmosomal components alters the composition of desmosomes formed, which is thought 
to be attributed to tissue differential and morphogenesis. (Figure adapted from (Getsios, et al., 
2004, Green and Simpson, 2007) 
Other desmosomal components 
Perp is an essential component of desmosomes of stratified epithelia and heart (Ihrie, 
et al., 2005, Marques, et al., 2006) and is required for normal desmosome assembly 
and function in these tissues (Ihrie, et al., 2005). However, the precise role of Perp is 
not fully understood. Corneodesmosin is a secreted glycoprotein incorporated into 
desmosomes of the cornified layers of the epidermis during the process of epithelial 
cornification. Corneodesmosin is thought to act as an adhesion molecule in the 
cornified layers of stratified epithelia (Jonca, et al., 2002). 
Desmosome composition varies with cell type and differentiation status. Such variation 
results in structural changes that are visible in desmosome appearance and size. Such 
tailoring is proposed to suit the specialised functions of the cells and tissues that 
possess them. This is well exemplified through the expression patterns of desmosomal 
components restricted to specific layers in the epidermis. As illustrated in Figure 1.11 
Dsg1, Pkp1 are highly expressed in the differentiated cells of granular and spinous 
layers where as Dsg3, Dcs3 and Pkp2 and predominately expressed in the proliferating 
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granular and basal layers, respectively, while Pkp3, Pg and Dp exhibit more ubiquitous 
expression through the epidermis. 
1.5.2 Desmosome assemble, adhesion and regulation 
Desmosome assembly 
Initiated by cell-cell contact and adherens junction formation, desmosomes assemble 
to confer and stabilise strong intracellular adhesion (Lewis, et al., 1997). The precise 
sequence of events of desmosome assembly has been hindered by the relative 
insolubility of the junctions. However, technological advances including live-cell 
imaging and fluorescent reporters have begun to overcome this obstacle. As currently 
understood and illustrated in Figure 1.12, desmosome assembly occurs in several 
phases (Nekrasova and Green, 2013). Firstly, the desmosomal cadherins assemble at 
the plasma membrane as illustrated in Figure 1.8 A. Specifically, Dsc-enriched vesicles, 
which initiate assembly (Burdett and Sullivan, 2002, Collins, et al., 1995), followed by 
Dsg-enriched vesicles are transported to the plasma membrane associated with Dp in a 
microtubule-dependent fashion spatially and temporally coordinated by kinesin-2 and 
Pkp2 for Dscs and kinesin-1 for Dsgs (Green, et al., 2010, Nekrasova, et al., 2011). To 
complete assembly, targeting and tethering of these vesicles into the plasma 
membrane has been proposed to be facilitated through the Sec3 exocyst protein 
complex (Andersen and Yeaman, 2010) 
The next phase is cytoplasmic plaque assembly. As sumaried in Figure 1.8B this phase is 
already initiated during Dsg recruitment to the plasma membrane, where Dp in concert 
with Dsg3 accumulates at the cell cortex. This is quickly followed by the recruitment of 
non-membrane-bound Dp-containing particles associated with the IF cytoskeleton. 
Once at the cell cortex Dp is translocated to cell-cell contacts where it binds to the C-
terminus of desmosomal cadherin via Pg in the formation of the IDP in a microtubule- 
and actin -dependent manner (Godsel, et al., 2005). The translocation of Dp-associated 
complexes is regulated and promoted by Pkp2 which acts as a scaffold for a complex 
containing plakin and PKCα which modulate the interaction between Dp and 
intermediates filaments. The contribution of Pg and other Pkps to the desmosome 
assembly are still unclear although both have been shown to be required for normal 
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Figure 1.12 Model of Desmosome assembly. Illustrated in two phases, (A) illustrates 
the assembly of desmosomal cadherins at the plasma membrane, during this phase 
desmocollins- followed by desmogleins- containing vesicles are transported from the 
golgi along microtubules in a kinesin-2 and kinesin-1 dependent manner (1). Once at 
the plasma membrane they are incorporated into desmosomes a process facilitated by 
Secs3 (2). (B) Illustrates cytoplasmic plaque assembly. Initiated during Dsg3 membrane 
recruitment during which Dp is also recruited, Dp:Pkp enriched particles are 
transported to the plasma membrane via IF (1) where it is translocated to cell-cell 
contacts (2). Once at contact Dp binds associated and bind desmosomal cadherins via 
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desmosome plaque assembly (Acehan, et al., 2008, Grossmann, et al., 2004, McGrath, 
et al., 1997, Ruiz, et al., 1996). For a more detailed description of desmosome assemble 
see Nekrasova and Green, 2013. 
‘Hyper’ and ‘hypo’ adhesion  
Desmosome exists in two adhesive states, calcium-dependent (hypo-adhesive) and 
calcium-independent (hyper-adhesive). During assembly and before desmosome 
stabilisation, desmosomes are calcium-dependent. At this stage desmosome adhesion 
can be dissociated by extracellular calcium depletion. After desmosome formation, a 
state of hyper-adhesion is gradually achieved allowing the structure to carry out its 
principle function in maintaining tissue integrity (Garrod, et al., 2005, Kimura, et al., 
2007). In this state desmosomes can no longer be dissociated by calcium depletion 
(Garrod, et al., 2005, Kimura, et al., 2007). In vitro, hyper-adhesion of desmosomes is 
achieved through the maintenance of confluent culture for a few days and occurs, as 
currently understood, without altering molecular composition of the desmosome, but 
rather through the molecular re-arrangement of desmosomal cadherins through the 
entrapment of Ca
2+
 ions (Garrod, et al., 2005, Kimura, et al., 2007). 
The adhesive state of desmosomes in early passage culture is reversible but ultimately 
replaced by calcium-independence (hyper-adhesiveness). During wound healing, 
desmosomes shift to a calcium-dependent state in order to facilitate cell migration and 
re-epithelisation. The ability of desmosomes to modulate their adhesive state is 
essential as they need to be as dynamic as the tissues they support. In vitro studies 
have shown that activation of PKCα causes reversion of desmosomes to calcium-
dependence to facilitate epithelial remodelling in wound healing (Garrod, et al., 2005, 
Wallis, et al., 2000). 
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Regulation 
Whilst being essential in providing mechanical strength, desmosomes themselves are 
dynamic structures with changes in their molecular composition and structure during  
processes such as epithelial differentiation and stratification, tissue remodelling and 
wound healing (Green, et al., 2010). Desmosomes are regulated at both transcriptional 
and post-transcriptional levels. Transcriptionally, understanding of how desmosomes 
are regulated is still limited. However, preliminary studies based on the 
characterisation of desmosomal cadherin promoters revealed that desmosomal 
cadherins are regulated by different promoters and the specific expression of each 
cadherin can be achieved without affecting the others (Denning, et al., 1998, Hunt, et 
al., 1999, Smith, et al., 2004). On a post-transcriptional level, signals generated by cell-
cell contacts and junction assembly provoke protein phosphorylations that in turn 
positively and negatively regulate desmosome formation (Pasdar, et al., 1995). It has 
been shown that phosphorylation of serine residues of Dscs promotes Pg association 
and Dsg binding to confer desmosome formation in response to calcium (Aoyama, et 
al., 2009). PKCα has been demonstrated to have a pivotal role in the regulation of 
desmosomes, with its activation able to promote desmosome formation in a calcium- 
and adherens junction-independent manner (Sheu, et al., 1989, van Hengel, et al., 
1997). PKCα has also been reported to be involved in Dp trafficking for its junctional 
incorporation through a Pkp2-dependent mechanism (Bass-Zubek, et al., 2008). 
Furthermore, it has been shown that the activity of PKCα is directly associated with the 
adhesive state of desmosomes with its suppression rendering desmosomes in a status 
of hyper-adhesion, whereas PKCα activation promotes calcium-dependence (Garrod, et 
al., 2005).  
Both intracellular and extracellular calcium are required for desmosome junction 
formation and the stability of desmosomal components (Pasdar, et al., 1995, Pasdar 
and Nelson, 1988, Pasdar and Nelson, 1988, Pasdar and Nelson, 1989). Finally, 
desmosome assembly is dependent on adherens junction formation (Amagai, et al., 
1995, Fujimori and Takeichi, 1993, Jensen, et al., 1997, Lewis, et al., 1994), with the 
relationship between these junctions attributed to Pg (Lewis, et al., 1997). However it 
has been shown that desmosomes formation can exhibit adherens junction 
independence (van Hengel, et al., 1997). 
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Table 1.1 Human desmosome-associated diseases. This table illustrates some of the 
human disease attributed to genetic, autoimmune or bacterial toxin factors mediating 
alteration of specific desmosomal components. Table adapted from (Green and 
Gaudry, 2000, Green and Simpson, 2007). 
 
1.5.3 Desmosomes in disease  
The functional importance of desmosomes and their constitutive molecular 
components in cell-cell adhesion is highlighted by a variety of human diseases which 
arise when desmosomal protein function is compromised. As illustrated in Table 1.1 
predominantly the heart and skin, which are subjected to routine and substantial 
mechanical forces, are adversely affecting by a loss of desmosomal integrity and 
function. Interestingly, a variety of clinical presentations arise when different 
components are compromised, suggesting that whilst desmosomal components 
contribute to a shared common adhesive function, they also possess specific or unique 
functions in ensuring desmosomal integrity. 
Desmosomal 
component 
Human disease References 
Dsg 1  (genetic 
alteration) 
Striate palmoplantar keratoderma (SPPK) (Kljuic, et al., 2003, 
Rickman, et al., 1999) 
Dsg 2 (genetic 
alteration) 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
(Pilichou, et al., 2006) 
Dsg 3 
(autoantibodies) 
Pemphigus Vulgaris (mucosal dominant), Suprabasal 
epidermal acantholysis 
(Amagai, et al., 1991, 
Lever, 1953) 
Dsg 4 (genetic 
alteration) 
Hypotrichosis (Kljuic, et al., 2003) 
Dsc 2 (genetic 
alteration) 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
(Heuser, et al., 2006, 
Syrris, et al., 2006) 
Plakoglobin (genetic 
alteration) 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC), Palmoplantar keratoderma 
(McKoy, et al., 2000) 
Desmoplakin (genetic 
alteration) 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
(Rampazzo, et al., 2002) 
Plakophilin 1 (genetic 
alteration) 
Ectodermal dysplasia and skin fragility syndrome (McGrath, et al., 1997) 
Plakophilin 2 (genetic 
alteration) 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 




Pemphigus foliaceus, Superficial and suprabasal 
epidermal Acantholysis, Pemphigus vulgaris 
(mucocutaneous), Mucosal erosions. 
(Amagai, et al., 1991, 
Koulu, et al., 1984, 
Lever, 1953) 
Dsg 1 (Bacterial 
toxins) 
Staphylococcal scalded skin syndrome First described by Ritter 
von Rittershain 1878 
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1.5.4 Desmosomal cadherin: Desmoglein 3 
Desmoglein 3 (Dsg3), a 130 kDa protein, belongs to the desmoglein subfamily. As 
illustrated in Figure 1.5, Dsg3 exhibits tissue- and differentiation-specific distribution 
patterns, predominantly expressed in the basal and immediate supra-basal layers of 
the epidermis and throughout the entire squamous epithelium of the oral mucosa. 
Dsg3 is also known to be expressed in cardiomyocytes, brain arachnoid cells and the 
dendritic reticulum cells of lymph nodes (Schwarz, et al., 1990). The functional 
significance of Dsg3 in mediating cell-cell adhesion in desmosomes is demonstrated by 
the autoimmune blistering disease, Pemphigus Vulgaris (PV), where circulating auto-
antibodies bind to Dsg3 in epithelia and oral mucosa, disrupting cell-cell adhesion.  
Role of Dsg3 in epidermal proliferation, differentiation and morphogenesis  
The tissue-specific expression profiles of desmosomal cadherins (Figure 1.11 and 1.13) 
have been shown by various research groups to serve a purpose. Dsg3 is 
predominantly expressed in proliferating epithelial cells, hence its restricted 
distribution in the epidermis (Mannan, et al., 2011). It has also been demonstrated in 
transgenic mice that the distribution of desmoglein isoforms regulates the structure 
and function of the epithelia. One such study by Elias et al. showed that by altering the 
expression profile of Dsg3 in stratified epithelia to that similar to the oral mucosa 
caused the epidermal tissue to exhibit histological and phenotypic characteristics 
resembling that of mucosal epithelium (Elias, et al., 2001). In line with this study, mis-
expression of Dsg3 in the supra-basal layers of the epidermis resulted in abnormal 
hyper-proliferation and differentiation (Merritt, et al., 2002). Furthermore, a study 
using blocking peptides targeting the CAR site of desmosomal cadherins inhibited 
alveolar morphogenesis and positioning of mammary epithelial cells (Runswick, et al., 
2001). It has been shown that the protein kinase C (PKC) isoenzymes antagonistically 
regulate differentiation-dependent expression of desmosomal cadherins in human 
keratinocytes. For instance, the differentiation-promoting novel PKCδ promotes Dsg1 
expression while the growth-promoting novel PKCε decreased its expression. In the 
same way, the expression of Dsg3 is regulated by these two Ca-independent PKC 
isoenzymes (Szegedi, et al., 2009). Taken together these studies suggest that the 
expression of desmosomal cadherins including Dsg3 is associated with epithelial 
proliferation, differentiation and homeostasis.  
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Figure 1.13. Desmoglein 3 expression in skin and oral mucosa. Tissue sections of human skin 
and oral mucosa were probed with Dsg3 specific antibody (green). Desmoglein 3 is expressed 
in the basal and immediate supra-basal layers of the epidermis (dotted line illustrates were the 
Stratum corneum ends) and throughout the entire stratified epithelium of oral mucosa 
(courtesy of Dr Hong Wan). Scale bar, 50µm.  
Role of Dsg3 in the pathogenesis of pemphigus vulgaris 
In 1991, Dsg3 was identified as the autoantigen in PV (Amagai, et al., 1991). PV is a rare 
autoimmune disorder characterised by the loss of keratinocyte adhesion within the 
spinous layer of the epidermis, in a process called ‘acantholysis’, which clinically 
manifests as blistering of the skin and oral mucosa. There are two subtypes of PV, 
mucocutaneous PV where autoantibodies targeting both Dsg3 and Dsg1 are produced, 
and mucosal dominant PV where autoantibodies against Dsg3 are circulating. Two 
additional types of pemphigus have also been characterised, Pemphigus Foliaceus (PF) 
in which autoantibodies target Dsg1 and Paraneoplastic Pemphigus (PNP) where 
autoantibodies target desmosomal and hemidesmosomal proteins (Anhalt, 2004). 
Pemphigus vulgaris is the most common form of pemphigus accounting for up to 80% 
of pemphigus cases with PF and PNP being less servers and least common, 
respectively. Histological examination shows that in PV blisters are largely restricted to 
the basal and immediate suprabasal layers of the epidermis and/or throughout the oral 
mucosa, in contrast blisters are restricted to the superficial layer of the epidermis with 
no mucosal involvement in PF. Despite many studies, the molecular mechanism of 
blister formation in PV remains unclear.  
  
Oral mucosaSkin
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Pemphigus pathogenesis 
Several hypotheses have been proposed to explain the mechanisms by which 
pemphigus manifests. Since the discovery of circulating auto-antibodies targeting Dsg3 
and Dsg1 in the sera of PV patients, it was proposed that these auto-antibodies 
mechanically inhibit the adhesive function of Dsg1 and Dsg3 giving rise to the ‘steric 
hindrance’ hypothesis‘. Other hypotheses include the ‘desmoglein compensation’ 
hypothesis (Brennan, et al., 2010) which attempts to explain the different clinical 
phenotypes between PV and PF. In accordance, Dsg3 is proposed to compensate, 
where possible, for the loss of Dsg1 and vice-versa. In the case of PF where Dsg1-
mediated adhesion is compromised, the uniform expression of Dsg3 throughout the 
oral mucosa compensates its loss-of-function. However, in the epidermis where Dsg3 
expression is limited to the basal layers of the epidermis; it is unable to compensate for 
the loss of Dsg1 in the stratum granulosum, as a result blister formation is limited to 
the superficial layers of the epidermis with no mucosal involvement. In PV where auto 
antibodies result in the loss of Dgs3-mediated adhesion, Dsg1 is unable to compensate 
for the loss of Dsg3-mediated adhesion throughout the oral mucosa resulting in 
mucosal dominant PV. Where auto-antibodies to both Dsg1 and Dsg3 are in circulation 
neither is able to compensate resulting in both epidermal and mucosal involvement, 
hence muco-cutaneous PV. Although a large body of evidence supports the 
‘desmoglein compensation’ hypothesis clinical studies have found that the 
autoantibody titres do not always correlate with the clinical presentation, suggesting 
other factors, such as intracellular signalling, may play a role in the pathogenesis of 
pemphigus acantholysis.  
Signalling hypothesis 
Studies using anti-Dsg3 auto-antibodies to elucidate the possible signalling mechanism 
of pemphigus acantholysis, have uncovered overwhelming evidence of the ability of 
Dsg3 to initiate signalling cascades. The addition of such anti-bodies to keratinocyte 
culture has been shown to promote the re-organisation of cortical actin filaments 
(Berkowitz, et al., 2005, Gliem, et al., 2010), induce the phosphorylation of Dsg3 and its 
dissociation from desmosomes (Aoyama and Kitajima, 1999, Aoyama, et al., 1999, 
Yamamoto, et al., 2007), increase intracellular calcium concentrations (Kitajima, et al., 
1999) and activate various signalling molecules such as Pg, PKC, p38 MAPK, heat shock 
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protein p27, Src and c-Myc (Berkowitz, et al., 2005, Kawasaki, et al., 2006, Spindler and 
Waschke, 2011, Waschke, et al., 2006). Taken together these findings not only affirm 
the signalling capabilities of Dsg3 but strongly suggest a signalling component in PV 
pathogenesis.  
Role of Dsg3 in cancer 
Traditional views consider desmosomes, and other intercellular junctions, as having a 
protective function in cancer through cell-adhesion-mediated contact inhibition. In 
accordance, the loss of cell-cell adhesion is an essential event in Epithelial to 
Mesenchymal Transition (EMT) (see section 1.1.2). In-keeping with this proposal, loss 
of desmosomes and their constitutive proteins have been found in various tumours in 
the body. EMT is a biologic process that transforms polarized epithelial cells through 
multiple morphological and biochemical changes to become mesenchymal in 
phenotype with characteristics such as, enhanced migration and invasion capability, 
resistance to apoptosis and increased production of extracellular matrix (ECM) 
components. Emerging evidence suggests that EMT is a prerequisite to pathological 
processes including cancer progression and metastasis. Loss of cadherin junctions and 
desmosomes occurs in epithelial cells to allow cellular dissociation in the conversion 
from benign to metastatic tumours (Chidgey and Dawson, 2007).  
Paradoxically, several independent studies have shown Dsg3 to be up regulated in 
squamous cell carcinoma (SCC) of the head and neck, oesophageal and lung (Chen, et 
al., 2007, Fang, et al., 2014, Fukuoka, et al., 2007, Huang, et al., 2010) as well as cancer 
cell lines derived from head and neck SCC (Chen, et al., 2007). Furthermore, the level of 
overexpression correlating with clinical stage of disease and regional lymph node 
metastasis (Chen, et al., 2007, Fang, et al., 2014, Ferris, et al., 2005, Ferris, et al., 2011, 
Huang, et al., 2010). Dsg3 silencing suppressed cancer cell growth, migration and 
invasion in vitro and in vivo (Chen, et al., 2007). Analysis of clinical samples and cancer 
cell lines in a recent patent application for the use of Dgs3 in the diagnosis of cancer, 
report elevated Dsg3 expression in cancers of the colon, oesophagus, stomach, 
pancreas and skin (Aburatani, et al., 2013). Finally Dsg3 has been identified as an 
accurate biomarker for the detection of metastatic spread of SCC (Ferris, et al., 2005, 
Ferris, et al., 2011, Patel, et al., 2013, Wang, et al., 2007) and ancillary marker to 
separate SCC from other subtypes of lung cancer (Savci-Heijink, et al., 2009).  
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Figure 1.14 Structure of ERM family proteins. Ezrin, Radixin and Moesin share a common 
globular FERM domain at their N-terminus which is composed of three sub-domains (F1, F2 
and F3) arranged in a cloverleaf configuration to confer membrane binding. The central 
domain form a monomeric α-helical rod which links the FERM domain to the F-actin binding 
domain at the C-terminal ERM associated domain C-ERMAD. The charged C-ERMAD contains a 
conserved sequence motif for the actin binding. Ezrin and Radixin contain an additional poly-
proline region which is absent in Moesin.  
Collectively, these findings indicate a positive role for Dsg3 in cancer, however, little is 
known about its actual function and mechanisms by which Dsg3 regulates cancer cell 
growth and invasion.  
1.6 ERM family proteins 
Ezrin, Radixin and Moesin make up the ERM family proteins that belong to the band 
4.1 superfamily, and function as regulated molecular linker proteins between the 
plasma membrane and the actin cytoskeleton (Arpin, et al., 1994, Bretscher, et al., 
1997, Tsukita and Yonemura, 1997, Vaheri, et al., 1997). In doing so they have been 
implicated in the regulation of the actin cytoskeleton and actin based processes, such 
as membrane projections and dynamics (Bretscher, 1999, Bretscher, et al., 2002, 
Louvet-Vallée, 2000, Mangeat, et al., 1999, Tsukita and Yonemura, 1997), epithelial 
morphogenesis, cell adhesion and migration (Arpin, et al., 2011, Bretscher, et al., 2002, 
Fehon, et al., 2010). 
1.6.1 Structure of ERM proteins 
Figure 1.14 illustrates the structure of the ERM family proteins, characterised by the 
presence of a ~300 amino acid FERM (Four.one Ezrin, Radixin and Moesin) domain at 
the N-terminus followed by a α-helical domain capped by a C-terminal ERM associated  
domain (C-ERMAD) (Algrain, et al., 1993, Gary and Bretscher, 1995, Turunen, et al., 
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Figure 1.7 Model of the ERM protein activation. In a dormant state C-/N-terminus interaction 
masks the plasma membrane and F-actin binding sites of the molecule. The activation of the 
ERM proteins involves their recruitment to the plasma membrane and association with 
phosphatidylinositol 4,5-bisphosphate where they are subsequently phosphorylated at a 
conserved threonine residue which provokes a conformational change thus unmasking F-actin 
and plasma membrane binding sites.  
shape and confers binding to the plasma membrane through direct association with 
integral membrane proteins or indirectly through membrane associated proteins. The 
C-ERMAD contains the actin binding site mediating the link between the plasma 
membrane and the actin cytoskeleton (Berryman, et al., 1993, Pearson, et al., 2000). 
The C-ERMAD can also associate with the FERM domain through self association or 
with other ERM molecules to form either homo- or hetero-dimers (Gary and Bretscher, 
1995). This C-/N-terminal association masks the plasma membrane and actin binding 
sites rendering the protein inactive (Bretscher, et al., 2002, Gary and Bretscher, 1995). 
1.6.2 Activation of ERM proteins 
The activity of Ezrin, Radixin and Moesin is regulated by their confirmational state. In 
the inactive state, an intra- or inter-molecular interaction between the C- and N-
terminal domains masks the actin and membrane binding sites (Berryman, et al., 1995, 
Bretscher, et al., 1995, Gary and Bretscher, 1993, Gary and Bretscher, 1995, 
Magendantz, et al., 1995). In this inactive conformation the protein adopts a diffused 
cytoplasmic localisation (Hirao, et al., 1996, Takeuchi, et al., 1994). Upon activation 
ERM proteins unfold revealing their binding sites for the plasma membrane and 
cortical actin. As currently understood, activation is achieved in a 2-step model where 
inactive ERM proteins are targeted to regions of the plasma membrane rich in 
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to provoke a confirmational change (Fievet, et al., 2004, Nakamura, et al., 1999, 
Yonemura, et al., 2002) unmaking the C- and N-terminus binding sites. This event is 
followed by the phosphorylation of a conserved C-terminal threonine residue T567, 
T564 and T558 for Ezrin, Radixin and Moesin respectively, located at the C-ERMAD 
domain (Fievet et al. 2004, Zhu et al. 2007). Studies have found that the 
serine/threonine kinases responsible for this phosphorylation event include PKCα and 
θ, NIK (NFκB-inducing kinase), LOK (Lymphocyte-Orientated Kinase) and MST4 
(Baumgartner, et al., 2006, Belkina, et al., 2009, Ng, et al., 2001, Pietromonaco, et al., 
1998). As illustrated in Figure 1.7, In the open confirmation the N-terminal FERM 
domain of Ezrin interacts and binds to the plasma membrane directly through integral 
proteins such as CD44 or ICAM2 (Yonemura, et al., 1998), or indirectly through 
cytoplasmic membrane associated proteins, such as EBP50 and E3KARP via their PDZ 
domains (Reczek, et al., 1997). The C-terminal domain of Ezrin interact and bind to 
cortical F-actin.  
1.6.3 Function of ERM proteins 
Co-expressed and colocalised in most cultured cells, ERM proteins are found 
concentrated at membrane associated structures such as microvilli, ruffles, cell-cell 
contacts and cell-matrix adhesion sites where actin cytoskeleton is densely associated 
with the plasma membrane (Arpin, et al., 1994, Takeuchi, et al., 1994). The ERM 
proteins exhibit tissue- and cell type-specific expression and distribution patterns with 
Ezrin most abundant in epithelial cells, Radixin in hepatocytes and Moesin in 
endothelial cells. Irrespective of their specific expression and distribution, the 
commonality of their principle associations with the actin cytoskeleton and plasma 
membrane, unite them in regulating and organisation of actin-rich plasma membrane 
domains (Bretscher, 1989, Takeuchi, et al., 1994). The specific function of ERM 
proteins is dictated by the ERM protein involved, the mode of phosphorylation and 
phosphorylation site, a selection of which are illustrated in Table 1.2. 
1.6.4 Functional redundancy of ERM proteins 
The similarities in ERM protein expression, localisation and binding affinities for the 
plasma membrane (Hirao, et al., 1996, Turunen, et al., 1994) and F-actin in addition to 
a high level of amino acid identity (>70%), favours the idea that ERM proteins exhibit 
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Table 1.2 Specific functions of ERM family proteins with respect to phospho-site and 
mode of phosphorylation. Adapted from (Clucas and Valderrama, 2014) 
functional redundancy. Early in vivo studies to elucidate specific ERM protein function 
showed that the individual silencing of ERM proteins brought about no significant 
phenotypic affect with only the combined suppression of all three ERM proteins 
resulting in the destruction of cell-cell and cell-matrix adhesion and concomitant 
disappearance of microvilli in mouse epithelial and thymoma cells (Takeuchi, et al., 
1994) . Later studies suggest that ERM proteins are able to compensate for one 
another (Doi, et al., 1999, Kikuchi, et al., 2002, Saotome, et al., 2004). These 
reportssupport the concept of functional redundancy amidst ERM family proteins. 
However, their structural differences, cell-specific expression patterns and specific 
protein functions suggest functional diversity. Several research groups are dedicated to 








Function of activated ERM 
Ezrin Thr567 Akt2 NHE3 translocation and activation 
 Thr235, T567 CDK5 Cell senescence 
 Thr567 LOK Cytoskeleton rearrangement in hematpoietic cells 
 Thr567, Tyr145, 
Try353 
EGFR Cell proliferation, lamellipodia formation 
 Tyr145, Tyr477 Src Cell spreading 
 Thr567 SLK Microvilli formation in polarised epithelial cells 
 Thr567 ROCK Effector of RhoA 
 Thr567 PKC Cell migration 
 Ser66 PKA Gastric parietal cell activation 
Radixin Thr564 NIK Lamellipodia formation and cell morphogenesis 
 Thr564 PKC Cell migration 
 Thr 564 ROCK Fas-mediated apoptosis 
Moesin Thr588 LOK Microvilli formation in polarised epithelial cells 
 Thr588 NIK Lamellipodia formation and cell morphogenesis 
 Thr558 PKC Cell migration 
 Thr588 ROCK Cell migration and invasion 
 Thr588 MRCK Effector of Cdc42 in filopodia formation 
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identifying tissue specificity, unique features such as exclusive phosphorylation sites 
(Takeuchi, et al., 1994) and specific functions (Table 1.3). Thus, when attempting to 
ascertain individual functions related to any one member of the ERM family proteins, 
caution and consideration for possible compensatory events should be taken when 
drawing conclusions.  
1.6.5 Ezrin 
As the most extensively studied ERM protein, Ezrin has provided the basis of our 
understanding of ERM protein function. Ezrin is an 81 kDa protein and, like other ERM 
proteins, functions as a regulated linker protein. As shown in Figure 1.16, in its active 
conformation, the FERM domain of Ezrin is able to associate directly with the plasma 
membrane through binding to integral proteins including CD44 (Hirao, et al., 1996, 
Tsukita, et al., 1994), ICAM-2 (Yonemura, et al., 1998), PA2.26 (Scholl, et al., 1999) and 
syndecan 2 (Granés, et al., 2000) or indirectly through membrane associated proteins 
including EBP50 (Ezrin binding phospho-protein 50) and E3KARP (Bretscher, et al., 
1997, Reczek, et al., 1997). Other residues including Thr235 (Yang and Hinds, 2003), 
Tyr145 and Tyr353 (Krieg and Hunter, 1992) have been shown to be phosphorylated 
(Krieg and Hunter, 1992), associated with functions such as, cell proliferation, 
senescence and spreading (Table 1.3). 
Role of Ezrin in cell morphology, adhesion, migration and apoptosis 
Beyond acting as a membrane cytoskeleton linker protein, functional analysis of Ezrin 
has demonstrated significant effects on actin cytoskeletal organisation with the 
formation of numerous cellular projections in insect Sf9 or CHO cells overexpressing 
the truncated C-terminus of ezrin (Martin, et al., 1995). Likewise the expression of 
Ezrin T567D mutant (permanent phospho-mimic) caused elongated projections of the 
plasma membrane of cultured gastric parietal cells (Zhou, et al., 2005). Knockdown 
studies support the role of Ezrin in the formation and maintenance of actin rich 
structures. In vivo studies performed by Takeuchi et al. who showed that the 
suppression of all ERM protein resulted in the disappearance of microvilli in epithelial 
cells (Takeuchi, et al., 1994), while the ablation of Ezrin at the tips of membrane 
extensions in Rat-1 fibroblasts, results in membrane retraction (Lamb, et al., 1997). 
With respect to cell migration, the inactivation of the cytoplasmic pool of Ezrin results 
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Figure 1.16 Structure of Ezrin including binding sites, phospho-sites and protein associations. 
Illustrated is the domain organisation of Ezrin that is composed of a N-terminal FERM domain 
followed by a α-helical domain, a polyproline rich linked by a C-terminal C-ERMAD domain. 
Also indicated are the identified residues for the phosphorylation and the particular domains 
for protein interaction. 
in retraction of the plasma membrane from the leading edge in Rat-1 cells lines. 
Another study carried out by Crepaldi et al. showed that Ezrin is able to regulate cell 
migration induced by HGF stimulation in LLC-PK1 cells (Bretscher, 1989, Crepaldi, et al., 
1997). Similarly PKCα dependent phosphorylation of Ezrin-T567 promotes cell 
migration, while the Ezrin mutant T567A impairs PKCα mediated motility in the MCF-7 
breast carcinoma cell line (Ng, et al., 2001). 
Ezrin has also been shown to enhance cell adhesion (Kaul, et al., 1996, Martin, et al., 
1995) as knockdown of Ezrin inhibits both cell-cell and cell-substrate adhesion 
(Bretscher, et al., 1997, Hiscox and Jiang, 1999, Takeuchi, et al., 1994). Studies have 
also implicated Ezrin in cell survival through PI 3-Kinases/Akt pathway in epithelial 
cells. In these experiments they demonstrated that Ezrin interacts with p85, the 
regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase), at two distinct sites to 
convey an anti-apoptotic signal (Gautreau, et al., 1999). Finally, Zhu et al. 
demonstrated that the establishment of cell polarity is also dependent upon the Ezrin 
activity (Zhu, et al., 2010). Taken together, these findings suggest that Ezrin plays a role 
in multiple cellular processes including cell adhesion, morphology, migration and 
apoptosis.  
Role of Ezrin function in Signal transduction 
It has been shown that ERM family proteins associate with a variety of signalling 
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downstream effectors of specific molecules. Several groups have shown that Ezrin 
activation is the event downstream of signalling by Rho and PKC, with Rho kinases and 
PKC responsible for the phosphorylation of the conserved C-terminal threonine 
residues of Ezrin (Matsui, et al., 1998, Shaw, et al., 1998) that renders the 
conformational change and mobilisation of ERM from cytoplasmic pool to the plasma 
membrane protrusions (Shaw, et al., 1998). Furthermore, Rho-dependent activation of 
ERM proteins is shown to be crucial for Rho-induced cytoskeleton rearrangements 
(Mackay, et al., 1997). In support, inhibition of Rho kinases inhibits the 
phosphorylation of Ezrin T567 in hepatocarcinoma and Jurkat cells (Chen, et al., 2011, 
Hébert, et al., 2008). Rho is also shown to function as a downstream effector of Ezrin as 
shown by Hatzoglou et al. In this study activated Ezrin binds Gem, to down-regulate 
RhoA signalling pathways through interactions with Gem-interacting protein (Gmip) 
(Hatzoglou, et al., 2007). Gem is a GTP-binding protein of the Ras superfamily which 
regulates cytoskeleton organisation and calcium channels (Maguire, et al., 1994). Gmip 
is a novel Rho-GTPase-activating protein (Rho-GAP) which functions, like other the 
GAPs, to increases the intrinsic GTPase activity of Ras-related proteins returning them 
to their GDP-bound state i.e. a state of inactivation or basal state (Aresta, et al., 2002).  
Role of Ezrin in cancer progression 
An Ezrin-dependent mechanism, through the activation of RhoA, has been shown to 
promote EMT (Martín-Villar, et al., 2006). Furthermore, Ezrin has been shown to be 
associated with cancer progression (Hunter, 2004, Khanna, et al., 2004, Ren, et al., 
2009, Yeh, et al., 2009), dynamically up-regulated during tumour metastasis (Khanna, 
et al., 2004, Ren, et al., 2009). In particular, Ezrin is found to be transiently upregulated 
in early metastatic progression and again during metastatic expansion but down-
regulated during the establishment and survival of metastatic nodules. Chen et al. 
demonstrated that the hyper-phosphorylation of Ezrin Thr567 correlates with an 
invasive phenotype in hepatocarcinoma, with the inhibition of invasion achieved by 
Rho kinase-dependent inhibition of Ezrin activity (Chen, et al., 2007). Taken together, 
this suggests that Ezrin plays an important role in cancer progression and metastasis. 
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Figure 1.17 Activating Protein-1, bZip family proteins. Activating Protein-1 (AP-1) is composed 
of homo- and hetero-dimers of AP-1 bZIP proteins, including Jun, Fos, ATF, Maf and JDP 
subfamilies. The dimeric composition is determined by the abundance of the constituents and 
the varying affinities they have for each other. 
1.7 Transcription factor: Activator Protein 1  
As mentioned in section 1.3 several transcription factors have been identified as 
regulators in EMT such as the ZEB, Snail and Twist (Sánchez-Tilló, et al., 2012) and also 
play a central role in cancer progression such as GATA and E2F (Hollern, et al., 2014, 
Lopez-Bergami, et al., 2010, Zheng and Blobel, 2010). In both cases AP-1 has also been 
implicated (Davies, et al., 2005, Lopez-Bergami, et al., 2010), furthermore Ezrin is a 
known transcriptional target of AP-1 that confers invasiveness (Jooss and Müller, 1995) 
and AP-1 activity has been shown to be required for the correct localisation of Ezrin to 
the plasma membrane following EGF treatment (Stapleton, et al., 2002). 
Activator protein 1 (AP-1), originally described as the TPA (12-O-tetradecanoyl-
phorbaol-13-acetate) inducible transcription factor, is a dimeric complex that regulates 
gene transcription by binding to the TPA response elements (TRE, consensus sequence 
5’-TGAG/CTCA-3’) and the cAMP-response elements (CRE, consensus sequence 5’-
TGACGTCA -3’) located in the promoter and enhancer regions of AP-1 inducible genes. 
AP-1 has an expansive transcriptional repertoire propagated by its diverse homo- and 
hetero-dimeric compositional array of Jun, Atf, Fos and Maf bZIP protein families, a 
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Figure 1.18 Expression patters of AP-1 bZip proteins in human and mouse skin. As illustrated 
AP-1 subunit cJun. JunB, JunD, cFos, FosB, Fra-1 and Fra-2 are expressed in specific layers of 
the epidermis which differ in their state of keratinocyte differentiation (Adapted from (Angel, 
et al., 2001) 
characterised by the presence of a C-terminal highly charged basic DNA binding 
domain and a dimerisation domain referred to as a ‘Leucine zipper’, in short referred 
to a bZIP (basic region leucine zipper) proteins. AP-1 has been shown to regulate a vast 
array of cellular processes including development, proliferation, apoptosis, immune 
responses, and stress responses (Foletta, et al., 1998, Shaulian and Karin, 2001, 
Wagner, 2002, Zhou, et al., 2001) Moreover, the deregulation of AP-1 has been 
associated with a variety of pathologies including inflammatory disease of the bone, 
skin and liver (Thomsen, et al., 2013, Zenz, et al., 2008) and upregulated in numerous 
malignancies, including skin breast, cervix and lung (Eckert, et al., 2013, Ouyang, et al., 
2008, Prusty and Das, 2005, Shen, et al., 2008, Yu, et al., 2012). 
1.7.1 Regulation of AP-1 activity  
The diversity of the genes regulated by AP-1 is due to the complex regulatory 
mechanisms which either increase the abundance of AP-1 proteins or those that 
stimulate their activity. Through these mechanisms the state of AP-1 activation, bZIP 
protein abundance and expression patterns, translational and post translational 
modifications and interaction with ancillary proteins are modulated. Dimer 
composition is a powerful means of regulating AP-1 activity as DNA binding affinity,  
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Figure 1.19 PKC-dependent Phospho-regulation of cJun. Phosphorylation of cJun at N-terminal 
S63 and S73 residues (green ovals) promotes transcriptional activation by increasing its 
stability and transactivation potential. Additionally JNK-dependent phosphorylation of Thr91 
and Thr93 (green ovals). is required for DNA binding and activation of transcriptional activity 
Phosphorylation of C-terminal residues down regulates cJun activity represented by the red 
ovals. Phosphorylation of Ser226 inhibits DNA binding and phosphorylation of serine 443 
followed by Thr239 by Glycogen synthase 3 (GSK3) marks cJun for degradation via 
ubiquitylation. 
response element affinity, and transactivation potential of individual bZIP proteins 
varies widely to tailor the activity of the AP-1 dimer to ultimately determine its 
transcriptional output. As the predominant regulatory mechanism, dimer composition, 
is primarily modulated through differential and tissue specific expression patterns of 
the individual AP-1 components (Karin, 1995) and this is most evident in the expression 
profile of bZip proteins throughout the epidermis (Angel, et al., 2001, Welter and 
Eckert, 1995), as illustrated in Figure 1.18. In addition to patterns of expression, the 
composition of AP-1 is further influenced by bZip protein dimer preferences/affinities. 
For example, Jun proteins are able to form homodimers and heterodimers with Fos- 
and ATF-family members (Dorsey, et al., 1995, Hai and Curran, 1991, Smeal, et al., 
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Figure 1.20 Overview of transcriptional and post-translational regulation of AP-1. As 
illustrated, the activation of MAPKs ERK1/2, p38 and JNK promotes the transcription of cFos 
and cJun. cFos:cJun AP-1 dimer can be further regulated through phosphorylation to promote 
transcription of AP-1 target genes (JNK, ERK, p38, RSK2) or inhibit transcription (GSK-3, CKII). 
Adapted from Eferl et al., 2003.  
AFT proteins are also able to homodimerise but Fos proteins cannot (Ziff, 1990). Dimer 
composition also has a direct effect on the DNA-binding site preference, as individual 
proteins exhibit response elements preferences (Eferl and Wagner, 2003), which when 
dimerised determines which element is bound and subsequently which genes are 
transcribed. Jun/Jun and Fos/Jun have been shown to bind with high affinity to TRE 
whereas Jun/ATF dimers and ATF homodimers bind to CRE (Hai and Curran, 1991). 
Additionally, some dimer combinations including Maf family proteins preferentially 
bind to other elements including MARE I, MARE II (MAF-recognition elements) and ARE 
(antioxidant element) (Eferl and Wagner, 2003). Transcriptionally, the abundance of 
AP1-components can be influenced by various extracellular signals transduced through 
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Table 1.4 Target genes of AP-1 implicated in cancer development and suppression. 
Adapted from Eferl and Wagner et al and Ozanne et al (Eferl and Wagner, 2003, 
Ozanne, et al., 2007) 
 
MAPK. For example, the activation of JNK in turn activates ternary complex factors 
(TCFs) to induce cFos expression (Cavigelli, et al., 1995) while activated p38 induces 
cJun expression through the activation of transcription factor MEF2C (Wei, et al., 
2003). Post-transcriptionally, the activity of both pre-existing and newly synthesized 
AP-1 components can be achieved through phosphorylation. With respect to cJun, PKC-
dependent phosphorylation of the N-terminal residues inhibits DNA binding of cJun 
homodimers but not cJun:cFos heterodimers (Boyle, et al., 1991). Whereas 
phosphorylation of cJun at serine 73 and, to a lesser exstent, serine 63 by JNK 
enhances its ability to activate transcription (Smeal, et al., 1994) (Figure 1.19). The 
transcriptional and post-transcriptional regulation of AP-1 components is summarised 
in Figure 1.20. Phosphorylation of AP-1 components has also been shown to play a role 
in protein stability with the phosphorylation of amino-terminal serine/threonine 
residues of cJun to reduce its ubiquitination and subsequent degradation (Musti, et al., 
1997). Finally, the activity of AP-1 is also regulated by its interaction with ancillary 
proteins and co-factors. Interactions of JNK phosphorylated cJun with co-factor CBP 
(CREB-binding protein) is proposed to confer an increase in cJun transcriptional 
activation (Bannister, et al., 1995, Kwok, et al., 1994). Interaction with JAB1 (Jun 
activating domain binding protein) with cJun:JunD stabilises the AP1 complex and 
enhances transcriptional activity (Claret, et al., 1996). Nuclear receptors including GR 
(glucocorticoid), and RAR (retinoic-acid receptor) and nuclear protein p202 inhibit AP-1 
activity through trans-repression, a process of mutual negative interference between 
Process AP-1 target genes 
Oncogenic transformation cJun, cFos 
Angiogenesis VEGF-D, uPA, uPAR, Proliferiin 
Apoptosis Bcl2, Bclxl, FasL Bcl2, BIM, FAS, p53 
Migration, invasive growth and metastasis MMP-1, MMP-3, MMP9, uPA, Cd44, Ezrin, 
Cathepsin, MTS1,KRP1, TSC36/FRP, 
Tropomyosin 3, Tropomyosin 5b, ARP 2/3, 
CapG, CD44, Ezrin, SSeCKs,  
Proliferation p53, p21,p19, cyclin D1, EGFR, HB-EGF, GM-
CSF,KGF, WAF1, INKA4 
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transcription factors, though direct interaction, and the inhibition of DNA binding in 
the case of p202 (Benkoussa, et al., 2002, Min, et al., 1996, Schüle, et al., 1990, Yang-
Yen, et al., 1990). 
1.7.2 Role of AP-1 in Cancer 
The major mammalian components of AP-1, cJun and cFos were originally identified as 
the viral oncoproteins vJun and vFos, shown to have positive effects on cell 
transformation. Today, other AP-1 proteins have been identified, some of which have 
also been associated with cancer progression whereas others identified as potential 
tumour suppressors. The pro- or anti-oncogenic functions of AP-1 in tumorigenesis is 
attributed to normal or aberrant regulation of target genes that influence cell 
proliferation, apoptosis, survival, invasive growth and angiogenesis (Table 1.4). 
AP1 in tumour suppression 
Some AP-1 components lack transforming ability such as the Jun family proteins, JunB 
and JunD. Interestingly, both these proteins as well as others have been identified as 
having tumour suppressor functions (Deng and Karin, 1993). Both JunB and JunD 
down-regulate processes of proliferation and/or stimulate apoptosis (Passegué, et al., 
2001, Passegué and Wagner, 2000, Pfarr, et al., 1994, Shaulian, et al., 2000, Szabowski, 
et al., 2000). Furthermore, both in vivo and in vitro studies have shown that 
heterodimers containing JunB with oncogenic bZip proteins can antagonise oncogenic 
transformation (Chiu, et al., 1989, Passegué, et al., 2001). The ability of AP-1 to 
function as a tumour suppressor is still debateable as comparatively few studies have 
been conducted to investigate its anti-oncogenic function. However, protective 
function of AP-1 is believed to be dependent on cell type, state of differentiation, 
tumour stage and genetic background (Eferl and Wagner, 2003). 
AP-1 in epithelial to mesenchymal progression 
The process of EMT is an essential programme in processes including wound healing, 
development and the inflammatory response plays an essential role in cancer 
progression, with cancer cells using this programme to metastasise and colonise distal 
sites (Nieto, 2013) (see section 1.1.2). Various signalling pathways are involved in 
inducing EMT including TGFβ, Integrin, RTKs and WNt signalling via GSK, p38, JNK, ERK, 
and β catenin:TCF/LEF, (Lamouille, et al., 2014) all of which are implicated in the 
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Table 7.1 AP-1 components overexpressed in various cancers. 
Cancer AP-1 component(s) reference 
Breast c-Jun,Fra1 
c-Jun 
(Baan, et al., 2010) 
(Liu, et al., 2002) 
(Sankpal, et al., 2011) 
Ovarian c-Jun (Neyns, et al., 1999) 
(Hein, et al., 2009) 
Endometrial 
 
c-Fos, Fra2 and JunB 
c-Jun 
(Bamberger, et al., 2001) 
(Alkhalaf, et al., 1993) 
Hodgkins Lymphoma AP-1  
c-Jun, JunB 
(Green, et al., 2012) 
(Mathas, et al., 2002) 
Colorectal c-Jun, JunB 
c-Jun 
(Wang, et al., 2000) 
(Suto, et al., 2004) 
Cervical c-Fos:JunB 
c-Jun 
(Prusty and Das, 2005) 
(Maritz, et al., 2011) 





(Papachristou, et al., 2003) 
(Leaner, et al., 2009) 
(Wang, et al., 1995) 
Head and Neck cFos 
AP-1 
(Swenson, et al., 2011) 
(Chen, et al., 2008) 
(Ondrey, et al., 1999) 
(Bancroft, et al., 2002) 
 
activation or regulation of AP-1 activity (Figure 1.12) (Davies, et al., 2005, Eferl and 
Wagner, 2003, Lamouille, et al., 2014). 
AP-1 in cancer progression 
The role of AP-1 in cancer promotion is complex with aberrant expression of various 
components attributing to numerous cancers (Table 1.4). It has been shown that AP-1 
is activated in response to oncogenic signalling transduction cascades as well as 
displaying oncogenic potential through its constituents, with the overexpression of a 
variety of bZip proteins including cJun, cFos and FosB able to transform cells efficiently 
(Hartl and Bister, 1995, Wang, et al., 1991). The transforming ability of these proteins 
is believed to be conferred by their potent transactivation potential (Jochum, et al., 
2001). However, activating mutations in Jun have yet to be identified in human cancers 
(Lopez-Bergami, et al., 2010), therefore increased AP-1 activity and expression 
associated with cancer progression and metastasis is attributed to the constitutive up 
regulation of upstream Kinases (Lopez-Bergami, et al., 2010) such as ERK as a result of 
mutations in B-raf or N-ras (Davies, et al., 2002, Gorden, et al., 2003). Irrespective of 
the mode of increased AP-1 activity, the effect is the aberrant expression of AP-1 
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target genes that promote cancer progression and metastasis. As in normal physiology, 
the transcriptional array of AP-1 target genes in response to oncogenic activation will 
be governed by the dimeric composition of AP-1 which alters promoter binding 
specificity, transcriptional capacity and protein stability as outlined previously. This is 
then further influenced by the genetic background of the malignancy which will 
initially dictate the mode of oncogenic AP-1 activation, and furthermore by factors 
such as cell cycle progression and specific stimuli such as those from the tumour 
microenvironment (Lopez-Bergami, et al., 2010). To implicate a pivotal transcriptional 
regulator such as AP-1 a possible mechanism of Dsg3-induced cancer cell migration 
and invasion would strongly suggest that Dsg3 plays an active role in cancer 
progression through the regulation of the migration invasion programme. 
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Figure 1.21 The overexpression of Dsg3 promotes membrane dynamics, cell spreading and 
membrane protrusion in A431 cells in which the colocalisation of Dsg3 and the membrane 
actin liker protein, Ezrin was shown. (A) Time lapse microscopic examination of A431 cells 
with transduction of full length human Dsg3 (hDsg3.myc) or empty vector (Vector control) that 
serves as a control. Image acquisition started immediately after plating cells. The 
overexpression of Dsg3 promoted cell spreading, membrane dynamics and protrusions 
compared to vector control. (B) Fluorescence confocal microscopy of A431-hDsg3.myc cells 
dual labelled with the Dsg3 (Red) and Ezrin (green) specific antibodies revealed the 
colocalisation of these two proteins, particularly at the plasma membrane and membrane 
protrusions (white arrows). Scale bars 10 μm, Inset shows x5 magnification. 
1.8 Preliminary data 
In order to investigate the function of Dsg3 in cancer in detail, Dr Wan generated a 
stable A431 cell line overexpressing full length human Dsg3 (Tsang, et al., 2010). 
Preliminary analysis of these cell lines using time lapse and confocal microscopy 
revealed that the overexpression of Dsg3 in A431 cells (A431-hDsg3.myc) provoked 
pronounced membrane projections and dynamics, as well as enhanced cell spreading 
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compared to the vector control (Figure 1.21A) (Tsang, et al., 2010). Furthermore, 
fluorescent confocal microscopy of A431-hDsg3.myc cells immunostained for Dsg3 and 
Ezrin illustrated colocalisation of these two proteins, particularly at the plasma 
membrane and membrane projections (Figure 1.21B) (Tsang, et al., 2010). 
  











Evidence that Dsg3 elicits function beyond the mediation of adhesion within 
desmosomes began with studies to elucidate the mechanism of PV implicating the 
ability of Dsg3 in the regulation of the actin cytoskeleton as well as induce intracellular 
signalling cascades. More recently Dsg3 has been identified, against conventional 
understanding, to be upregulated in a variety of cancer. Together there is a suggestion 
that Dsg3 may carry out functions outside of the desmosome and identifies an area 
which is under developed in literature. As discussed in this chapter, many studies have 
independently implicated both Dsg3 and Ezrin in oncogenesis with the upregulation of 
Dsg3 and Ezrin expression as well as increased Ezrin activity being associated with 
cancer progression. However a functional or mechanical link between these proteins 
has not been identified in literature. The preliminary observations above demonstrate 
that the overexpression of Dsg3 promotes actin dynamics and cell spreading which is 
consistent with the observed Dsg3-dependent actin re-organisation identified in PV 
studies. It is therefore possible, under specific circumstances that Dsg3-dependent 
actin regulation could promote cellular events such as cell migration, consistent with 
Dsg3-associated cancer cell behaviour. The preliminary findings further suggest a 
possible association between Dsg3 and established actin cytoskeleton regulator, Ezrin, 
which could theoretically facilitate Dsg3-dependent cellular events with respect to 
actin based processes, namely cell morphology, migration and invasion.  
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Hypothesis  
With respect to current understanding and the presented preliminary findings, I 
propose that Dsg3 associates with Ezrin to co-operatively function in regulating the 
actin based processes that attribute to the positive role of Dsg3 in cancer progression 
and metastasis. 
Aims of this study 
To examine this hypothesis the aims of this study were as following: 1) to characterise 
the phenotype of cells overexpressing Dsg3; 2) to characterise the association between 
Dsg3 and Ezrin in A431 cell lines, and finally 3) to elucidate the underlying molecular 
mechanisms involved. 
  











2.1 Cell culture 
2.1.1 Cell lines and culture condition. 
A431 cell line 
Established by Giard and colleagues in 1973, the A431 cell line is a human cancer cell 
line derived from the vulva squamous cell carcinoma of a 85 year old female (Giard, et 
al., 1973). It expresses high levels of EGF receptor and harbours a loss-of-function p53 
mutation. These cells are morphologically similar to normal differentiated squamous 
epithelial cells and exhibit reduced expression of junctional proteins (Atsumi, et al., 
2008). In this study A431 cell lines were maintained in normal growth media, 
Dulbecco's Modified Eagle Medium (DMEM) (Gibco, UK) supplemented with 10% 
foetal calf serum (FCS) (Biosera, UK). Media were changed every 3 days to maintain cell 
cultures. 
SqCC/Y1 cell line 
SqCC/Y1 cells are a human head and neck cancer cell line derived from buccal 
squamous cell carcinoma. These cells were maintained in normal growth media, EpiLife 
(Gibco) supplemented with EpiLife Defined growth supplement (Gibco). Media was 
changed every 3-4 days to maintain cell cultures. All cell lines were maintained in a 
humidified atmosphere at 37°C and 10% CO2 in tissue culture incubators. 
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Cell passage 
Once cell lines reached a density of 80% confluence, cells were split in a 1:10 ratio. To 
passage cells, the growth media were removed and replaced with 2 ml, 5 ml or 8 ml of 
trypsin/EDTA (Lonza, UK) for cells grown in T25, T75 and T175 tissue culture flasks, 
respectively. Cells were incubated with trypsin until completely detached from the 
flask, this would take approximately 5-10 min for SqCC/Y1 and 10-15 min for A431 
cells. Once detached, an equal quantity of growth media containing serum was added 
to the trypsin:cell suspension. The serum was required to deactivate the proteolytic 
activity of trypsin. The cell suspension was then transferred to a conical centrifuge 
tube and centrifuged at 800 rpm for 5 min to pellet cells. The supernatant was 
carefully removed without disturbing the pellet. Cells were then re-suspended in fresh 
growth media supplemented with 10% serum. An aliquot of the cell suspension (10%) 
was seeded into a new flask containing growth medium. 
2.1.2 Cryopreservation and recovery of cell stocks 
Cells for cryopreservation were grown to 70% confluence before passaging as 
described above. However, in this case cell pellets were re-suspended in Freeze down 
media (FDM) (10% DMSO in FSC). For T25, T75 and T175 tissue culture flasks, pellets 
were re-suspended with 4 ml, 8 ml and 12 ml of FDM, respectively. Aliquots of 1ml 
were then transferred to 2.5 ml cryovials and frozen down at -80 °C in a ‘Mr frosty’ 
(Nalgene, UK), filled with Isopropanol. Cells were stored at -80 °C for 48 h before being 
transferred to liquid nitrogen for long term-storage. Cells that would be required 
within 6 months of freeze down were maintained at -80 °C. The use of FDM and slow 
programmable freezing facilitated by Isopropanol, which reduces temperature in a 
controlled manner (1 °C/min), protects cells against intracellular and extracellular ice 
formation and dehydration which occurs during the freeze down stage of 
cryopreservation. 
For the recovery of frozen aliquots, cryovials were removed from -80 °C or liquid 
nitrogen and immediately placed in a water bath set at 37 °C until completely thawed. 
Once thawed vials were removed from the water bath and cleaned with 70% Industrial 
methylated spirit (IMS). The aliquots of cell suspension were then transferred into 5ml 
bijous to which an equal volume of culture media was added in a drop-wise fashion 
over 1 min to prevent osmotic shock and maximise the number of viable cells 
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recovered. The cell suspension was then added to an additional 5 ml of culture media 
and transferred to a 15 ml conical centrifuge tube. Cells were centrifuged for 5 min at 
800rpm to pellet the recovered cells. The supernatant was carefully removed and the 
cell pellet re-suspended in normal growth before transfer to a T25 culture flasks. Once 
cells reached ~70% confluence in T25, flasks cells were transferred and maintained in 
T75 tissue culture flasks.  
2.2 The Experimental Model 
2.2.1 Desmoglein 3 Gain-of-function 
Stable overexpression 
In order to examine the signalling role of Dsg3, the unique retroviral construct of full 
length human Dsg3 (hDsg3.myc) was transduced into A431 cells (Tsang, et al., 2010). 
A431 cells made a suitable model in this study as they exhibit a low level of 
endogenous Dsg3 expression. The transduction of Dsg3 in A431 cells resulted in a 
stable increase in Dsg3 protein expression (at least 2-fold, compared to vector control) 
The construct for full length human Dsg3 with a mycTag epitope located at the C-
terminus (hDsg3.myc) was successfully cloned and constructed into the pBABE.puro 
retroviral vector (pBABE-hDsg3.myc) by Dr Hong Wan (Wan, et al., 2007). The empty 
vector control (pBABE-puro), as well as the mycTag control (pBABE-mycTag), was used 
alongside the hDsg3.myc construct. The constructs were packaged into retroviruses by 
Dr Ahmed to generate condition media for infection of target cells, A431 and SqCC/Y1. 
For infection, A431 parental cells were seeded to achieve 30% confluence following 
overnight culture. The following day growth media was replaced with the respective 
retroviral condition media (filtered through 0.45 µm) supplemented with polybrene (8 
µg/ml). Polybrene increases the efficiency of transduction by neutralising the charge 
repulsion between virions and sialic acid of the cell membrane. To further increase 
infection efficiency the cell cultures with condition media were centrifuged at 360rmp 
at 32 °C for 1hour and then placed back in an incubator. After 48 h of infection, 
condition media was replaced with normal growth media and allowed to recover for 2-
3 days before drug selection for successfully transduced cells. For selection, cells were 
cultured in normal growth media supplemented with puromycin (2 ug/ml) for a period 
of 2 weeks. During this time period a majority of cells dyed leaving behind a polyclonal 
population of cells with positive expression of hDsg3.myc.(A431-D3) After selection 
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cells were maintained in normal growth media, a recovery period of a week was 
adhered to prior to experimentation and cryopreservation. 
Generation of single cell clones 
Limiting dilution followed by clonal expansion was carried out with A431-D3 polyclonal 
cells (Courtesy of Dr M Tsang). In brief, A431-D3 cells suspended in normal growth 
media were subjected to a series of increasing dilutions to achieve a cell concentration 
of ~10 cells/ml. Aliquots of 100µl of the cell suspension were then seeded into a 96-
well plate. One week later each well was examined and those identified as having a 
single colony were allowed to propagate for several weeks. These clones were 
trypsinised and transferred to T25 culture flasks for further clonal expansion. Aliquots 
from each clone were then analysed by both Western blot (courtesy of Dr M Tsang) 
and real time qPCR (courtesy of Dr Tech) to characterise the level of Dsg3 expression 
on both a translational and transcriptional level (data not shown). High and low 
expression clones where then selected and used in this study alongside the vector 
control (Vect Ct) and polyclonal A431-D3 cells. All monoclonal population derived from 
A431-D3 cell are denoted by the affix ‘C#’, for example, the high expression clone, 
A431-C7 and low expression clone, A431-C11. 
Transient overexpression. 
In preparation, A431-parental cells (2x10
5
) were seeded into each well of a 6-well plate 
24 hours before transfection. The following method is for the transfection of one well 
in a 6-well plate. In a 1. 5ml polystyrene microcentrifuge tube 100µl of Opti-MEM 
(Gibco) and 1 μg of either hDsg3.myc or Vect Ct cDNA was added, the solution was 
mixed gently by pipetting. Then, 6 µl of Fugene HD (Promega) was added directly into 
the Opti-MEM:cDNA solution with care taken not to touch the tube wall. After gentle 
mixing the transfection solution was incubated for 15 min at room temperature (RT). 
In the meantime, the media of the prepared A431 cells was replaced with 2.5 ml of 
fresh growth media. Following the 15 min incubation period the transfection solution 
was added to the cells in a drop-wise fashion. Transfection was carried out for 24 h 
after which, cells were trypsinised and re-seeded at the desired concentration for the 
assay to be carried out 48 h after transfection. 
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Table 2.1 siRNA sequences, target genes, manufacturer and working concentrations. 







Designed by Dr 











Moesin Dharmacon 50 nM 
AACGATGATACATGACACG
AG 
Scrambled control Dharmacon 50 nM 
*Scrambled sequence was used as a scrambled control siRNA 
2.2.2 Desmoglein 3 Loss of function 
Transient siRNA transfection for Dsg3 silencing. 
The protocol of siRNA transfection and a significant reduction of Dsg3 are shown 




were seeded in 
each well of a 6-well plate in normal growth media 24 h prior to transfection. The 
following method is for a transfection of one well in a 6-well plate. For siRNA 
transfection, two solutions (A and B) were prepared and then combined to give rise to 
a siRNA transfection solution of 200 µl. For solution A, scrambled control or target 
specific siRNA (see Table 2.1) was added to Opti-MEM to achieve a siRNA 
concentration of 0.25 µM in 185 µl of Opti-MEM. For solution B, 5 µl of oligofectamine 
(Invitrogen) and 10 μl of Opti-MEM were combined. Both solution A and B were mixed 
gentle by pipetting and incubated at RT for 15 min. Solution A and B were then 
combined, mixed by gentle pipetting and incubated for a further 20 min at RT. In the 
meantime, the prepared cells were washed three times with Opti-MEM before the 
addition of 800 µl of Opti-MEM. Once the incubation of the transfection solution was 
complete it was added to the culture in a drop-wise fashion. Transfection was allowed 
to occur for 4 hours before the addition of 500 µl of Opti-MEM supplemented with 
30% FCS to achieve a final concentration of 10%FCS as a routine. The following day 
cells were trypsinised and re-seeded at the desired density for assay 48 h after 
transfection. All transfections had a final siRNA concentration of 50 nM. 
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2.3 Molecular Biology Methods 
2.3.1 Western blot 
Before cell lysis, media were swiftly removed before placing the culture plate on ice. 
Total cell lysates were extracted using 2x sample buffer (see below for volumes) and 
collected with the aid of a cell scraper (BD, UK). Lysates were then transferred to pre-
labelled 1.5 ml microcentrifuge tubes and boiled for 5 min at 95-100 °C to reduce the 
viscosity of the sample, before being placed on ice. Samples for SDS-PAGE at a later 
date were stored at -80°C at this stage.  
In all Western blots in this study an equal protein concentration of samples was loaded 
into gels. Protein concentration was determined using the DC
TM
 protein assay kit (Bio-
Rad) which is a colorimetric assay compatible with SDS containing buffers. Briefly, 5 µl 
of each test sample was loaded into a 96-well plate alongside a set of bovine serum 
albumin standards (0, 0.25, 0.5, 0.75, 1.0, 1.52, 2.5 and 5 µg/ml) to which 25 µl of 
Reagent A (solution A + solution Dc, 50:1) followed by 200µl of Reagent B were added. 
The blue colour was allowed to develop for 15 min at RT followed by the measurement 
of sample absorbance using a plate reader. Absorbance of each sample and standard 
was obtained at a wavelength of 650 nm. The protein concentration of test samples 
was extrapolated from the standard curve generated from the BSA standards. Once 
protein concentration was obtained a portion of each sample was combined with an 
equal volume of sample buffer containing bromophenol blue dye to assist gel loading. 
All samples were boiled again for 2 min at 95-100 °C prior to centrifugation at 13,000xg 
for 1 min. An equal amount of total protein was loaded into each lane of the 
appropriate gel (see below) ranging from 5-40 µg depending on target protein 
abundance and volume of lysate available. At least one lane in each gel was reserved 
for a molecular weight marker (full range rainbow marker, Invitrogen).  
All samples were resolved by SDS-PAGE using the NuPAGE®SDS-PAGE gel system 
(Invitrogen), followed by electrophoretic transfer of proteins from polyacrylamide gels 
to nitrocellulose membrane carried out at 30 V for 90 min at 4  ̊C. The nitrocellulose 
membranes were then subjected to blocking of non-specific binding sites by incubation 
with blocking buffer for 30 min at RT or overnight at 4 °C. Membranes were then 
incubated with primary antibodies diluted in blocking buffer (see Table 2.3 for 
antibody concentrations) for 1 h at RT or overnight at 4  ̊C. After three washes (3x5 
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min) in TTBS the membranes were incubated with secondary antibodies conjugated 
with HRP diluted in blocking buffer (1:1000) for 1 h at RT. Finally, after 3x5 min washes 
in TTBS the membranes were subjected to the Enhanced Chemiluminescence (ECL) 
Plus Western Blotting detection system (Amersham) or Femto Chemiluminescent 
Substrate (Pierce) to detect target proteins according to the manufacturers 
specifications, and recorded using hypersensitive ECL film (GE Healthcare Bio-Sciences 
Corp). 
2x sample buffer 
• 0.14 MTris –HCL 
• 4.5% SDS 
• 22.5% Glycerol 
In H20 
 
Running buffer (Invitrogen) 
• NuPAGE® MES SDS running buffer 
(20x): For Bis tris gels 
• NuPAGE® Tris-Acetate SDS running 
buffer(20x): for Tris Acetate gels 
 
1x Transfer buffer 
• 25 mM Tris Base 
• 192 mM Glycine 
• 20% Methanol 
1x TTBS 
• 0.1 M Tris buffer (pH 7.5)  
• 0.1% Tween 20 
• 154 mM Sodium Chloride 
 
Blocking Buffer 
• 5% non-fat dry milk in TTBS 
2x Sample buffer (plus Bromophenol 
blue) 
• 0.12 M Tris -HCL 
• 3.8% SDS 
• 18.4% Glycerol 
• 0.009%Bromophenol Blue 
• 9.1% Mercaptoethanol 
 
Gels used (NuPAGE® Invitrogen) 
• General use= 1mm, 4-12% and 
10% BisTris precast gels 10 - 12 
wells 
• pERM=1mm, 3-8% Tris Acetate 
precast gels 10 well 
Cell lysis volumes 
• 12 well tissue culture plate 50 ul 
• 6 well tissue culture plate=75 ul 
• 10cm tissue culture plate=300 ul 
 
 
Western blot analysis. 
The films of Western blots with different exposure were scanned using a flatbed 
desktop scanner at a minimum of 600 dpi and the band density of blots was 
determined using ImageJ. As shown in Figure 2.1A, a set of blot bands for a target 
protein were selected and analysed together Figure 2.1A shows bands densities for 
Dsg3 expression in A431-Vect Ct, -D3, -C7 and -C11 cells, respectively. This selection 
was then identified as the 1
st
 lane (Analyze>Gels>Select 1
st
 lane) followed by ‘Plot 
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Figure 2.1. Western blot analysis using ImageJ. (A) bands selected for analysis. (B) Band 
density plot with ImageJ. (C) Blot peaks separated by lines to allow quantification of each peak 
individually. (D) Quantification of individual peaks.  
lanes’ (Analyze>Gels>Plot lanes) to generate a ‘Western demo plot’ (Figure 2.1B). The 
lanes were then divided using the line tool to allow for the area of each peak to be 
determined separately (Figure 2.1C). Using the ‘Wand (tracing) tool’ each peak was 
selected to generate a band area (Figure 2.1D). The peak values were then exported 
into an Excel spreadsheet where all values were normalisation against a loading 
control (GAPDH, β actin or α Tubulin). Once normalised band density were expressed 
relative to the vector control or scrambled control density set at 1 arbitrary unit. Data 
presented as mean fold change ± SD with respect to the control. 
2.3.2 Experiment with inhibitors 
For experiments with pharmacological inhibitors in conjunction with calcium switch, 
cells were seeded at sub-confluence and allowed to adhere for 3-4 h. Once adhered 
cells were subjected to serum starvation by replacing normal growth media with 
serum-free DMEM and incubated overnight. The following day the serum-free DMEM 
was replaced with calcium-free DMEM without serum for <1 h under close inspection 
to ensure cells were rounded but did not detach. Media was replaced with either 
calcium-free DMEM supplemented with 10% decalcified serum or normal growth 
media, in the presence or absence of inhibitors. DMSO was used as vehicle control in 
the absence of inhibitor. Cells were incubated with or without the inhibitors for 5 
hours before cells were lysed for examination by Western blot. 
Calcium free DMEM w/o Serum 
• 3 mM EGTA in DMEM 
 
Calcium free DMEM with calcium free 
Serum 
• 3 mM EGTA 
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Table 2.2 Pharmacological inhibitors, their targets, working concentrations and 
incubation time periods. 
Inhibitor Target Concentration Incubation 
time 
Manufacturer Reference 
BIM PKC 5 µM 
10 µM 
0.5-25 µM 
0.5, 1 & 5 h 
5 h 
4 h 
Cell signalling (Rigot, et al., 1998) 




Calbiochem (Moon, et al., 2009) 
Gö 6976 PKC 1 µM 5 h Calbiochem (Tomic, et al., 2011) 
SP600125 JNK 10 µm 4 h Sant Cruz (Moon, et al., 2009) 
SB 203580 P38 20 µM 5 h Calbiochem (Wang and Ron, 
1996) 
NSC23766 Rac1 30 µM 5 h  (Gao, et al., 2004) 
C3 RhoA 0.1 µg/ml 5 h Cytoskeleton 
Inc 
(Waschke, et al., 
2006) 
Y-27652 ROCK 10 µM 4 h Ascent (Sahai and Marshall, 
2002) 
PP2 Src 10 µM 5 h Calbiochem (Nam, et al., 2002) 
Calcium-free serum was prepared as follow (courtesy of Dr Tsang). Briefly, the 
chelating resin was mixed into dH20 (250 ml of water/5 g of resin) for 1 hour at RT, pH 
was then adjusted to 7.4. After 3 h equilibration the resin:H20 mix was filtered through 
Whatman No1 filter paper. The equilibrated resin was then mixed with FCS overnight 
at 4°C (5 g of Chelex resin/50ml of FCS). The following day resin was removed via 
centrifugation at 1500xg for 10 min. The resulting serum was then sterilised by passing 
through a 0.22 µm filter, 50ml aliquots were stored at -20°C until required. 
For other experiments with the inhibitors, cells were seeded and serum starved as 
described above. The following day cells were treated with various inhibitors that were 
diluted in normal growth media (see Table 2.2 for concentrations and incubation time 
periods). Finally, cells were lysed and analysed by Western blot. 
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2.3.3 Co-immunoprecipitation assay 
Cells were seeded at sub-confluent density in T75 flasks and grown overnight. Cells 
were then washed with ice-cold PBS and lysed on ice for 10 min with ice cold 1x RIPA 
buffer (Upstate) containing a protease inhibitor cocktail. The lysates were collected 
with aid of a cell scraper and transferred to microcentrifuge tubes prior to 
centrifugation at 13,000xg for 5 min to eliminate cell debris. The supernatant were 
then carefully transferred to a fresh pre-labled microcentrifuge tube and protein 
concentration for each sample was determined by the DC
TM
 protein assay kit (Bio-Rad) 
as described in the Western blot protocol. For immunoprecipitation, 0.5-1mg of 
protein was incubated with 3-5 µg of primary anlbody at 4 C̊ overnight on a rotation 
wheel. The following day 1.7x10
5
 Protein G magnetic Dynabeads® (Novex, Invitrogen) 
were added to the Lysate:antibody solution and incubated for a further 1 hr at 4 C̊ on a 
rotation wheel. The bead-bound immuneprecipitates were washed 4x in RIPA buffer 
and 1x in 1xTTBS. The resulting immuneprecipitates were re-suspended in 11 µl of 2x 
sample buffer and boiled for 2 min at 95-100 C̊. Finally, the proteins of the 
immuneprecipitates were resolved by 4-12% or 3-8% SDS-PAGE followed by 
procedures described in the Western blot protocol.  
1xRIPA Buffer 
• 1x RIPA solution (Upstate Biotech) 
• 1 mM Sodium Orthovanadate 
• 15 mM sodium fluoride 
• 1 mM PMSF 
Just before use protein inhibitor cocktail 
was added (1:1000) 
1xTTBS 
• 0.1 M Tris buffer (pH 7.5)  
• 0.1% Tween 20 




2x Sample buffer (plus Bromophenol 
blue) 
• 0.12 M Tris -HCL 
• 3.8% SDS 
• 18.4% Glycerol 
• 0.009% Bromophenol Blue 
• 9.1% Mercaptoethanol 
Volume of RIPA buffer 
• 10cm tissue culture plate=300 µl 
• T75 tissue culture flask = 500 µl 
 
2.3.4 Cell fractionation 
Cells were seeded to achieve sub-confluence following overnight incubation. The 
following day cells were lysed using Triton X-100 buffer on ice for 10 min to extract 
Triton soluble proteins. The Triton insoluble proteins were precipitated out of solution 
by centrifugation at 14,000xg for 30 min at 4°C. The supernatant (Triton soluble 
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protein) was carefully transferred to a fresh pre-labelled microcentrifuge tube and 
kept on ice. The remaining pellet (Triton insoluble protein) was solubilised in 20 µl of 
2x sample buffer. Protein concentration of each sample was determined as described 
in the Western blot protocol. Consistent amounts of Triton soluble and Triton insoluble 
protein were loaded and resolved by 4-12% or 3-8% SDS-PAGE followed by procedures 
described in the Western blot protocol. 
Triton X-100 Buffer 
• 10 mM Tris-HCl 
• 1% Triton X-100 
• 145 mMNaCl 
• 2 mM EGTA 
• 5 mM EDTA 
• 1 mM PMSF 
• 10 mM Sodium orthovanadate 
• 10 mM Sodium fluoride 
Just before use Protease inhibitor cocktail 
was added (1:100)  
Volume of Triton X-100 buffer 
• 10 cm tissue culture plate=300 µl 
• T75 tissue culture flask = 500 µl 
 
2x Sample buffer (plus Bromophenol 
blue) 
 
• 0.12 M Tris -HCL 
• 3.8% SDS 
• 18.4% Glycerol 
• 0.009% Bromophenol Blue 
• 9.1% Mercaptoethanol 
 
2.3.5 Luciferase assay 
In preparation cells were subjected to transient co-transfection with AP1 luciferase 
reporter and hDsg3.myc constructs 2 days before the luciferase assay. Briefly, cells 
were seeded at ~30% confluence in a 6-well plate and allowed to propagate overnight 
in normal growth media. The following method is for a transfection of one well in a 6-
well plate. In a 1.5 ml polystyrene microcentrifuge tube 100 µl of Opti-MEM (Gibco) 
was added followed by 2 µg of cDNA directly into the media with care taken not to 
touch the tube walls. The solution was mixed by gentle pipetting. The 2µg of cDNA 
added was a mixture of 0-1 µg pBABE-hDsg3.myc together with 1 ug of wild type pGL-
AP-1 luciferase reporter or its mutant or empty pGL-Vect Control. The amount of 
pBABE-hDsg3.myc cDNA when less than 1 µg was substituted using the pBABE-GFP 
cDNA in order to make the total concentration of cDNA transfected consistent at 2 µg 
for all co-transfections. Next, 6 µl of Fugene HD (Promega) was added into the Opti-
MEM:cDNA solution to complete the transfection solution which was mixed gently for 
15 s followed by incubation at RT for 15 min. In the meantime, the media of the 
prepared cells were changed with 2.5 ml of fresh growth media. Following the 15 min 
incubation the transfection solution was added to the culture in a drop-wise fashion. 
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Transfection was allowed to occur for 24 h. Cells were then harvested and re-seeded 
into 12-well plates to achieve sub-confluence and incubated for a further 24 h.  
For experiments without inhibitors, 48 h after transfection the luciferase assay was 
performed using the Progmega Luciferase Assay System. Here, cells were lysed using 
70 µl/well of 1xReporter lysis buffer (Promega, E397A) for 5min on ice and collected 
with the aid of a cell scraper. Lysates were then transferred to fresh microcentrifuged 
tubes and frozen immediately in dry Ice for 30 min and then thawed. Samples were 
vortexed for 15 s followed by centrifugation for 15secs at room temperature. Five µl of 
each sample was used to determine protein concentration as described previously, 
and 10-15 µl aliquots of the remaining sample were assayed in duplicate or triplicate, 
depending on the amount of lysates available, in a white flat bottom 96-well plates. 
Once loaded, the plate was taken near the plate reader which was set to detect 
luminescence. Then, 100 µl of luciferase assay reagent (Promega, E151A+E152A) was 
added to each well and the plate reading initiated immediately. Each reading was 
normalised against protein concentration and volume of lysate in order to determine 
Luciferase activity per µg of protein. An average of duplicate or triplicate readings was 
then determined in an Excel spreadsheet and presented as Mean fold change in 
Luciferase activity/μg of protein ±SD. 
For experiments with inhibitors, the transfected cells were re-seeded into a 12-well 
plate 24 h after co-transfection and allowed to adhere for 3-4 h before serum 
starvation overnight. The following day cells were treated with inhibitors diluted in 
normal growth media (the concentrations and incubation time periods of the inhibitors 
are illustrated in Table 2.2). Once complete, the Luciferase assay was performed as 
described above. 
2.3.6 Real-time absolute quantitative RT-PCR 
Standard Curve 
In preparation, 50 µl PCR reactions were run in 96-well plates to amplify a large 
quantity of PCR product for Dsg3. Each reaction contained the following: 
• 2x SYBR Green 1 Mastermix  25 μl 
• dH20     15 μl 
• Template    5 μl 
• 5uM Dsg3 F/R primer   7 μl 
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At this stage the template was from a cocktail cDNA. The Dsg3 primers used were as 
follows, Forward ‘CCGAATCTCTGGAGTGGGAA’, reverse ‘GCCCAAGGACTAGATGTAGA’ 
which yield a 164 bp product. The resulting PCR product was purified in MinElute PCR 
purification spin columns according to the manufacturer’s specifications to yield a 20 
µl DNA elute in dH20. The DNA concentration was determined using Nanodrop and a 
Dsg3 DNA stock with a concentration of 10
11
 copies/2µl was achieved using the 
following equation: 
  .	×	
()/()×  × 2 ×  − 	= vol. to generate 1011/2µl DNA stock 
From the 10
11 

















 copies per 2µl. The resulting standards were 
stored at -20°C until required. To set up the standard curve, a 96-well plate was used 
and each well contained the following: 
• 2x SYBR Free master mix 5 µl 
• 5µM Dsg3 F/R primers 1 μl 
• dH20    3 µl 
• Template   2 µl 
Here, the template used was the Dsg3 standards. Once loaded the plate was sealed 
with a Roche sealing film and centrifuged for 30 s at ~3000 rpm. The qPCR was carried 
out on the LightCycler 480 (Roche) using the following protocol: 
• Denaturation (hot start)  95°C 5 min 
• Amplification (45 Cycles) 
Melting   95°C 10 s 
Annealing   60°C 6 s 
Extension   72°C 6 s 
Acquisition   76°C 1 s 
• Melting Analysis 
Melting   95°C 30 s 
Cooling/annealing  65°C 30 s 
Gradual heating + acquisition 65-99°C 
Cooling/termination  40°C 5 s 
The standard curve generated is stored in the LightCycler 480 software for application 
in subsequent experiments. 
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Real-time absolute quantitative RT-PCR 
Here, A431 cells were seeded in a 6-well plate to achieve sub-confluence followed by 
culture overnight. The mRNA was purified from the cells using Dynabeads®mRNA 
Direct kit (Invitrogen) according to the manufacturer’s specification. Reverse 
transcription reactions were carried out in 0.2 ml PCR tubes, each reaction contained 
the following using Transcriptor cDNA Synthesis kit (Roche): 
• 5x buffer   4 µl 
• dNTP    2 µl 
• Random+OligoDT primers 0.8 µl 
• RNasin    0.4 µl 
• Reverse Transcriptase  0.4 µl 
• mRNA    13 µl 
Reverse Transcription reactions were carried out using a thermocycler block with the 
following protocol 42°C 30 min, 85°C 5 min and 4°C 5 min. The resulting cDNA was 
diluted in 40 µl of dH20 and stored at -20°C until required. 
For qPCR of the cDNA products of A431 cells, reactions were set up and ran as 
described above for the generation of the standard curve. The absolute copy number 
was determined by normalising against reference genes and compared to the Dsg3 
standard curve. 
2.3.7 Mass spectrometry  
The following method provided by Dr Isa Cruz 
SDS-PAGE 
Samples were mixed with 1x SDS loading buffer and, after denatured for 10 min at 
95⁰C, they were loaded onto a precast gel, Mini-Protean TGX Precast Gels, any kD, 10-
well comb, 30 μL/well (Bio-Rad). Electrophoresis was carried out on a Mini-Protean 
Tetra Cell System (Bio-Rad) at 150 V, using 1x Tris-Glycine-SDS running buffer, until the 
dye front had reached the bottom of the gel. Proteins were visualised with silver stain 
(Pierce Silver Stain Kit, Thermo Scientific). 
Native-PAGE 
1x native loading buffer was added to each sample and the mixtures were loaded into 
the wells of a 10% polyacrylamide native gel. Proteins were separated in the absence 
of SDS by native gel electrophoresis at 150 V and visualised with silver stain (Pierce 
Silver Stain Kit, Thermo Scientific). 
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Protein Band Excision and In-gel Trypsin Digestion 
Bands of interest were excised and cut in 1 – 2 mm
3
 gel pieces, which were placed into 
0.6 mL siliconized tubes. Gel pieces were rinsed twice with 190 μL of wash solution 
(50% methanol + 5% acetic acid) at room temperature; the first wash was for 3 h and 
the second overnight. Wash solution was removed and gel pieces were dehydrated in 
190 μL of acetonitrile at room temperature for 5 min. After that, acetonitrile was 
removed from the samples and they were dried in a vacuum centrifuge for 3 min. 
Sample reduction was then performed with 30 μL of 10 mM DTT at room temperature 
for 30 min, followed by alkylation with the same volume of 100 mM iodoacetamide at 
room temperature for another 30 min. Iodoacetamide solution was removed from 
samples and they were dehydrated once again in 190 μL of acetonitrile at room 
temperature for 5 min and dried in a vacuum centrifuge for 3 min. Gel pieces were 
rehydrated in 190 μL of 100 mM ammonium bicarbonate at room temperature for 10 
min. After removing the previous solution, gel pieces were dehydrated in acetonitrile 
and dried in a vacuum centrifuge another time.  
Finally, samples were rehydrated on ice, for 10 min, with 20 μL of trypsin solution (20 
ng/μL sequencing grade modified porcine trypsin (Promega) in 50 mM ice-cold 
ammonium bicarbonate pH 8.0) with occasional vortex mixing. After rehydration, 
samples were spun down for 30 sec and excess trypsin solution was removed. An 
aliquot of 10 μL of 50 mM ammonium bicarbonate solution was added to the gel 
pieces to prevent dehydration and proteins were digested overnight at 37⁰C.  
Peptide Extraction from Gel Pieces 
To begin with, 30 μL of 50 mM ammonium bicarbonate solution were added to the 
digests and, after a 10 min incubation period, supernatant was collected and 
transferred to a new tube. Peptides were firstly extracted from gel pieces with 30 µL of 
extraction buffer I (50% acetonitrile + 5% formic acid), incubation for 10 min and 
supernatant collection. A second extraction was performed with 30 µL of extraction 
buffer II (85% acetonitrile + 5% formic acid) for 10 min, followed by a 30 sec 
centrifugation and supernatant collection. After extraction, the extracts volume was 
reduced to <5 µL by evaporation in a vacuum centrifuge. Finally, the dried extracts 
were redissolved in 0.1% formic acid, sonicated for 10 min, centrifuged for 5 min and 
transferred to mass spec vials.  
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LC-MS/MS Analysis 
LC-MS/MS analysis was performed on a Waters CapLC system coupled to the front end 
of a Waters Micromass Q-ToF Premier. Depending on the intensity of the spot on the 
2-D gel, 1-5 µL were injected per sample. A 63 min gradient LC method was followed: t 
= 0.1 min, 5% B; t = 3 min, 5% B; t = 40 min, 28% B; t = 49 min, 80% B; t = 52min, 80% 
B; t = 53 min, 5% B and t = 63 min, 5% B (A, 5% ACN + 0.1% formic acid (FA); B, 95% 
ACN + 0.1% FA). Initial flow from the CapLC was at 6 µL/min, which was split prior to 
the column so the flow through the column to the mass spectrometer was only 200 
nL/min. Peptides eluted off the column were directly sprayed into the mass 
spectrometer for analysis. The acquisition and processing software used was Waters 
MassLynx Version 4.1. MS was monitored over a m/z range of 400-1700 Da and 
MS/MS was monitored over a m/z range of 50-1700 Da. Capillary was at 1.8 kV, cone 
voltage at 35 V and collision energy at 35 eV. 
MS/MS data were used to perform database searching using an online search engine, 
Mascot, choosing SwissProt databases to look for human proteins (taxonomy - Homo 
sapiens). Searches were performed without restriction of protein molecular mass or pI, 
but with variable modifications such as carbamidomethylation of cysteines and 
oxidation of methionine residues. One trypsin miscleavage was allowed. Peptide and 
fragment mass tolerances were set to ± 0.1 Da. 
2.4 Cellular Biological Methods 
2.4.1 Immunostaining  
Cells were seeded on coverslips to achieve sub-confluence followed by culture 
overnight. Twenty-four hours later, cells were washed twice with PBS and fixed with 
either ice-cold methanol:acetone (1:1) or 3.8% formaldehyde (F-actin) or 4% Para-
formaldehyde (pERM), for 10 min. Cells fixed with formaldehyde or para-formaldehyde 
were permeabilised with 0.1% Triton X-100 for 10 min (F-actin) or 1 min (pERM). Cells 
were washed 3x with PBS before immunostaining or stored in PBS at 4°C for later use.  
For fluorescent staining, coverslips were blocked for 30 min with blocking buffer 
followed by incubation for 1hr at RT with target specific antibody diluted in blocking 
buffer (see Table 2.3). Cells were then washed 3x with IMF washing buffer followed by 
incubation for 1hr at RT with Alexa Flour 488 and 546 conjugated secondary antibodies 
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diluted in blocking buffer (1:100). Cells were then washed 2x with washing buffer 
followed by a 10 min incubation with DAPI (1:1000) for nuclear counter-stain before a 
final wash. Coverslips were then mounted on slides using ProLong®Gold anti-fade 
liquid mount (Invitrogen) and sealed with clear nail varnish. Coverslips were imaged 
using either Leica DM5000 epi-fluorescence microscope, Zeiss 710 LSM confocal 
microscope, Meta 510 LSM confocal microscopes or MM Leica epi-flourescence 
microscope. 
Blocking buffer 
• 10% goat serum in IMF washing 
buffer 
IMF Washing Buffer 
• 0.2% Tween 20 in PBS 
Fixatives 
• General staining: Methanl:Acetone 
(1:1) 
• F-actin and pERM staining: 4% 
Para-formlaldehyde or 3.8% 
formaldehyde 
 
2.4.2 Immunofluorescence image analysis and Acquisition 
Images were acquire using the following microscopes: 
MM-Leica DM4000 microscope fitted with a QIClick Qimaging 12 bit monochrome 1.4 
megapixel camera which contains a Sony IC285 CCD chip for image acquisition. Image 
acquisition software used was Metamorph v7.7.10. Filter cubes used: DAPI Band Pass 
400nM +/- 20nM, FITC - Band Pass 490nM +/- 20nM and Rhodamine - Band Pass 
560nM +/-20nM. Images were acquired using a 20x, 40x oil or 63x oil objective. 
Acquired images were exported as Tiff files 
Leica epi-flouresence DM5000 microscope, fitted with a Leica DFC350Fx 12 bit 
monochrome 1.4 mega pixel camera with a Sony IC285 chip for image acquisition. 
Image acquisition software used was Metamorph v7.7.10. Filter cubes used: DAPI Band 
Pass 400nM +/- 20nM, FITC - Band Pass 490nM +/- 20nM and Rhodamine - Band Pass 
560nM +/-20nM. Images were acquired using a 20x, 40x oil or 63x oil objective. 
Acquired images were exported as Tiff files. 
Zeiss LSM710 Meta confocal microscope fitted with a 2 x Photomultiplier tubest 
(PMTs) 1 Quasar spectral detector 10nm grating step size detection system. Image 
acquisition software used was Zen 2012 Laser lines used: 458nm, 477nm, 488nm, 
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514nm Argon laser lines Images were acquired using a 20x, 40x oil, or 63xoil objective 
lens. Acquired images were exported at LSM files. 
Zeiss LSM710 meta microscope fitted with a 2 x Photomultiplier tubest (PMTs) 1 
Quasar spectral detector 10nm grating step size detection system. Image acquisition 
software used was Zen 2012. Laser lines used: 458nm, 477nm, 488nm, 514nm Argon 
laser lines. Images were acquired using a 20x, 40x oil, or 63xoil objective lens. Acquired 
images were exported at LSM files. 
Nuclear number: Using ImageJ software, channels for each image were split and the 
DAPI channel selected for nuclear number determination. A ‘Threshold’ was set to 
select all nuclei, followed by conversion to a binary format. In some cases during 
thresholding, some background was detected, and this background was removed using 
the processing tools ‘erode’ and ‘despeckle’. The ‘watershed’ tool was then applied to 
split nuclei that are touching. The nuclear number was then determined using the 
‘analysis particles’ tool.  
Cell area: Using ImageJ, channels of each image were split, with the red and green 
channels analysed individually. Once a channel was selected, a ‘threshold’ was set to 
select the area covered by the cells, the same threshold was maintained the analysis of 
all images for that channel for each experiment. Cell area was measured 
(analyse<measure). Total cell area for each field was then divided by the nuclear 
number to generate an average cell area/field. At least three randomly selected fields 
were analysed from each coverslip and presented as mean ± SD in figures. 
Colocalisation analysis: Using WCIF ImageJ, channels for each image were split, only 
the red and green channels were used for analysis. Each channel was converted to a 8-
bit format for the determination of percentage colocalisation (Plug-in>colocalisation 
finder). The percentage colocalisation generated was then divided by the number of 
cells in each field. At least three randomly selected fields from each coverslip were 
analysed. Data presented as the mean percentage colocalisation/field ± SD in figures. 
Various colocalisation co-efficient were also calculated using the WCIF plug-in 
‘Intensity correlation analysis’ (Plugins > colocalisation analysis > Intensity correlation 
analysis). In the same way, channels were split and the red and green channel were 
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analysed. Using the ‘Intensity correlation analysis’ plug-in, Pearson’s correlation 
Coefficient, Mander’s Overlap Coefficient and Intensity Correlation Quotient were 
calculated. At least three randomly selected fields from each coverslip were analysed 
and data presented as average Coefficient value ± SD.  
Integrated density: Using ImageJ, channels for each image were split and the red and 
green channels were analysed. Thresholds for each channel were set individually to 
select positive fluorescence and exclude the background before the integrated density 
was measured (Analyse>measure). The same threshold was applied to all images 
across different samples for each channel. All integrated density were normalised by 
the cell count per field determined from the nuclear count (see above) to yield 
integrated density per cell. A minimum of 3 field per cover slip were analysed in this 
way to yield an average integrated density per cell line. In figures Integrated density 
per cell is referred to as ‘integrated density’. Integrated density as a function of target 
protein expression is expressed as either average fold change relative to the vector 
control or scrambled ct levels set at 1 arbitrary unit (data displayed as Mean fold 
change ± SD with respect to the controls); or relative integrated density where the 
average integrated density per cell line is presented (data displayed as integrated 
density / cell ± SD). 
Staining Profiles  
For staining profiles of Dsg3, Ezrin, Radixin, Moesin, images were analysed using 
ImageJ. Here a bisecting line of defined width (20) was used, as illustrated in Figure 
2.2A. Once in place the profile of fluorescent staining along the line was plot 
(Analyze>Plot profile) to generate a histogram similar to that in Figure 2.2B. The plot 
values as shown in Figure 2.2C were obtained, copied and exported to an Excel 
spreadsheet where the profiles of >70 cells were collated. Data are presented as the 
mean Grey value ± SD. 
For the analysis of nuclear staining profiles of cJun, the same approach was used as 
described above, except the bisecting line was reduced in width (10) and limited to the 
nucleus only. Data are presented as the mean Grey value ±SD 
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Figure 2.2. Analysis of individual cell staining profile. (A) A selected cell bisected with a line  
with 20 (arbitrary unit ) in width. (B) Plot of immunofluorescence profile of the bisecting line in 
(A). (C)  The actual values of the plot then can be exported to Excel for further analysis.  
2.4.4 Analysis of Triton soluble and insoluble protein 
Cells were seeded on coverslips to achieve sub-confluence following overnight 
incubation. Twenty-four h later cells were incubated with 0.1% Triton buffer or PBS as 
a control, for 6 min. Cells were then washed 3x with ice cold PBS and fixed with 3.8% 
PFA on ice. Cells were finally stained as described in Part 2.4.1, and images were 
acquired and analysed using ImageJ to determine integrated density. 
2.4.5 FRET (Fluorescent Resonance Energy Transfer) by acceptor photo-bleaching  
FRET occurs on the principle that, between a FRET pair (donor and acceptor), the 
excitation energy of the donor is transferred to the acceptor without the emission of a 
photon in close proximity. Therefore positive FRET occurs when the excitation 
wavelength of the donor results in the fluorescence of the acceptor molecule alone. 
Assessment of FRET by acceptor photo-bleaching is one of various methods of 
detecting FRET. Here, photo-bleaching of the acceptor molecule inhibits its ability to 
be excited, resulting in the un-quenching of the donor. Experimentally this will be 
observed as an increase in donor fluorescence. Cells were seeded on coverslips to 
achieve sub-confluence following overnight culture. Cells were fixed (ice cold 
Methanol:Acetone) and labelled with primary antibodies specific to Dsg3 (5H10) and 






90 | P a g e  
analysis were mouse and rabbit IgGs conjugated with Alexa Flour 488 and 555 at 
dilutions of 1:100. Cells were examined using the 63x oil immersion objective. FRET 
was assessed using acceptor photo-bleaching approach according to A. K Kenworthy 
(Kenworthy, 2001). Briefly, cellular regions were selected and photo-bleached using a 
pre-tested protocol saved in the 710 LSM confocal microscope to achieve a ~60% 
reduction in fluorescence in the acceptor channel (Ezrin-A555). As a negative control, 
an intracellular region was collected and photo-bleached in each field. In addition, a 
peripheral region without photo-bleaching was collected for the calculation of photo-
damage in each field. The fluorescence intensities for both channels from 89 selected 
regions were recorded and saved for later analysis. The FRET efficiency for Dsg3-A488 
channel was calculated in an Excel spreadsheet as the percentage increase of donor 
fluorescence, with photo-damage to be taken into account, after photo-bleaching of 
the acceptor (Ezrin-A555) by the following formula (Tsang, et al., 2010): 
 !"# = %(&'()*)+,)-./#	 + 1ℎ3	45657))(&'()*)+,)	-!") 8 − 1 × 100 
Regions with FRET efficiency greater than 5% (threshold) were considered to be 
positive and are presented as mean±SD in Chapter 5.  
2.4.6 Proximity ligation Assay (PLA) 
The proximity ligation assay allows the detection of molecular interaction within 10 
nm. As illustrated in Figure 2.3A, two target molecules are identified with primary 
antibodies raised in different species, for example, rabbit and mouse. Proximity 
ligation probes, anti-mouse and anti-rabbit are then added, which have conjugated 
oligonucleotides (Figure 2.3B). Upon addition of ligase, ligation of the oligonucleotides 
conjugates will only occur when the complementary proximity probes are within 10-40 
nm distance (Figure 2.3C). Successful ligation provides a circular template. Upon the 
addition of polymerase and nucleotides rolling-circle amplification (RSA) occurs to 
generate a concatemeric product, which is detected by the addition of labelled 
oligonucleatides which hybridise to the RSA product (Figure 2.3D). The subsequent 
interactions can be identified, by fluorescent microscopy, as a single signal or ‘blob’. In 
preparation, cells were seeded onto glass coverslips to achieve sub-confluence 
following by overnight incubation. Cells were then fixed with ice cold 
Methanol:Acetone as described previously. The PLA assay was carried out in 
91 | P a g e  
Figure 2.3. Proximity Ligation Assay. (A) Target proteins identified by primary antibodies. (B) 
Proximity Ligation probes conjugated with complimentary oligonuleotides detect the primary 
antibodies. (C) Only when the probes are within 10-40nm will the ligation of oligo conjugates 
take place to form a closed circle template. (D) The addition of polymerase and nucleotides 
allows rolling circle amplification to occur, the product of which is detected as the fluorescence 
labelled oligonucleotides.  
accordance to the guidelines provided by Olink (Cambridge Bioscience) using blocking 
buffers, antibody diluents, antibody concentrations and incubation periods optimal for 
the primary antibodies used in fluorescence microscopy. Images were obtained using 
Zeiss 710 LSM confocal microscope. Image analysis was carried out using ImageJ to 
determine average dots per cell (Analyse>Analyse Particles) and presented as mean 
dots/cell±SD.  
2.4.7 Human Phospho-Kinase Array 
A431-Vect Ct and –D3 cells were seeded to achieve sub-confluence in 10cm tissue 
culture plates and allowed to propagate for 5 hours. Total cell lysates were then 
harvested and 500 μg protein was analysed immediately with R&D Proteome Profiler
TM
 
Array according to the manufacturer’s specifications. In parallel, A431-D3 cells with 
Dsg3 knockdown were also examined. The dot blots generated from the array 
displayed 46 kinases, each in duplicate. The density of each spot was determined using 
ImageJ. Values for each kinase were averaged and then background subtracted. 
Finally, the Log2 ratio of Vect Ct:D3 was calculated (see below) which allows for the 
identification of 2 fold variations in kinase phosphorylation in the Dsg3 overexpressing 
and knockdown cells with respect to their matched control. 
A B
C D
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2.5 Functional assays 
2.5.1 Scratch assay  
Scratch assay: manual 
Cells were seeded in a 6-well tissue culture plate to achieve a confluent monolayer 
following incubation overnight. Normal growth media was then replaced with growth 
media supplemented with Mitomycin C (4ug/ml) to inhibit cell proliferation and 
incubated for a further 4 h. The confluent monolayer was washed with PBS and 
scratched in a standardised manor using a P200 pipette tip to create a cell-free zone 
(wound) approximately 3 mm in width. Cells were washed further with PBS to remove 
any floating cells and cellular debris before addition of fresh growth media 
supplemented with Mitomycin C for the duration of the experiment. Images were 
acquired at various time points using the Nikon Eclipse TE2000-S inverted microscope. 
Cell migration was assessed by determining percentage wound closure of the cell-free 




Cell migration was further assessed by scratch-wound assay using IncuCyte™, a Kinetic 
Imaging System (Essen BioScience Inc., MI, USA). Here cells were seeded into 96 well 
image-lock plates in duplicate (Essen BioScience Inc., MI, USA) at 80% confluence to 
achieve a confluent cell monolayer after 24 hours. The cell-free zone (wound) was then 
created using the 96-well Woundmaker
TM
 (Essen BioScience Inc., MI, USA). Cells were 
washed 3 times with PBS to remove any cellular debris followed by the addition of 100 
µl growth media. Finally, the image lock plates were loaded into the IncuCyte
TM
 which 
was programmed to acquire an image from each well every 15 minutes for a time 
period of 28 hours. The data was analysed using the Relative Wound Density (RWD) 
metrics which is part of the IncuCyte software package, requiring the area of the 
wound and the cellular monolayer at either side of the wound at time zero to be 
defined. Based on these parameters the software determined RWD by measuring the  
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Figure 2.4. Transwell migration assay. A simplified schematic of the transwell migration assay. 
As depicted, cell line of interest, suspended in αMEM supplemented with 1% BSA, is added 
into the transwell insert. The medium containing 10% FCS in the bottom chember acts as a 
chemottractant. Cells are migrating through the porous membrane of the insert into the 
bottom chamber. After 24-48 hours, the number of cells that have migrated into the bottom 
chamber are counted 
spatial cell density in the wound area relative to the spatial cell density outside of the 
wound at every time point. Finally, the RWD of each duplicate was averaged and 
presented as Mean RWD. 
2.5.2 Transwell migration and invasion assay 
Transwell assays were conducted using 24-well transwell inserts with an 8 μm pore 
size permeable membrane (VWR international Ltd). As illustrated in Figure 2.4, 1x10
5
 
cells suspended in alphaMEM supplemented with 1% bovine serum albumin (BSA) 
were aliquoted into the insert and allowed to settle for 1 hour before the addition of 
500 μl of alphaMEM supplemented with 10% FCS for A431 cells or KGM supplemented 
with 10% FCS for SqCC/Y1 cells into the bottom chamber of each well. Plates were 
incubated for 24-48 hours to allow cells to migrate through the membrane of the 
insert. The number of migrated cells was determined using the CASY cell counter 
(ROCHE Innovastis). For transwell invasion assay, transwell inserts were coated with a 
thin layer (75 μl) of Matigel diluted in DMEM (1:3) which was allowed to gel for 2 h 
before the addition of cell suspensions as described above. For A431 cells, Matrigel 
was diluted 1:3 in DMEM supplemented with fibronectin (10 μg/ml).  
Cell line of interest (1x105) 
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Figure 2.5. Organotypic raft culture. Collagen:Matigel gels with the embedded primary 
fibroblasts and cell line of interest plated on top were prepared 24 hours before being lifted on 
a raft and grown at the air:liquid interface for 14 days before fixation for histological analysis.  
2.5.3 Organotypic raft culture  
Culture preparation 
Matrigel: Collagen gels for organotypic cultures were prepared as described by 
Thomas, et al., (Thomas, et al., 2001). Briefly, Collagen type 1 (4 mg/ml, Upstate), 
Matrigel (BD), 10x DMEM (Gibco), FCS and primary fibroblast (Isolated from human 
forskin) suspension in DMEM+10% FCS at 5x10
5
/ml were mixed at a ratio of 
3.5:3.5:1:1:1 on ice. One ml aliquots of this solution were added into wells of a 24-well 
plate and allowed to gel for 30min at 37°C. Once polymerised 1 ml of DMEM plus 10% 
FCS was added to each well and gels were allowed to equilibrate overnight at 37°C. For 
the preparation of nylon discs, sterile nylon discs (100 µM pore size, Tetko Inc) were 
coated with collagen gel mixed with the above solution without Matrigel and 
fibroblasts and incubated for 15 min at 37°C followed by fixation in 1% Glutaraldehyde 
for 1 h at 4°C. The fixed discs were then washed 3x in PBS and 2x in KGM and stored in 
DMEM+10% FCS at 4°C until needed. The following day media was aspirated in wells 
containing the Matrigel: collagen gels and replaced with 5x10
5
 SqCC/Y1-Vect Ct or 
SqCC/Y1-D3 cells suspended in KGM plus 10% FCS and allowed to propagate for 24 h. 
The next day each gel with SqCC/Y1 cells was removed from the 24-well plate and 
placed on an individual collagen-coated nylon disc. The gel:disc composite was then 






Cell line of interest
Liquid: Air 
interface
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well to reach the under-surface of the grid and epithelial monolayers were allowed to 
grow at the air:liquid interface (Figure 2.5). This point was defined as day 1. The 
cultures were incubated at 37°C for 14 days with media changed every 2 days. Steel 
grids were formed from 2.5cm
2 
stainless steel mesh with its edges bent down to form 
4-5 mm legs. Gels were harvested and fixed at day 14 by submerging in Trumps fixative 
(4% formaldehyde, 1% glutaraldehyde in phosphate buffer, pH adjusted to 7.2) 
overnight. Specimens were then bisected and embedded in paraffin wax for sectioning 
(5 µM). Sections were then stained with Haematoxylin and Eosin for the determination 
of the Invasion index or immunochemically stained with the mycTag specific antibody 
as described below.  
Staining of organotypic specimens. 
To confirm the overexpression of exogenous hDsg3.myc, sections were subjected to 
routine procedures for histology. Briefly; sections were de-waxed in xylene and 
brought to absolute alcohol. Antigen retrieval was achieved using ARS for 20 min at 
37°C. The detection of exogenous Dsg3 was achieved using rabbit mycTag antibody 
(Cell signalling) in conjunction with Dako cytomation EnVision+Dual Link System-HRP. 
Sections were counter stained in Mayer’s Haematoxylin. Images were acquired in a 
MBF stereology system (MBF Bioscience, USA).  
For Haematoxylin and Eosin staining, sections were de-waxed, rehydrated and placed 
in Ehrlichs Haematoxylin for 45-60 min. Sections were then rinsed in tap water for 30 s. 
Sections where examined at this stage and de-stained in 1% HCl in 70% alcohol as 
necessary to achieve good contrast. Once achieved, they were washed in tap water. 
Section were then dehydrated and counter stained with Eosin, dehydrated again 
before treatment with histoclear for 2 min before mounting. Images were acquired in 
a MBF stereology system (MBF Bioscience, USA). 
Analysis of Organotypic cultures: Invasion index 
Images were analysed using ImageJ as described previously (Thomas, et al., 2001). 
Briefly, images were converted to grey scale (8-bit). Using the threshold the positive 
stained areas were defined and converted into a binary image which rendered the 
stained area as saturated red pixels and the unstained, back pixels. This binary image 
was then subjected to two ‘Despeckle’ procedures to remove small artefacts. The 
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invasion distance, number of particles (invaded clusters), average size of particles and 
sum of the area of particles were then calculated using the ‘analyse particles’ tool. The 
invasion index was then calculated by the formula shown below: 
@+5*<+	<+4)A = @+5*<+	4)13ℎ × +'6B)(	&	15(3<,)* × 5()5	&	15(3,)* 
 
ARS (Antigen Retrieval solution) 
• 0.1% α-chmotrypsin 
• 0.1% calcium chloride 
In water, pH adjusted to 7.8. 
 
FGM (Fibroblast Growth media) 
DEMEM supplemented with 10% FCS and 
Glutamine. 
KGM (Keratinocyte Growth Media 
• DMEM:F12: 3:1 
• 0.4% µg/ml hydrocortisone 
• 10 ng/ml EGF 
• 10% FCS 
• 5 µg/ml insulin 
TBS 
• 50 mM Tris-Cl buffer, pH 7.5  
• 15 mM Sodium Chloride 
 
Trumps fixative 
• 100 nM NaH2PO4 
• 67.5 mM NaOH 
• 4% formaldehyde 
• 1% Gluteraldehyde 
 
2.7 Statistical analysis 
2.7.1 Descriptive statistics 
The mean of each test group i.e. A431-Vect Ct, -D3, -C7 and –C11  was determined for 
each repetition of an experiment and presented as the Mean ±Standard deviation (SD), 
to give an indication of the variation of the data. Where possible, comparison between 
control and test groups was normalised against the control and expressed as a fold 
change±SD relative to the control. 
 C)5+	(DE) = (F	G	FHG	……..FJ)K 	 
 /35+45(4	4)<53<+	(/) = 	√∑(FNF)EEEEHK  
2.7.2 Inferential statistics 
The statistical significance of differences between test samples and controls was 
achieved using the unpaired, 2 tail student’s t-Test, as data was assumed to be 
normally distributed and that the overexpression of Dsg3 had neither a positive or 
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negative effect on the parameters being tested. The student’s t-Test was calculated 
using the formula in Excel for a 2 tailed test on 2 samples of equal variance. P values 
less than 0.05 were considered statistically significant, i.e. * p<0.05, ** p<0.01, and *** 
p<0.001. 
2.6 Antibodies 
Table 2.3 Antibody used for Western blot analysis and immunofluorescence microscopy. 






Dsg3 5H10  
(Sc-
23912) 
 mouse Santa Cruz 1:1000 1:100 
Dsg3 H145  rabbit Santa Cruz 1:1000 1:100 





pERM  rabbit Cell signalling 1:1000 1:500 
Ezrin 3145 pAb rabbit Cell signalling 1:1000 1:100 
Radixin   mouse  1:1000 1:100 
Moesin  
(aa554-564) 
    1:1000 1:100 
CD44   mouse  1:1000 1:100 
beta Actin-loading 
control 








mouse Santa Cruz 1:1000 1:100 
Myc-Tag 71D10 mAb rabbit Cell signalling 1:1000 1:50 
Dsg2 G129 mAB mouse Progen 1:50 N/A 
Dsg1 P-124 mAB mouse Progen   
GAPDH 14c10 mAb rabbit Cell signalling 1:1000 N/A 
Tubulin Ab7291  mouse Abcam 1:1000 N/A 
cJun  mAb rabbit Cell signalling 1:1000 1:100 
Phosph-c-Jun 
(S73) 
 mAb rabbit Cell signalling 1:1000 1:100 
Phosph-c-Jun 
(Ser63) 
54B3 mAb rabbit Cell signalling 1:1000 1:100 
Phospho-p38 
MAPK 
28B10 mAb mouse Cell signalling 1:1000 1:100 
Phospho-PKC 
(pan) (βII Ser660) 
9317 pAb rabbit Cell signalling 1:1000 1:100 
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Table 2.3 continued… 








  goat Invitrogen N/A 1:100 
Anti-mouse 
Alexa Fluor®488 
  goat Invitrogen N/A 1:100 
Anti-rabbit 
Alexa Fluor®568 
  goat Invitrogen N/A 1:100 
Anti-mouse 
Alexa Fluor®568 














































































Chapter 3: Overexpression of full 
length human 
Desmoglein 3 in the A431 
epidermoid cancer cell 
line. 
3.1 Introduction 
Previous studies have used one or a combination of models, including primary tumour 
cells, cancer cell lines, stable knockdown cells, xenograft and allograft models and 
transgenic mice (Baron, et al., 2012, Chen, et al., 2013, Merritt, et al., 2002) to examine 
the functions of Dsg3 in the epidermis, the autoimmune disease PV and cancer. As 
animal work was not possible for this project, an in vitro cancer cell model was 
employed, using the epidermoid A431 cell line overexpressing full length human Dsg3. 
Using this approach, this study is the first of its kind to adopt a gain-of–function 
approach to examine the role of Dsg3 in cancer cell biology. 
There are a multitude of in vitro methods that can be adopted to examine protein 
function. In principle, they fall into two categories: 1) a gain-of-function approach 
achieved through the overexpression of target gene(s) or through the constitutive 
activation of the protein of interest through a gain of function mutation; 2) a loss-of-
function approach achieved through protein silencing by RNAi or the expression of 
dominant negative protein to reduce or abolish protein function. All these methods 
have their advantages and disadvantages as the manipulation of cellular genetic 
material, protein structure and expression may have biological effects not directly 
pertaining to the protein of interest resulting in misleading observations. By using a 
100 | P a g e  
combination of techniques one can compensate for some of the limitations of a single 
model for the examination of protein function. 
This chapter aims to characterise exogenous protein expression in the A431 
epidermoid cancer cell model, with both gain- and loss-of-Dsg3 function. Employing 
both qualitative and quantitative techniques, verification analyses of this model 
system was essential for the later functional and molecular study of Dsg3 in tumour 
cell biology, including migration and invasion, morphological changes and the 
mechanistic investigations. 
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3.2 Results 
3.2.1 Stable overexpression of full length human Dsg3 in A431 cancer cell line 
In order to examine protein function, stable overexpression is a common practice. In 
this study, full length human Dsg3 with mycTag (hDsg3.myc) was transduced into the 
A431 cancer cell line. The hDsg3.myc construct was generated, for the first time, by Dr 
Hong Wan at the Institute of Dentistry, QMUL in 2007, providing a unique tool to study 
the function of Dsg3 (Tsang, et al., 2010).  
As illustrated in Figure 3.1, the hDsg3.myc construct was cloned into the pBABE 
retroviral vector containing a puromycin resistant gene to facilitate selection of 
positively transduced cells. The vulva carcinoma cell line A431 and oral carcinoma cell 
line SqCC/Y1 were transduced with pBABE-hDsg3.myc alongside the empty vector 
which served as a control (pBABE-Vect Ct). Cells were infected with retroviral 
conditioned media for 48 h followed by selection for 2 weeks in growth media 
containing puromycin. From this point onwards, transduced A431 and SqCC/Y1 cell 
lines expressing hDsg3.myc or empty Vector will be followed by the suffix -D3 or -Vect 
Ct, respectively. 
To characterise the expression and localisation of exogenous hDsg3.myc, several 
methods were employed. Firstly, Western blot of total cell lysates from A431-D3 and -
Vect Ct cells seeded at 50-60% confluence for 24 h were probed with Dsg3 specific 
antibody, 5H10, which recognises an extracellular epitope located within the EC1-EC2 
domains of Dsg3 (Proby, et al., 2000) .As illustrated in Figure 3.2A, the expression of 
exogenous hDsg3.myc construct in A431 cells resulted in a significant increase (~4-fold) 
in Dsg3 expression compared to endogenous Dsg3 in Vect Ct cells. Secondly, to 
determine the localisation of exogenous Dsg3, fluorescence microscopy of A431 cells 
was performed. In preparation, cells were cultured on coverslips to achieve 50-60% 
confluence following overnight culture. The following day cells were fixed and 
immunostained for Dsg3 using 5H10, H145, which recognises a intracellular C-terminal 
epitope of Dsg3 (Lee, et al., 2009), and mycTag specific antibodies. As shown in Figure 
3.2B, there is a noteworthy increase in Dsg3 and mycTag staining in A431-D3 cells 
compared to Vect Ct cells. Quantitation of 5H10 staining alone demonstrated a ~15-
fold increase in Dsg3 expression compared to the Vect Ct (Figure 3.2C). With regard to 
protein localisation, Figures 3.2A & B clearly show that the increased Dsg3 staining was 
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Figure 3.1 Full length human Dsg3 construct in pBABE-puro retroviral vector. Simplified 
schematic of full length human Dsg3 with mycTag (hDsg3.myc) construct cloned into the 
pBABE-puro retroviral vector. pBABE-puro vector contain 2 markers, i.e. the Ampicillin 
resistance gene that allows the selection of transformed bacteria, and the Puromycin gene for 
the selection of positively transduced cells.  
predominately concentrated at the cell borders and cell-cell contacts as expected. 
Together, the data confirmed the overexpression of exogenous Dsg3 in A431-D3 cells. 
Furthermore, these results also demonstrate that the commercially available human 
Dsg3 antibodies, 5H10 and H145, recognise the hDsg3.myc construct. Finally, the 
exogenous Dsg3 appears to be functioning normally due to its expression and 
subsequent localisation at the plasma membrane alongside endogenous Dsg3. 
3.2.2 Sub-cloning of A431-D3 cells. 
The transduction of full length human Dsg3 into A431 cells generated a mixed 
population of cells (polyclonal) with a wide range of exogenous Dsg3 expression levels. 
In order to demonstrate a dose-dependent response of phenotypes observed, the 
variation of Dsg3 expression of polyclonal A431-D3 cells was used to an advantage. 
Sub-cloning of A431-D3 cells was performed by limited dilution assay (courtesy of Dr 
Tsang) to yield a panel of individual clones expressing high or low Dsg3 expression. This 
procedure should theoretically yield clones which display uniform Dsg3 expression 
compared to A431-D3 cells. Florescence microscopy illustrated in Figure 3.3B (n=5) 
demonstrates the high Dsg3 expression of A431-C7 clone and low expression of A431- 
FL Dsg3.myc
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Figure 3.2 Stable overexpression of full length human Dsg3 in A431 cells. (A) To assess the 
expression of the hDsg3.myc  construct in A431 cells, Western blot of total cell lysates of A431-
D3 and Vect Ct cells was performed with the mouse monoclonal antibody 5H10 (n=9). Blot 
densitometry: normalised against GAPDH and relative Vect control level set at 1 arbitrary unit. 
Dotted line indicates where parts of the same blot, of either the same or different exposure, 
was joined together. (B) Fluorescence micrographs of A431-D3 and Vect Ct cells stained with 
the Dsg3 antibodies, 5H10 (extracellular epitope) and H145 (intracellular epitope) as well as 
the mycTag specific antibody. Increased Dsg3 expression was readily observed in D3 cells 
compared to Vect Ct. (C) Quantitation of 5H10 staining in A431-D3 and Vect Ct cells (n=10, 
***P<0.001). Scale bar 30 μm.  
C11 clone. Western blot analysis (n=7) demonstrated a ~4-fold increase in A431-D3 
and C7 band density compared to that of Vect Ct and C11 cells (Figure 3.3A). In 
support, analysis using absolute quantative Reverse Transcription PCR (n=2) 
demonstrates a ~20- and ~30-fold increase in Dsg3 mRNA transcription in A431-D3 and 
C7, respectively, compared to Vect Ct and C11 cells (Figure 3.3C). For the absolute 
quantification of Dsg3 mRNA using real-time RT-qPCR as a means of assessing Dsg3 
transcription, mRNA was extracted from A431 -Vect Ct, -D3,- C7 and -C11 cells seeded 
at ~50-60% confluence 24 h prior to extraction. cDNA was generated by reverse 
transcription reactions from the mRNA transcripts recovered. The cDNA samples 
provided the template for real time qPCR reactions for target genes alongside the 
reference genes POLR1 and YAP1. The absolute Dsg3 mRNA copy number was 
determined by normalising against the reference genes followed by comparison to a 
Dsg3 standard curve. Both Western blot and fluorescence microscopy was performed 
and analysed as described above. 
In summary, the data shows the significantly high expression of exogenous Dsg3 in 
A431-D3 and -C7 cells compared to Vector Ct and C11 cells, of both transcriptional and 
translational levels. 
3.2.3 Overexpression of Dsg3 does not appear to affect Dsg1 or Dsg2 expression.  
There are seven desmosomal cadherins identified in man, Dsg 1-4 and Dsc 1-3, which 
share a common function in the mediation of cell-cell adhesion within desmosomes. As 
a result, a degree of functional redundancy amidst this group of cadherins has been 
proposed (Brennan, et al., 2010). However studies have highlighted some specific 
characteristics and functions among desmosomal cadherin isoforms (Garrod, et al., 
2002, Ishii, 2003). Desmosomal cadherin isoforms have been shown to adopt cell type 
and differentiation-specific expression patterns within stratified epithelia with Dsg3  
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Figure 3.3 Desmoglein 3 expression in A431-D3 clones. (A) Western blot of A431-Vect Ct, D3, 
C7 and C11 cells with high or low Dsg3 levels, probed with Dsg3 specific antibody 5H10. Bar 
chart on the right shows fold change in blot band density (n=7, mean ± SD,). Dotted line 
indicates where parts of the same blot, of either the same or different exposure, was joined 
together (B) Fluorescence microscopy of four cell lines shown in (A) stained with 5H10. Bar 
chart shows fold change in immunofluorescent staining (n=5, mean ± SD) Scale bar 20 μm. (C) 
Relative Dsg3 mRNA copy number in A431-Vect Ct, D3, C7 and C11 lines as determined by 
qPCR (n=2, ***p<0.001, **p<0.01). Blot densitometry: normalised against GAPDH and relative 
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Figure 3.4 Overexpression of Dsg3 does not appear to affect Dsg1 or Dsg2 expression. 
Western blotting analysis of total cell lysates of A431-Vect Ct, D3, C7 and C11 lines for Dsg1, 
Dsg2 and Dsg3 (n=2). There appears to be no significant affect on Dsg1 and Dsg2 expression in 
response to Dsg3 overexpression. Dotted line indicates where parts of the same blot, of either 
the same or different exposure, was joined together.  
being highly expressed in proliferating epidermal layers of the basal and immediate 
supra-basal layers of the epidermis while Dsg1 is expressed in the upper layers of the 
epidermis and considered an effective marker for keratinocyte differentiation (Amagai, 
et al., 1996, Arnemann, et al., 1993, Szegedi, et al., 2009). It has been suggested that 
these expression patterns are the consequence of PKC induced terminal differentiation 
of keratinocytes (Szegedi, et al., 2009). One such study carried out by Elias et al 
demonstrated that by altering the Dsg3 expression profile in the epidermis to 
resembling that of the oral mucosa, i.e. uniform expression of Dsg3 across the 
epithelium, resulted in histological and phenotypic characteristics consistent with the 
oral mucosa (Elias, et al., 2001). Similarly, overexpression of Dsg3 in the suprabasal 
layers of the epidermis in transgenic mice elicited hyper-proliferation and abnormal 
differentiation (Merritt, et al., 2002). Studies examining PV pathogenesis and the 
compensation hypothesis propose that Dsg1 is able to compensate for the loss of Dsg3 
adhesion and visa-versa (Brennan, et al., 2010, Mahoney, et al., 1999). In summary, 
these reports suggest that desmosomal cadherins confer cooperative and  
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Figure 3.5 Transient overexpression of Dsg3 in A431 parental cells. (A) Fluorescence 
microscopy of A431 parental cells transiently transfected with empty vector (pBABE-puro) or 
hDsg3.myc construct and immunostained with the Dsg3 antibody, 5H10. (B) Quantitation of 
Dsg3 staining in (A) (n=2), Scale bar, 30 μm. Blot densitometry: normalised against GAPDH and 
relative Vect control level set at 1 arbitrary unit (C) Western blot of A431 parental cells 
transiently transfected with hDsg3.myc or empty vector (pBABE-puro) construct. Blots were 
probed with the Dsg3 antibody, 5H10, and GAPDH as a loading control. Dotted line indicates 
where parts of the same blot, of either the same or different exposure, was joined together.  
compensatory functions in epithelial cells as well as isoforms specific functions. As a 
result an important question was to determine whether the overexpression of 
exogenous Dsg3 affects the expression of other desmosomal cadherins, especially 
Dsg1 and Dsg2. To address this question, Western blot of total cell lysates of A431 cell 
lines was performed as described previously with the anti-Dsg1, Dsg2 and anti-Dsg3 
specific antibodies. As illustrated in Figure 3.4, the overexpression of Dsg3 appeared to 
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3.2.4 Transient overexpression of Dsg3 in A431 parental cells 
While retroviral transduction of hDsg3.myc into A431 cancer cell lines is a cost 
effective means of studying protein function, the random integration of the construct 
into the host genome may elicit effects not attributed to Dsg3 overexpression. As a 
result, transient transfection of hDsg3.myc was also carried out to substantiate some 
observations made using stable overexpression cell lines. To access the transient 
overexpression of Dsg3 various techniques, as described above, were employed. In 
preparation, A431 parental cells were seeded at ~30% confluence 24 h prior to 
transient transfection with hDsg3.myc and empty vector cDNA. The following day cells 
were re-seeded at the desired cell density for assay 48 h after transfection. As 
illustrated in Figure 3.5, the transient overexpression of full length Dsg3 in parental 
A431 cells resulted in a ~2-fold increase in Dsg3 expression, assessed by Western blot 
(Figure 3.5C). This observation was supported by fluorescence microscopy that 
demonstrated a significant increase (~2 fold) in Dsg3 staining compared to cells 
transfected with Vect Ct (Figure 3.5A, B). 
3.2.5 Transient knockdown of Dsg3 in A431-D3 cells. 
In order to verify the observations from stable and/or transient Dsg3 overexpression, 
loss-of-function experiments were also performed by transient siRNA transfection. It 
was expected that Dsg3 knockdown in A431-D3 cells would restore the phenotypes 
similar to that of Vect Ct cells. Knockdown studies were carried out on A431-D3 or -C7 
cells and compared to cells transiently transfected with scrambled Ct siRNA. In 
preparation, cells were seeded at 30% confluence the day before transfection with 
Dsg3 specific and scrambled siRNA. The following day cells were harvested and re-
seeded at the desired cell density for assay to be carried out 72 h after initial seeding. 
As illustrated in Figure 3.6, Western blot analysis showed a 5-fold reduction in Dsg3 
band density in knockdown cells compared to control cells (Figure 3.6B). This 
observation was further supported by florescence microscopy analysis which showed a 
significant reduction in Dsg3 staining in A431-D3 cells treated with Dsg3 specific siRNA 
compared to those treated with scrambled control siRNA (Figure 3.6A). 
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Figure 3.6 siRNA mediated Dsg3 silencing in A431-D3 cells. (A) Fluorescence micrographs of 
A431-D3 cells transiently transfected with either Dsg3 specific or scrambled control siRNA for 2 
days. Quantitation on the right shows mean fold change of the Dsg3 staining (n=2, mean ± SD, 
**P<0.01). Scale bar, 10 μm. (B) Western blot of total lysates of A431-Vect Ct and D3 cells 
transfected with either Dsg3 specific (Kd) or scrambled control (Scram) siRNA. Right: 
quantitation of A431-D3 cells shows mean fold change in band density. Blot densitometry: 
normalised against αTubulin and relative Vect control level set at 1 arbitrary unit (n=3, mean ± 
SD, *P<0.05). Dotted line indicates where parts of the same blot, of either the same or 
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3.3 Discussion 
This chapter demonstrates the successful stable and transient overexpression of full 
length human Dsg3 in A431 epidermoid cancer cell line and efficient siRNA mediated 
Dsg3 silencing. Both overexpression and silencing elicited a detectable and significant 
increase and decrease in Dsg3 expression by Western blot and immunofluorescent 
microscopy using commercially available Dsg3-specific antibodies. The overexpression 
of Dsg3 does not appear to provoke a response from Dsg1 and Dsg2 compared to the 
vector control. However known positive controls of Dsg1 and Dsg2 expression such as 
F9 and A-375 cell lysates where not incorporated into this study. As a result it is not 
clear from the Western blots which bands are Dsg1 and Dsg2 specific. The inclusion of 
such positive controls would validate the apparent observation reported here. Finally, 
exogenous Dsg3 appears to be functioning normally due to its correct localisation at 
the plasma membrane alongside endogenous Dsg3.  
Both the loss- and gain- of-function approaches validated in this chapter provide the 
basis of the investigations described in subsequent chapters, the aim of which is to 
characterise the additional functions of Dsg3 and elucidate possible signalling 
mechanisms employed to achieve these functions. It is worth noting that a majority of 
this study utilises stable Dsg3 overexpression, with transient overexpression and 
knockdown models used to complement data where necessary.  
Due to the random or quasi-random incorporation of full length human Dsg3 into the 
host genome by retroviral transduction, it would be naïve to assume that all 
observations were specific to Dsg3 as some could be due to transgene incorporation 
affecting normal cell behaviours. To substantiate interesting findings and ensure that 
observations were specific to Dsg3 overexpression additional steps were taken. Firstly, 
the study was expanded to include stable monoclonal cell lines with high and low Dsg3 
expression, A431-C7 and A431-C11 respectively, alongside the mixed cloned A431-D3 
and -Vect Ct cells. Secondly, transient overexpression was used in parental A431 cells 
and finally, Dsg3 silencing mediated by RNAi. By using a combination of approaches 
the limitation of any one techniques are superseded by advantages of others allowing, 
with a high degree of certainty to substantiate findings and form valid conclusions. 
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The overexpression of Dsg3 using transient transfection was not as efficient as the 
transduction in A431 cells only achieving a 2-fold increase, compared to the 5-fold 
increase in stable cell lines (Figure 3.4-5). The reduced overexpression of Dsg3 as a 
result of transient transfection was most likely attributed to the cell system since 
greater expression was observed by colleagues in COS-1 cells. Further optimisation or 
an alternative transfection method could be examined for future work to improve 
transfection efficiency, such as lipid mediated transfection, magnet mediated 
transfection and electroporation. 
It has been reported that Dsg3 deficiency in Dsg3-/- mice results in compensation by 
Dsg1 and Dsg2 (Baron, et al., 2012) in the Urea soluble fraction or DSM associated 
cadherins. Furthermore Dsg2 has been shown to compensate for the loss of Dsg1-
mediated cell adhesion in PF (Brennan, et al., 2010) suggesting that Dsg1 and Dsg2 
may compensate for the loss of Dsg3 expression and function within desmosomes 
most likely in an adhesive capacity. My results suggest that the overexpression of Dsg3 
has no effect on the expression of Dsg1 and Dsg2. It is possible that the overexpression 
of Dsg3 does not elicit an expressional response from other desmosomal cadherins as 
there is not a biological need or deficit that requires compensation. The effect of Dsg3 
silencing on Dsg1 and Dsg2 expression was not evaluated in this study however, if I 
were to speculate, I believe the knockdown of Dsg3 in A431-D3 cells would have no 
effect on Dsg1 and Dsg2 expression since Dsg3 silencing would bring Dsg3 expression 
to basal levels of expression that would not require Dsg1 and Dsg2 compensation. It is 
also possible that Dsg1 and Dsg2 may not be able to compensate for Dsg3-specific 
functions. 
Overall the loss- and gain- of function approaches outlined in the chapter provide a 
suitable means to investigate the functional and mechanistic roles of Dsg3 in tumour 
cell biology. 
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3.4 Future work 
While a range of in vitro gain- and loss-of-function approaches allows confidence in the 
evidence provided in this thesis, for future development of this project and possible 
transferable implications, development of this model and the incorporation of others 
for the study of Dsg3 function would be advantageous.  
Retroviral transduction has many advantages such as simple vector design and high 
transfection efficiency. However, it has the disadvantage of variable site and frequency 
of genome integration which have been proven to have potentially mutagenic effect 
(Hacein-Bey-Abina, et al., 2003). Although often viewed as a disadvantage, the random 
integration also results in unpredictable stability of the transgene which results in 
varying levels of transgene expression. In our study this ‘limitation’ was used to an 
advantage in assessment of Dsg3-dependency. To address some of the limitations of 
the in vitro model the frequency of Dsg3 integration into the host cell genome of single 
cell clones could be determined using real time qPCR. By comparing the copy number 
of Dsg3 to a reference gene an accurate measure of insertion frequency can be 
determined. Subsequently, A431-D3 clones which exhibit a high insertion frequency 
could be excluded. Other methods that would also be advantageous in an extension of 
this study include other cancer cell lines characterised as having high Dsg3 expression, 
such as those used by Chen et al in 2007 which include oral carcinoma cells OECMI and 
SCC-25 and nasopharyngeal carcinoma cells BIMI and 076 (Chen, et al., 2007). These 
cells could also subjected to Dsg3 silencing or transduction with shRNA to generate a 
stable knockdown cell line. Finally, the use of primary tumour cells identified as over 
expressing Dsg3, could also be incorporated in future.  
  






Chapter 4: Desmoglein 3 regulates 
cell morphology, 





Changes in cell morphology and the acquisition of cell motility are known to play 
important roles in a multitude of cellular processes including tissue remodelling, 
wound repair, differentiation and embryogenesis. Regulators of these processes are 
essential to maintaining tissue homeostasis. However, aberrant modulation of these 
regulators is associated with pathological conditions, such as metastasis, by disrupting 
tissue organisation, increasing cell motility and promoting degradation of the 
extracellular matrix. One such group of regulators include Rho GTPases (Sahai and 
Marshall, 2002).  
Since the characterisation of seven desmosomal cadherin isoforms (Dsg1-4 and Dsc1-
3) questions have been raised, as to the need for so many? And whether they in fact 
confer unique functionalities? Studies examining functions of desmosomal cadherins 
have revealed additional roles beyond mediating cell-cell adhesion. Dsg3’s morpho-
regulatory functions are well documented in in vitro and in in vivo models with altered 
expression patterns or truncation of Dsg3 resulting in changes in histological and 
phenotypic characteristics (Elias, et al., 2001), abnormal hyper-proliferation and 
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differentiation (Merritt, et al., 2002), and inhibition of morphogenesis and cell 
positioning (Runswick, et al., 2001). Dsg3 has also been shown to be up regulated in 
cancer, including pulmonary SqCC (Savci-Heijink, et al., 2009), Head and neck SCC, 
malignant lymph nodes (Wang, et al., 2007) and breast cancer cell lines (Gordon, et al., 
2003). Additionally, the level of Dsg3 expression has been reported to correlate with 
clinical stage of head and neck malignancy (Chen, et al., 2007). Most recently, Dsg3 has 
been identified as a biomarker for the ultrasensitive detection of lymph node 
metastasis in oral cancer (Patel, et al., 2013) that led to a patent for its use as a 
biomarker for lymph node metastasis published in April 2012 (US 2012/008782 A1). 
Taken together, these findings strongly indicate a regulatory role of Dsg3 in tissue 
homeostasis, with aberrant expression associated with cancer progression, however, 
little is known about its precise function in tumour cell biology.  
The aim of this Chapter is to investigate the phenotypic effect of Dsg3 overexpression 
in the A431 cancer cell line with regard to cell morphology, migratory and invasive 
behaviour. 
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4.2 Results 
4.2.1 Desmoglein 3 enhances cancer cell spreading and membrane protrusion. 
Transformation of cells results in diverse changes in cell morphology, proliferation, and 
adhesion, many of which are prerequisite events to cell migration and invasion. One 
such morphological characteristic is cell spreading which is facilitated by the extension 
of filopodia- and lamellipodia-like membrane projections. Preliminary time-lapse 
microscopy, carried out by Dr Wan (Figure 1.13), suggests that the overexpression of 
Dsg3 in A431 cells (A431-D3) promotes cell spreading and membrane protrusions 
compared to Vect Ct cells. To substantiate this observation, fluorescence microscopy 
was carried out to examine Dsg3 expression and cell area, comparing A431-D3, -C2 
(high Dsg3 expression) with vector control cells (A431-Vect Ct). For this experiment 
cells were seeded at ~60% confluence on coverslips 24 h prior to fixation and staining 
using Dsg3 specific antibody, 5H10, and phalloidine conjugated with Alexa Flour 488 
for F-actin detection. Figure 4.1A illustrates that the level of Dsg3 expression 
correlated with increased cell area. To confirm this relationship, cell area and Dsg3 
expression (integrated density) from two independent experiments were collated. The 
mean cell area and Dsg3 integrated density per field were then plotted against each 
irrespective of the specific cell lines used (A431-Vect Ct, -D3, and -C2). As illustrated in 
Figure 4.1B a positive correlation between the Dsg3 expression and cell area suggests 
that Dsg3 regulates cell spreading.  
With respect to membrane protrusions consistently an increased frequency and 
exaggerated filopodia-like protrusion were seen in cells overexpressing Dsg3 compared 
to the Vector control. Illustrated in figure 4.2 are representative images of high 
expression clones A431-D3, C2 and C7 and Vector control cells seeded a day prior to 
fixation and staining using Ezrin. As shown the overexpression Dsg3 increases the 
frequency of membrane protrusions which also appears to more pronounced .To 
substantiate that the effect of Dsg3 overexpression on membrane protrusions was 
Dsg3-dependent, Dsg3 knockdown experiments were performed in A431-D3 cells. In 
preparation cells were seeded 24h prior to transient transfection with Dsg3 specific 
and scrambled control siRNA. After 24 h, cells were re-seeded at 50-60% confluence on 
coverslips and grown for a further 24 h before fixation. Cells were then immunostained 
for Dsg3 (5H10) and Ezrin. 
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Figure 4.1. Overexpression of Dsg3 increases cell area. (A) A431-V, D3, and C2 cells were 
seeded at 50-60% density on coverslips and allowed to propagate for 24 h. Cells were fixed and 
stained for Dsg3 (5H10, red) and F-actin (A488-Phalloidin). Images were acquired using Leica 
epi-fluorescence microscope. Dsg3 integrated density and cell area in each field were 
determined using ImageJ and divided by total cell number. At least 3 fields/cell line were 
analysed in 2 independent experiments. Data presented in bar charts are the average Dsg3 
expression and cell area ± SD (*P<0.05, **P<0.01). Scale bar 30 μm (B) The correlation 
between cell area and relative Dsg3 levels per field was plotted from 2 independent 




























































































































Figure 4.2 Desmoglein 3 overexpression promotes membrane protrusions
images of A431-V control, D3 polyclonal, C2 and 
mouse Ezrin antibody. The i
on membrane protrusions Scale bar, 20µm
As illustrated in Figure 4.3
significant reduction in Dsg3 expression
Dsg3 silencing inhibited
cells, suggesting that the enhanced me
is Dsg3-specific.  
In summary, through both gain
appears that Dsg3 regulates cell morphology by promoting cell spreading and 
membrane protrusions in A431 cell
C7 monoclonal cell lines, labelled with
nserts in each image is the enlarged image of dotted box focusing 
.  
 Dsg3 knockdown in RNAi treated cells resulted in a 
 compared to scrambled control. Furthermore, 
 membrane protrusions (white arrows) 
mbrane protrusions in Dsg3 overexpressing cells 
- and loss-of-function experimental
s. 
117 | P a g e  
. (A) Confocal 
 the 
compared to control 
 approaches, it 
















Ezrin Dsg3 Ezrin Dsg3
DAPI Dsg3:EzrinDAPI DAPI Dsg3:EzrinDAPI
Ezrin Dsg3 Ezrin Dsg3





119 | P a g e  
Figure 4.3 Desmoglein 3 silencing inhibits membrane protrusion in A431 cells. (A, B, C & D) 
A431-D3 cells treated with either scrambled control (Scram Ct: left panels) or Dsg3 specific 
siRNA (Dsg3 KD: right panels) were fixed and immunostained for Dsg3 (green) and Ezrin (red). 
(A) and (C) illustrate merged Dsg3 and Ezrin staining for Scrambled Ct and Dsg3 KD cells. 
Enlarged images of dotted boxes focus on membrane protrusions, or lack of membrane 
protrusions (left of square images). (B) and (D) Illustrate the split channels of the images in A & 
C in black and white. Particular regions of interest (membrane protrusions or lack of highlight 
with white arrows) The knockdown of Dsg3 resulted in the inhibition of membrane 
protrusions. Scale bar 20 μm and 10 μm, n=2. 
4.2.2 Desmoglein 3 promotes cancer cell migration. 
A previous study showed that Dsg3 overexpression in A431 cells did not enhance cell-
cell adhesion but rather promoted cell migration as assessed by a scratch-wound assay 
(Tsang, et al., 2010). Furthermore, the data presented thus far suggest that Dsg3 
overexpression promotes cell spreading and membrane protrusions as possible 
prerequisite events of cell migration. To test this hypothesis, various A431 cell lines 
with different levels of Dsg3 expression were examined by transwell migration and 
scratch wound assays. The transwell assay of both A431 and SqCC/Y1 were conducted 
by BSc students, Miss T Mannan and Emina Gunic. In this case, the indicated cell lines 
were counted and re-suspended in α-DMEM (for A431) or DMEM:Ham’s F12 (3:1) (for 
SqCC/Y1) supplemented with 1% bovine serum albumin. A defined amount of cells 
were seeded into each 24-well transwell insert. The bottom well was filled with α-
DMEM supplemented with 10% FCS for A431 cells or keratinocyte growth medium for 
SqCC/Y1 Cells. Cells were incubated for 2-3 days to allow migration through the 
transwell insert into the bottom chamber. The total number of cells that had migrated 
into the bottom chambers was determined using an automated cell counter. Three 
independent experiments in triplicate, were performed and demonstrated that the 
overexpression of Dsg3 in both A431 and SqCC/Y1 cancer cell lines significantly 
increased cell migration compared to Vect Ct cells and immortalised keratinocyte 
HaCat cell line which retain normal cell-cell adhesion and served as a negative control 
(Figure 4.4). Dsg3 silencing in SqCC/Y1 parental cells transduced with Dsg3 specific 
shRNAs (shRNA-1 and -2), did not show any significant differences compared to Vect Ct 
cells (V) (Figure 4.4). Cell migration was further assessed by a scratch-wound assay 
using IncuCyte™, a Kinetic Imaging System which allows for live cell video imaging from 
within the incubator. In this study, the indicated cell lines were seeded into 96-well 
image-lock plates at 80% confluence to achieve a confluent monolayer after 24 h. The  
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Figure 4.4 Desmoglein 3 promotes transwell cell migration. Various cell lines in two cancer 
cell types were assessed, including A431 and SqCC/Y1. Two stable SqCC/Y1 lines with 
transduction of Dsg3 specific shRNAi-1 and -2 were included. Left bar chart shows that 
overexpression of Dsg3 in A431 cells resulted in a significant increase in cell migration 
(*p<0.05, **p<0.01 and ***p<0.001). HaCat cells which retain normal cell-cell adhesion was 
used as negative control in this assay and showed a significantly reduction of cell migration as 
compared to A431-V cell (***p<0.001). Similarly, overexpression of Dsg3 in SqCC/Y1 cells also 
shows a significant increase in cell migration (pooled data from 3 experiments, triplicate in 
each experiment, mean ± S.D.) For knock down efficacy in SqCC/Y1 cells see Figure 4.6. 
cell free zone (wound) was created using a 96-well Woundmaker
TM
. Cells were washed 
3 times with PBS to remove any cellular debris followed by addition of growth media 
supplemented with 10% serum. Finally, the image lock plates were loaded into the 
IncuCyte™ which was programmed to acquire an image from each well every 15 
minutes for 28 h. Dsg3 overexpressing cell lines displayed an increased rate of wound 
closure compared to Vect Ct cells (Figure 4.5). In support, Dsg3 silencing in A431-D3 
cells, as described previously, reduced the rate of wound closure compared to A431-
D3 cells treated with scrambled Ct siRNA (Figure 4.5). Taken together, these results 
support the notion that Dsg3 regulates cell migration in cancer cell lines (Chen, et al., 
2007). 
4.2.3 Desmoglein 3 promotes cancer cell invasion 
Thus far it has been demonstrated that the overexpression of Dsg3 significantly 
increases membrane protrusion, cell spreading and migration. These observations 
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Figure 4.5 Desmoglein 3 promotes two dimensional cell migration. A431 cells either with 
Dsg3 overexpression or knockdown were seeded at ~80% density in 96-well plate and allowed 
to form a monolayer overnight. The cell free zones (scratch) was created using a 96-well 
Woundmaker
TM
 (Essen). The plate was placed into the IncuCyte where images were acquired 
every 15 minutes over a period of 28 h. Dotted lines represent migrating fronts. (A) Illustrates 
representative images at t 0 and at 27 h for A431-Vect Ct and A431-D3 cells. Dotted lines 
highlight the invasive fronts. Scale bar 100μm (B) Relative Wound Density (RWD) was 
determined by the IncuCyte software, this metric measures the spatial cell density in the 
wound area relative to the spatial cell density outside of the wound area at every time point. It 
was designed to be zero at t=0 and 100% when the cell density inside the wound was the same 
as the cell density outside the initial wound. Compared to control cells, D3 cells showed higher 
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Figure 4.6 Desmoglein 3 promotes cancer transwell cell invasion. (A) Transwell cell invasion of 
A431 and SqCC/Y1 cell lines was examined and showed consistently that D3 cells displayed 2- 
or 7-fold increase in cell invasion, respectively. (B) Various SqCC/Y1 cell lines along with two 
stable shRNAi cell lines with Dsg3 knockdown, shRNAi-1 and -2 were also tested (courtesy of 
Miss Emina Gunic). Only Dsg3 overexpressing cells showed increased cell invasion. In contrast, 
both knockdown cell lines exhibited similar rate of invasion to that of control cells (**p>0.05). 
(C) Western blot of SqCC/1 cell lines to illustrate Dsg3 over expression and silencing efficacy. 
test this hypothesis two means of assessing invasion were adopted, the transwell 
invasion assay and organotypic raft culture, the latter of which is a more 
physiologically relevant method of assessing cell invasion. The transwell invasion 
assays were carried out similarly to the above migration assay except here cells are 
required to invade through a thin layer of Matrigel applied to each insert before the 
addition of cell suspension. As illustrated in Figure 4.6, a significant increase in cell 
invasion was observed in A431-D3 (2-fold) and SqCC/Y1-D3 (7-fold) compared to Vect 
Ct cells (Figure 4.6A). The same observation was made independently by other 
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Dsg3 knockdown in SqCC/Y1 parental cells had no effect in cell invasion compared to 
control.  
Finally, an organotypic cell invasion assay with Matrigel:collagen gel embedded with 
primary fibroblasts was performed (courtesy of Miss E Gunic). This assay enables the 
assessment of cell invasion in a 3-dimensional tissue culture setting that facilitates the 
full differentiation of a cell monolayer into a Matrigel:collagen gel embedded with 
primary fibroblasts which mimics physiological condition at the air-liquid interface. 
Following gel preparation (see methods and materials\) cultures were maintained for 
14 days. The organotypic cultures were then fixed by submerging in Trumps fixative 
overnight. Specimens were then embedded in paraffin wax and sectioned for staining 
with haematoxylin and eosin. Histological images were acquired (Figure 4.7A) and 
analysed to determine invasion index (Figure 4.7C) as previously described (Thomas, et 
al., 2001). The invasion index was devised by as a means to estimate the cell invasion 
in vitro taking into account the parameters including average depth of invasion, the 
number and area of invading cell clusters (particles), an example of which is indicated 
by the red arrow in Figure 4.7A. This index maximises differences in cell invasion and 
also reflects the cell invasion pattern in the gels. A significantly high invasion index 
with respect to the control indicates increased cell invasiveness. Analysis of ~13 images 
in each specimen revealed that D3 cells, compared to the vector control, showed 
significantly increased invasive depth, number of particles, invasive area and the 
average size of the particles (Figure 4.7B), which consequently resulted in a 3-fold 
increase in the invasive index in SqCC/Y1-D3 compared to SqCC/Y1-Vect Ct cells (Figure 
4.7C). Immunohistochemistry with anti-Myc tag antibody was also performed to 
confirm the expression of exogenous hDsg3.myc in SqCC/Y1-D3 cells (Figure 4.7A). 
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Figure 4.7 Desmoglein 3 promotes three dimensional cell invasion.(A) Hematoxylin and eosin 
staining of 2-weeks organotypic culture of SqCC/Y1 cells that shows augmented cell invasion in 
cells with overexpression of Dsg3 (D3, red arrow). The middle panels (Red/Black overlay) are 
the representative binary images, the epithelial compartment is highlighted in red that enable 
better visualization of cell invasion. The lower panels are the immunohistochemistry of myc-
tag staining demonstrating positive staining of myc-tag in D3 cells (hDsg3.myc transduced 
cells) but only weak nuclear staining (endogenous c-Myc) in the control sample. (B) 
Quantification of the cell invasion (pooled from two independent experiments). The invaded 
epithelial cell clusters were scored for the indicated parameters (n=13, mean ± SD, *P<0.05, 
***P<0.001). (C) cell invasion index that indicated a nearly 4-fold increase in D3 compared to 
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4.3 Discussion 
This chapter provides evidence that Dsg3 promotes cell spreading, membrane 
protrusions, migration and invasion in cancer cell lines using a variety of techniques. 
These findings are consistent with previous reports demonstrating a positive role in 
cancer progression and metastasis (Bancroft, et al., 2002, Chen, et al., 2007, Patel, et 
al., 2013, Savci-Heijink, et al., 2009).  
Dsg3, like other desmosomal cadherins, principally functions in mediating cell-cell 
adhesion in desmosomes. Logically, one would expect Dsg3 promotes cell-cell 
adhesion and concomitantly inhibits cell migration when overexpressed (Tselepis, et 
al., 1998). Paradoxically, the upregulation of Dsg3 was independently reported in 
SqCCs of the head and neck (Huang, et al., 2010, Patel, et al., 2013), lung (Fukuoka, et 
al., 2007) and oesophagus (Fang, et al., 2014). Knockdown of Dsg3 in cancer cell lines 
reduces tumour growth and invasion (Chen, et al., 2013, Chen, et al., 2007). 
Furthermore, the level of Dsg3 expression has been shown to correlate with the T 
stage, N stage and overall stage of malignant disease, tumour depth and extra-capsular 
spread in lymph nodes (Chen, et al., 2007, Ferris, et al., 2005, Patel, et al., 2013). These 
reports collectively support the participation of Dsg3 in cancer progression. However, a 
majority of these studies are based on genetic profiling apart from one study which 
investigated, mechanistically, the consequence of DSG3 knockdown in head and neck 
cancer cell lines (Chen, et al., 2007). Studies using a controlled model system with 
respect to Dsg3 expression is still lacking, in particular a gain-of-function model with 
ectopic Dsg3 overexpression. This study provides the first attempt of such an 
experimental approach. Thus the findings from this study further implicate Dsg3 in the 
promotion of cancer cell migration and invasion supporting it’s potential as a potential 
therapeutic target in preventing cancer progression and metastasis, as proposed by 
others (Chen, et al., 2007). 
Recently, a study examining the role of Dsg3 in carcinogenesis based on the Dsg3 
knockout mouse model has been carried out (Baron, et al., 2012). Using two models of 
skin carcinogenesis, they concluded that the suppression of Dsg3 does not inhibit 
carcinogenesis. In the first approach, they examined tumourigenicity potential of 
transformed Dsg3-/- and Dsg3+/- keratinocytes in immune-compromised scid mice and 
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showed a 20% reduction in tumour development and a reduction in tumour volume in 
mice injected with Dsg3-/- keratinocytes compared with those infected with Dsg3+/- 
keratinocytes, suggesting that Dsg3 may facilitate tumour growth in certain settings. 
Their second approach examined UVB-induced SCC development in Dsg3-/- mice 
compared to wild type mice. This study revealed no significant difference in tumour 
latency, size and multiplicity between the two cohorts suggesting that Dsg3 deficiency 
does not promote nore inhibit tumorigenesis in the epidermis upon UVB exposure 
(Baron, et al., 2012). Another study carried out by Garrod and colleagues in which Dsg3 
was mis-expressed in the epidermis of transgenic mice driven by the K1 promoter. 
They found that these mice exhibited hyperproliferation, abnormal differentiation and 
parakeratosis of the epidermis but no evidence of tumour development was reported 
in this Dsg3 overexpression model (Merritt, et al., 2002). Parakeratosis describes the 
incomplete maturation of epidermal keratinocytes resulting in abnormal retention of 
nuclei and this condition is seen in diseases associated with increased cell turnover 
including SCC. While these studies are not in keeping with the data presented, they 
suggest that Dsg3 may not function as a main driver in tumorigenesis. However what 
these studies do not exclude is the role of Dsg3 in cancer progression and metastasis, 
where aberrant Dsg3 expression has been identified and suggested to participate 
(Chen, et al., 2007, Gordon, et al., 2003, Patel, et al., 2013, Savci-Heijink, et al., 2009, 
Wang, et al., 2007). 
In agreement with my proposal, a recently publication reported that Dsg3 regulates 
Rac1/Cdc42 to modulate actin organisation and dynamics (Tsang, et al., 2012). Rac1 
and Cdc42 belong to the family of small Rho GTPases and, upon activation they confer 
the formation of lamellipodia and filopodia, respectively (Tsang, et al., 2012). 
Activation of Rac1 and Cdc42 has long been known to be associated with tumour cell 
invasion and metastasis (Ma, et al., 2013, Zins, et al., 2013). These findings support the 
observations of cell spreading and membrane protrusion in association with Dsg3 
expression and are also consistent with previous reports (Tsang, et al., 2010).  
Taken together, the specific role of Dsg3 in cancer is still open to interpretation. Thus 
far studies suggest Dsg3 overexpression is not tumourigenic. However its 
overexpression promotes migratory and invasive behaviour in cancer cells and it’s 
inhibition reduce invasive behaviour in vivo. Together with the clinical correlation 
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between Dsg3 expression cancer stage and detection in metastatic lymph nodes 
support its role in cancer progression and metastasis.  
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4.4 Future work  
To develop this aspect of the project the use of animal models would undoubtedly 
provide invaluable information as to the role of Dsg3 in tumorigenesis. In the few 
studies that have overexpressed Dsg3 in vivo (Elias, et al., 2001, Merritt, et al., 2002) 
neither have looked at the oncogenic potential of Dsg3 in these scenarios, however in 
both cases precancerous events including decreased cell-cell adhesion and 
hyperproliferation respectively were observed. One question that remains is whether 
Dsg3 has the ability to transform cells or whether it is a latter participant in the 
progression of disease. To address this question analysis of Dsg3 overexpression in 
normal cells would provide information on the transforming ability of Dsg3. 
Additionally, using transgenic mouse models engineered for the targeted conditional 
knockout and overexpression of Dsg3 by using the Cre-Lox recominbination system for 
example which would allow Dsg3 targeting without disrupting it’s essential function in 
epithelial junctions and tissue integrity. The understanding yielded from such projects 
with regards to Dsg3s participation in the development and/or progression of cancer 
would justify the use of Dsg3 as a potential therapeutic target. Currently there is no 
definitive evidence as to its precise role in cancer, however its inhibition in cancer cell 
lines and Xenograft models identifying it as an effective therapeutic target. Its use as a 
biomarker for lymph node metastasis highlights that Dsg3 should not be ignored. If I 
were to speculate, how Dsg3 interacts with and subsequent signalling events arising 
from the tumour environment may provide the answer by providing key understanding 
as the precise role of Dsg3 in the progression of cancers which may yield a 
comprehensive understanding of Dsg3’s role in oncogenesis. To compliment the above 
a prognostic study could determine is Dsg3 over expression has any prognostic value 
by look at survival in a cohort of patients with early stage SqCC of the head and neck 
and lung. 
The techniques used to examine morphology in this study were largely qualitative with 
which could arguably be considered subjective and open to bias. In future, by 
employing automated tool such as FiloDect (Nilufar, et al., 2013) for quantification of 
filopodia in microscopy images and a quantitative metrics approach to characterise 
other morphological characteristics would be strengthen the data presented.  
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Another consideration is the potential contribution of cell proliferation on the out 
come of migration and invasion analysis where mitomycin C was omitted, specifically 
in the scratch assay assessed using IncuCyte, transwell and organotypic assays. While 
the time periods over which the scratch and transwell assays were limited to 24-48 h, 
would limit proliferative affect without the direct assessment of proliferation in both 
Vect Ct and –D3 cells its potential contribution to the migration front in the scratch 
assays and the number of migrated cells in the transwell assays cannot be ignored 
particularly as the aberrant expression of Dsg3 in vivo and in vitro has been reported to 
affect cell proliferation (Chen, et al., 2007, Merritt, et al., 2002). However, despite the 
potential proliferative contribution the results from experiments without mitomycin C 
supports those carried out in its presence, suggesting that in the cell systems used the 
proliferative affect is small and possible negligible. Again a definitive conclusion can 
only be attended upon investigation.  
Finally, the fibroblasts in the organotypic cultures are difficult to identify in the gels. 
Staining using fibroblast markers such as type III Intermediate filament protein, 
Vimentin, which is frequently found in fibroblasts and fibroblast surface antigen (SFA) 
a glycoprotein produced by fibroblasts. 
  






Chapter 5: Desmoglein 3 colocalises 






Desmoglein 3 has been shown to participate in a multitude of cellular functions 
beyond mediating cell-cell adhesion as outlined in chapter one. In particular, it has 
been implicated in promoting membrane dynamics and changes in cell morphology 
that are associated with cell migration, invasion and metastasis consistent with the 
evidence presented in the previous chapter. However, how Dsg3 is able to achieve 
these functions is not fully understood.  
Cell morphogenesis, migration and invasion are cellular processes to which the actin 
cytoskeleton is essential as it provides the driving force behind membrane dynamics 
and plasticity to initiate and facilitate these highly integrated and multistep processes. 
In pathological situations, such as tumour cell migration and invasion, which evoke 
these actin-based cellular processes, modulation of actin and its regulators is essential. 
Dsg3-dependent regulation of actin organisation has been suggested previously in 
mechanistic studies of PV, which showed that binding of auto-antibodies to the 
keratinocyte provokes cortical actin reorganisation (Gliem, et al., 2010, Waschke, et al., 
2006). In support, a recent study has demonstrated that Dsg3 is required for peripheral 
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cortical actin assembly (Tsang, et al., 2012) Another independent study showed that 
desmosome assembly and dynamics in the process of epithelial cell migration requires 
the actin cytoskeleton (Roberts, et al., 2011). Collectively, these reports suggest 
crosstalk between Dsg3 and the actin cytoskeleton and that desmosomes and their 
constitutive proteins, including Dsg3, are capable of modulating actin and its 
associated regulators to facilitate membrane dynamics and cell migration. This 
crosstalk may provide a mechanism by which Dsg3 regulates cell migration and 
invasion. This proposal is supported by the implication of Rho GTPases as downstream 
effectors of Dsg3-dependent actin organisation (Spindler and Waschke, 2011, Tsang, et 
al., 2012, Waschke, et al., 2006). 
Actin based processes such as membrane dynamics, cell motility and invasion require 
orchestration and regulation. The ERM (Ezrin, Radixin and Moesin) family proteins are 
identified as playing a key role in these processes through their cross-linking activity. 
The ERM proteins are concentrated at cell-surface structures, such as microvilli, 
filopodia, uropods, ruffling membranes and cell adhesion sites where actin is 
associated with the plasma membrane (Amieva and Furthmayr, 1995, Bretscher, 1999, 
Sato, et al., 1991, Serrador, et al., 1997). It has been shown that silencing of ERM 
proteins using antisense oligonucleotides inhibits microvillus formation and cell 
adhesion (Takeuchi, et al., 1994) and perturbs membrane ruffling and cell motility 
(Lamb, et al., 1997, Paglini, et al., 1998). Precisely how ERM proteins regulate the 
formation and/or maintenance of these structures remains unclear. However, there is 
evidence to suggest that the ERM proteins not only directly link the actin cytoskeleton 
to the plasma membrane but also may exert orchestrative functions through multi-
protein complex assembly in specific cellular compartments (Arpin, et al., 2011) (see 
section 1.3.3 Function of ERM proteins). The ERM protein, Ezrin, has been shown to be 
dynamically regulated during cancer progression, with reports of hyper-
phosphorylation (activation) and increased expression levels in a variety of cancers 
(Chen, et al., 2011, Chuan, et al., 2006, Huang, et al., 2011, Khanna, et al., 2004, Ma 
and Jiang, 2013, Meng, et al., 2010, Ren, et al., 2009, Saito, et al., 2013, Xie, et al., 
2011). 
The colocalisation between Dsg3 and Ezrin in cancer cells was initially demonstrated by 
Dr Wan (Tsang, et al., 2010). The characterisation of such an association and the 
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nature of their interaction could provide a novel mechanism for Dsg3 in regulating 
tumour cell morphology, migration and invasion and further our understanding of the 
role of Dsg3 in cancer progression and metastasis. This Chapter aims to characterise 
the association between Dsg3 and Ezrin using a combination of microscopy and 
biochemical techniques. 
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5.2 Results 
5.2.1 Desmoglein 3 colocalises with Ezrin predominantly at the basal domain of the 
plasma membrane. 
The preliminary analysis revealed that Dsg3 colocalises with Ezrin, particularly at 
protrusions of the plasma membrane (Figure 1.X) (Tsang, et al., 2010). To validate this 
finding, confocal and epi-fluorescence microscopy was performed on A431-D3 and 
A431-Vect Ct cells grown on coverslips for 24 h (n=10). The following day cells were 
fixed and stained using Dsg3 (5H10) and Ezrin specific antibodies. At least, 3 random 
fields from each coverslip were acquired. Figure 5.1A illustrates representative images 
of Dsg3 and Ezrin staining, as shown there is a clear over expression of Dsg3 in A431-
D3 cells compared to the Vect Ct as well as a high level of colocalisation (represented 
by the yellow/orange pixels). Analysis of the observed colocalisation using ImageJ to 
determine average percentage colocalisation per cell revealed a significant (p<0.01) six-
fold increase in the average percentage colocalisation in A431-D3 cells compared to 
A431-Vect Ct. In support knockdown of Dsg3 in A431-D3 cells reduced Dsg3:Ezrin 
colocalisation (Figure 5.1B), suggesting the observed colocalisation is Dsg3-
dependent.In support analysis of percentage colocalisation per cell revealed a 
significant (p<0.01) reduction in Dsg3:Ezrin colocalisation in knock down cells compared 
to the scrambled Ct. This analysis was expanded to include Dsg3, A431-C11 (low 
expression) and C2, C6 and C7 (high expression) to reveal a similar trend (Figure 5.2) 
with a clear correlation between Dsg3 relative expression and Dsg3:Ezrin 
colocalisation, represented by the yellow/orange pixels. ImageJ analysis of 
colocalisation with respect to Dsg3 expression revealed a positive correlation. Finally 
the overexpression of Dsg3 appeared to have no significant effect on the total ezrin 
expression (Figure 5.2). Similarly the colocalisation between Dsg3 and pERM in cells 
with high Dsg3 expression (A431-D3, C2, C6 and C7), exhibited high levels of 
colocalisation in the basal planes compared to the vector control and low expression 
clone C11 (Figure 5.3B).  
5.2.2 Desmoglein 3 colocalises with Ezrin in close proximity. 
The above analysis of the Dsg3:Ezrin colocalisation was based on the qualitative 
assessment and quantification of overlapping pixels for both channels as measured by 
ImageJ, expressed as percentage colocalisation. However, the threshold for  
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Figure 5.1. Desmoglein 3 colocalises with Ezrin. (A) A431 cell lines of vector control (A431-
Vect Ct) and Dsg3 overexpressing D3 cells were seeded on coverslips at 50-60 % confluence 
prior to fixation 24 h later. Cells were fixed with ice cold Methanol:Acetone (1:1) before 
immunostained for Dsg3 and Ezrin.(n=10) (B) In the knockdown experiment, A431-D3 cells 
were transiently transfected with either Dsg3 specific or scrambled control siRNA. Cells were 
fixed and immunostained 48 h after transfection (n=5). In each experiment at least three fields 
per coverslip were imaged using confocal or epi-flourescence microscopy. Representative 
images are shown in this figure Scale bars, 20 µm. 
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Figure 5.2. Desmoglein 3 colocalises with Ezrin in a dose-dependent manner. (A) A431-Vect 
Ct, -C2, -C6, -C7 (Dsg3 high) and -C11 (Dsg3 low) were double immunostained for Dsg3 and 
Ezrin 24 h after being seeded at 50-60% confluence. Colocalisation between Dsg3 and Ezrin 
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Figure 5.3. Desmoglein 3 colocalises with Ezrin at the basal domain of the plasma membrane. 
Confocal Z stacks of A431-Vect Ct and –D3 cells double stained for Dsg3 and Ezrin (Top: Z 
Stack: 1μm intervals. total Z distance: 6 μm) or pERM (bottom: Z stack V and D3 cells at 
intervals: 0.29 μm and 0.34 μm respectively. Total distance: 2.29 μm and 12.07 μm, 
respectively). Colocalisation between Dsg3 with Ezrin and pERM is represented by 
yellow/orange pixels. Colocalisation of Dsg3 with Ezrin and pERM appears to be concentrated 
at the plasma membrane where membrane projections are predominant and in the basal plans 
the of the Z stacks (white arrows). Scale bars, 20 µm. 
colocalisation of flourescence using epi fluorescence and confocal microscopy between 
400-600 nm. As a result it remained unclear how closely these two molecules were 
associated at the plasma membrane. To further examine the intimate relationship 
between Dsg3 and Ezrin several techniques were employed. Firstly, the Proximity 
Ligation Assay (PLA) was performed which allows for the identification and 
quantitation of molecular interactions within 10-40 nm (see section 2.4.6 Proximity 
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Figure 5.4. Desmoglein 3 and Ezrin associate between 10-40 nm in a Dsg3-dose dependent 
nature. A431 cells seeded at 50-60% density followed by fixation with Methanol:Acetone (1:1). 
The assay was carried out according to manufacturers guidelines, using blocking buffers, 
incubation times and antibody concentrations optimised for immunofluorescence protocols. 
Images were acquired using confocal microscopy and analysed using ImageJ. (n=2, 3 fields per 
cell line were analysed. (A, B) show Dsg3 and Ezrin interactions within 10-40 nm, each 
interaction is represented by a single red signal. (C) Positive and negative Ct, here signal 
represent interactions between Dsg3 and MycTag in A431-D3 and –Vect Ct cells respectively. 
(D) Quantitation of interactions frequency per cell, presented as Mean fold change ± SD., **P 
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(n=2) which shows a 3.5, 5 and 4-fold increase in the frequency of interactions (Figure 
5.4 C) between Dsg3 and Ezrin in A431-D3, C2 and C7 cells, respectively, compared to 
Vector Ct cells. No difference was seen between C11 and control cells.  
Secondly, FRET (Fluorescence Resonance Energy Transfer) analysed by acceptor photo-
bleaching was performed to determine if Dsg3 and Ezrin were interacting within 10 nm 
(see section 2.4.5 Fret by acceptor photobleaching). For this analysis, A431-D3 and 
Vect Ct cells were stained with Dsg3 and Ezrin specific antibodies. The secondary 
antibody pair in this case was anti-mouse IgG conjugated with Alexa Flour 488 for Dsg3 
and anti-rabbit IgG with Alexa Flour 555 for Ezrin labelling. FRET analysis was 
performed on numerous cellular regions, including cell-cell contacts, membrane 
protrusion and cytoplasm of A431-Vect Ct and-D3 cells alongside the acquisition of 
controls. Altogether, 89 potential FRET regions were analysed. Figure 5.5 A, B 
illustrates representative examples of pre- and post-bleaching images with test and 
control regions identified alongside relative integrated density of the donor and 
acceptor fluorescence. Positive FRET was detected and exhibited as an increase in 
donor fluorescence (Region 1 and 2 in the Dsg3 post-bleach images in Figure 5.5A. Of 
the 89 regions analysed, 13 (14%) displayed positive FRET above the threshold of 5%, 
with an average FRET efficiency of 8% ± SD (5.5 C), these regions were predominantly 
located at membrane protrusions.  
Finally, further quantification of the Dsg3:Ezrin colocalisation was performed in order 
to establish that the percentage colocalisation obtained in Figure 5.1-5.3, which was 
based on the assessment of overlapping pixels, were of equal significance in both 
A431-Vect Ct and -D3 cells. This was necessary to establish due to the vast difference 
in Dsg3 expression which may skew the qualitative outcome. Using ImageJ’s Intensity 
Correlation Analysis plug-in which employs a number of coefficients, including 1) 
Pearson’s Coefficient which determines the strength of the linear relationship between 
two channel intensities and is not influenced by background or image brightness. This 
Coefficient yields values ranging from +1 for perfect colocalisation to -1 for perfect 
exclusion with a value of 0 occurring due to random localisation; 2) Mander’s 
Coefficient assesses the fraction of pixels that overlap and is not influenced by the 
differences in absolute signal intensities. Mander’s Coefficient ranges from 0 for no 
colocalisation and 1 for complete colocalisation; and 3) Intensity Correlation Quotient 
Figure 5.5. Desmoglein 3 and Ezrin associate with 10nm and the plasma membrane
acceptor photobleaching a
at 50-60% confluence 24 h before fixation with Methanol:Acetone (1:1). Dsg3 and Ezrin were 
detected using Ezrin and Dsg3 primary antibodies followed by the secondly FRET pair ab FITC 
and TRITC. The figure illustrates a representative region that was analysed with donor and 
acceptor channel displayed pre and post photobleaching in addition to enlarges images of 
highlighting region 1 (reg 1). Photo
photobleaching. Fluorescent intensities of all highlighted regions are quantified graphically in 
the right hand panel. Among 89 regions which include membrane protrusion and intracellular 
junctions 13 (~14%) displayed positive FRET 
FRET efficiency of ~8% (C)
(ICQ) which assesses the synchrony of two signals by analysing the 
Difference from the 
whereas asynchronous intensities
distributed between 0.5 and 
asynchronous staining = 0 >
nalysis using confocal microscopy: A431 D3 cell lines where seeded 
-damage of approximately 60% was achieved duri
efficiency above a threshold of 5%
. 
Mean (PDMs). Synchronous intensities result in positive PDMs
 give rise to negative PDMs.
-0.5 where random staining = 0, segregated or 
ICQ > -0.5, dependent or synchronous staining = 0< 
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Figure 5.6 Colocalisation between endogenous and exogenous Dsg3 with Ezrin is equally 
significant in A431-Vect Ct and A431-D3 cells. The colocalisation parameters were determined 
with ImageJ plug-in, such as Pearson’s correlation Coefficients, Mander’s Overlap Coefficients 
and 9 Correlation Quotient for Dsg3 and Ezrin staining and showed the colocalisation in both 
cells types was of equal significance (Data presented are the coefficient value ± SD, n=2) 
0.5. All these coefficients have an advantage over percentage colocalisation as they 
analyse all pixels based on their intensity rather than pixel ‘overlapping’. As shown in 
Figure 5.6, all the coefficient analyses supports the qualitative percentage 
colocalisation for both endogenous and exogenous Dsg3 with Ezrin in A431-Vect Ct 
and A431-D3 cells with coefficient values consistent with near perfect correlation, i.e. 
Pearson correlation Coefficient: A431-Vect Ct, ~0.6 and A431-D3, 0.6; Mander’s 
Overlap Coefficient: A431-Vect Ct, ~0.8 and A431-D3, ~0.75; and ICQ: A431 Vect Ct, 
~0.25 and A431-D3, 0.3 (Figure 5.6). Taken together, the data suggest that Dsg3 and 
Ezrin are in close proximity with interactions occurring within ~10 nm particularly atthe 
membrane protrusions located at the basal domains of the plasma membrane. 
5.2.3 Desmoglein 3 forms a molecular complex with Ezrin and possibly Radixin. 
Given the above observation suggesting a close association between Dsg3 and Ezrin, it 
seemed possible that these two proteins may physically interact with each other in a 
molecular complex. To address this question, co-immunoprecipitation (co-IP) assay of 
lysates from A431-Vect Ct and -D3 cells were performed. Cells were grown at 50-60% 
confluence for 24 h, cell lysates were then extracted with RIPA buffer (Materials and 
Methods). One mg of total protein per sample was used for co-IP with Ezrin antibody 
(rabbit) and isolated immunoprecipitates were analysed by Western blot. The 
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Figure 5.7 Dsg3 form a molecular complex with Ezrin in a dose dependent manor. A431-Vect 
(V) and –D3 cells were seeded at 50-60% confluence 24 h before cell lyses. Cell lysates were 
cleared before being incubated with the rabbit Ezrin Ab overnight at 4°C, followed by 
imunoprecipitation with G-protein conjugated beads for 4 h at 4°C. The immune complexes 
were then washed thoroughly before Western blotting analysis. (A) A representative blot from 
six independent experiments shows that there was more Dsg3 associated with Ezrin in A431-
D3 cells compared to Vect control. Lysate indicates the input of proteins, and Rb serum on the 
left lane served as a negative control for this assay. (B) Western blotting analysis of co-
immunoprecipitation in four A431 lines including Vect Ct, D3, C7 and C11, showing consistently 
an increased association between Dsg3 and Ezrin in D3 and C7 lines compared to Vect control 
and C11 with low Dsg3 levels. Dotted line indicates where parts of the same blot, of either the 
same or different exposure/re-probe, was joined together. 
demonstrating that Dsg3 immunoprecipitates with Ezrin, particularly enriched in A431-
D3 cells compared to the Vect Ct. To further confirm whether this interaction was 
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Dsg3-dose-dependent, this study was expanded to include A431-C7 and -C11 cells, 
further demonstrated a correlation between Dsg3 expression and the amount of 
associated with Ezrin (Figure 5.7B). 
In parallel, the reverse approach using Dsg3-specific antibodies, probing for Ezrin was 
performed (n=3), no detectable association of these two proteins was observed. 
However co-IP assay using mycTag specific antibody resulted in the identification of a 
discrete band at the molecular weights similar to that of Ezrin and other ERM proteins 
(data not shown). However this assay required further optimisation in order to draw a 
definitive conclusion. 
There is evidence suggesting functional redundancy amidst the ERM family proteins, 
which raised the question whether Dsg3 could potentially associate and possibly form 
a complex with the other ERM proteins, Radixin and Moesin. To address this question, 
immunofluorescent microscopy was carried out on A431-Vect Ct, -D3, -C7 and -C11 
cells. As illustrated in Figure 5.8, Dsg3 exhibited a predominant plasma membrane 
localisation, a pattern similar to that of Ezrin. Radixin displayed a predominantly 
diffused cytoplasmic staining with some membrane association while Moesin is 
localised heavily in the cytoplasm with strong nuclear staining and respectively exhibits 
the least plasma membrane localisation (Figure 5.8A). Analysis of immunostaining 
profiles generated from fluorescent micrographs clearly indicated that Ezrin but not 
Radixin and Moesin shares similar cellular distribution to Dsg3 (Figure 5.8B). To 
examine whether Dsg3 could also from a complex with Radixin or Moesin, co-IP with 
Radixin and Moesin antibody was performed (n=3). The results suggest that Dsg3 
might form a complex with Radixin but not Moesin (Figure 5.7C).  
5.2.4 Non-junctional Dsg3 colocalises and forms a complex with Ezrin. 
Two pools of Dsg3 proteins are found to be present in epithelial cells, characterised as 
detergent soluble and insoluble, these pools have been shown to be non-junctional 
and junctional, respectively, the latter of is being associated with desmosomes 
(Aoyama and Kitajima, 1999, Jennings, et al., 2011, Yamamoto, et al., 2007). Although 
the function of junctional Dsg3 in cell-cell adhesion has been characterised it remains 
unclear whether Triton X-100 soluble, non-junctional Dsg3, has additional roles beyond  
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Figure 5.8 Ezrin but not Radixin and Moesin colocalises with Dsg3 at the plasma membrane. 
(A) 24 h after seeding A431-D3 cells at 60-70% confluence on coverslips, cells were fixed and 
immunostained for Dsg3, Ezrin, Radixin and Moesin. Three images per coverslip were 
obtained, from which representative images are displayed (Exp n=2). Scale bar, 20µm. (B) 
Staining intensity profiles acquired using ImageJ. Seventy-five cells in total were analysed to 
determine the cellular localisation of Ezrin, Radixin and Moesin. Data presented are Mean Gray 
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acting as precursors for desmosome assembly and turnover (Green, et al., 2010). 
Recent studies carried out by Dr Wan’s group suggest that non-junctional Dsg3 is 
involved in regulating Src activation and actin dynamics (Tsang, et al., 2012, Tsang, et 
al., 2012, Tsang, et al., 2010). Thus, it was hypothesised that non-junctional Dsg3 may 
possess a function in signal transduction and actin organisation through associations 
with Ezrin. To address this question, the colocalisation of Dsg3 with Ezrin was analysed 
in cells where detergent soluble proteins were extracted with Triton X-100 before 
fixation (Tsang, et al., 2012). To this end, A431-C7 cells were grown on coverslips and 
treated with 0.1% Triton buffer or PBS that served as a control, for 6 minutes before 
fixation. As illustrated in Figure 5.9A, subsequent immunofluorescent staining of 
treated cells showed a significant reduction in pERM staining and colocalisation with 
Dsg3 compared to control cells treated with PBS. In support, Western blot analysis of 
Triton soluble and insoluble fractions from A431-Vect Ct , -D3, -C7 and –C11 cells 
showed that Dsg3 was distributed in both fractions but predominately distributed in 
the triton insoluble fraction. Interestingly, pERM proteins were predominantly 
detectable in the Triton soluble fraction (Figure 5.8B), suggesting complex formation of 
non-junction Dsg3 with Ezrin. This was substantiated by co-IP that demonstrated 
clearly that Dsg3 co-IPed with Ezrin in Triton soluble fraction but not in the insoluble 
fraction (Figure 5.8C). Collectively, these results strongly suggest that non-junctional 
Dsg3 associates and forms a complex with Ezrin. 
5.2.5 Mass spectrometry analysis of the association between Dsg3 and Ezrin. 
To identify other candidate proteins that may be in complex with Dsg3, mass 
spectrometry analysis was carried out on protein complexes isolated using Dsg3 C-
terminal truncated protein. To this end, the C-terminus (intracellular domain) of Dsg3 
was cloned into a pFN21A HaloTag CMV Flexi vector with the HaloTag located at the N-
terminus (HaloTag-Dsg3 C-terminus design, courtesy of Dr Jaroslaw Szary), a schematic 
of the construct is illustrated in Figure 5.10A. A431 parental cells were transiently 
transfected with the C-terminal construct (C-term.Dgs3.Halo) and empty vector with 
HaloTag (Halo.Vet Ct) which served as a control as described previously. 
Immunofluorescent microscopy and Western blot analysis of A431-parental cells 48 h 
after transfection showed positive expression of both HaloTag.Vect Ct and the C-
term.Dgs3.Halo constructs using both the HaloTag and Dsg3 C-terminal specific 
antibody (H145). Specifically, expression of the Halotag.Vect Ct exhibited a band with a  
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Figure 5.9 Triton soluble pool of Dsg3 colocalises and co-immunoprecipitates with Ezrin. (A) 
A321-C7 cells seeded on coverslips at 50-60% confluence 24 h prior to treatment with either 
sterile 1x PBS or 0.1 % Triton X-100 in PBS for 6 minutes. Cells were then washed with PBS 
before being fixed and immunostained for the indicated proteins. Compared to PBS treated 
cells, marked reduction was seen in pERM fluorescent staining and to a less degree for Dsg3 in 
cells treated with Triton. (B) Western blotting and co-immunoprecipitation analyses of Triton 
soluble (TSF) and insoluble (TISF) fractions of A431 cell lines. Cells seeded at 50-50% 
confluence 24 h prior to fractionation. The Triton insoluble proteins were dissolved in RIPA 
buffer. Both fractions were analysed by Western blotting. (C) The fractions of Triton soluble 
and insoluble protein described in (B) were incubated with the Ezrin antibody and the immune 
complex was purified using G-protein conjugated beads. Immunoprecipitates were solubilised 
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molecular weight of ~37kDa by Western blot while C-term.Dgs3.Halo expression 
showed an approximate molecular weight of 80 kDa (Figure 5.10B). The expression of 
the C-terminus of Dsg3 did not show any effect on the expression of endogenous Dsg3. 
Immunofluorescent microscopy was also performed with anti-Dsg3 antibody, 5H10 
which recognises an epitope located in the extracellular EC1-EC2 domains. As 
expected, negative staining using 5H10 was observed in cells expressing the C-terminal 
construct, nor does it’s expression appear to have any effect on the expression of 
endogenous Dsg3 (Figure 5.10C).  
Next, the C-term.Dgs3.Halo and HaloTag.Vect constructs were transiently transfected 
in to parental A431 cells and subsequently purified using the HaloTag®Complete pull-
down system (Promega) according to the manufacturer’s specifications prior to mass 
spectrometry analyses (courtesy of Dr Min Yang and Miss Isa Cruz, UCL School of 
Pharmacy). Two independent experiments were performed and relevant proteins were 
identified by searches using SwissProt human protein databases without restrictions 
on protein molecular mass or pl. Variable modification of cysteines and oxidation of 
methionine residues was permitted along with one trypsin mis-cleavage. Peptide and 
fragment mass tolerances were set at 1+/- Da. Proteins identified with the highest 
degree of confidence from pull-downs separated by SDS-PAGE were actin proteins 
which were abundantly present in the C-term.Dgs3.Halo pull-down and absent and 
HaloTag.Vect Ct pull down (Figure 5.10D). Aside desmosomal components, Desmoglein 
1, Desmoplakin and keratin filament associated protein, Filaggrin-2, other proteins 
identified included Transcription Factor 7-like 1 which participates in the Wnt signalling 
pathway, Heat shock cognante 71kDa protein (also known as HSC70). The latter has 
numerous function reviewed by Liu et al, in brief, it has been shown to participate in 
modulating clathrin dynamics (Newmyer and Schmid, 2001) acting as a molecular 
chaperon in the regulation of cell signalling (Rutherford and Zuker, 1994) and 
mediating receptor signalling (Fan, et al., 2002). It is also found to be highly expressed 
in cancer with its knockdown altering tumour cell morphology (Rohde, et al., 2005). A 
protein identified from pull-downs separated by native gel–PAGE was actin. Ezrin was 
not detected in the analysis. 
As demonstrated in Figure 5.10C, the expression of C-term.Dgs3.Halo exhibited 
diffused cytoplasmic staining, with no localisation at the plasma membrane. This posed  
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Figure 5.10 Mass spectrometry analysis of isolates from Halo tagged truncated Dsg3 (C-
terminus) pull down. (A) Diagram illustrating the construct of Halo:Dsg3 cytoplasmic tail. The 
antibody binding sites are indicated by double arrows in red. (B) Western blotting of lysates of 
A431 parental cells with transient transfection of the construct shown in (A) (two clones C14 
and C15 were tested). Halo vector was used as a control. Truncated Halo:Dsg3 cytoplasmic tail  
was readily detectable with the Halo tag and Dsg3 antibody H145 that targets to C-terminus of 
Dsg3. (C) Immunostaining of A431-P cells transfected with C-term.Dsg3.Halo using Halo tag, 
5H10, and H145 antibodies. scale Bar, 20 µm. (D) Proteomic analysis of protein bands in 1D 
SDS-PAGE. Actins are found to associate with Dsg3 with the highest scores in the table (Exp 
n=2). Additional proteins found to be associated with Dsg3 in the native gel include 
desmoplakin and ubiquinone biosynthesis protein COQ4 homolog (data not shown).  
the question whether the localisation of the C-term.Dgs3.Halo protein would affect the 
profile of proteins it would associate and form complexes with as well as altering its 
binding capabilities and/or specificities. To address this question mycTag-pull downs 
from A431-D3 and A431-mycTag Vect Ct cells were analysed as described above. As 
illustrated in Figure 5.11 Western blot of myc.Tag pull-downs demonstrated sufficient 
isolation of hDsg3.myc protein from A431-D3 that was further confirmed by 
immunofluorescence. As illustrated in Figure 5.11B & C, full length Dsg3 associates 
with the plasma membrane, as described in Chapter 3. 
Proteins identified with the highest degree of confidence in isolates separated by SDS-
PAGE were actin proteins (Figure 5.11D). Other proteins indentified included Plectin, 
which acts as a link between the three main components of the cytoskeleton, i.e. actin 
microfilaments, microtubules and intermediate filaments, and has been proposed as a 
biomarker for pancreatic cancer (Bausch, et al., 2011); A-kinase anchor protein (AKAP) 
SPHKAP which acts as a scaffold for the coordination of phospho-events at specific 
cellular localisation through sequestering kinases and phosphatases with the 
appropriate substrates; RhoGEF exchange factor 10-like protein (GEFs) that stimulates 
the exchange of GDP for GTP to activate Rho GTPases, Rac1, Cdc24 and RhoA, which in 
turn bind downstream targets or effector proteins. It is accepted that all Rho GTPases 
are involved in most, if not all, of the actin-dependent processes, including migration, 
adhesion and morphogenesis (Chimini and Chavrier, 2000, Kaibuchi, et al., 1999, Luo, 
2000). Unconventional myosin lc or class I myosin, that has been shown to be essential 
to the establishment and maintenance of cortical actin, cell motility and endocytosis 
was also found. Finally, Protein Inturned is implicated in the organization of the apical 
actin cytoskeleton and the positioning of the basal bodies at the apical cell surface, 
particularly in ciliated cells, and also an important regulator of Hedgehog (Hh) signal  
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Figure 5.11 Mass spectrometry analysis of isolates from myc tagged full length Dsg3 pull 
downs. (A) Western blot of total cell lysats and those from Myc:tag Immunoprecipitates 
probed with, Halo tag and H145 antibodies demonstrates the expressions of both the myc:tag 
Ct and full length constructs (B), supported by Immunostaining using 5H10 and Myc:tag 
antibodies, scale Bar 20 µm (C). (D) Proteomics analysis of 1D SDS-PAGE gel. Actins are found 
to associate with Dsg3 with the highest scores (Exp n=1). Additional proteins including  RhoGEF 
exchange factor 10-like protein and GEF 33 and Sodium-dependent phosphate transporter 2 
Dsg3 in native gel were identified (data not shown).  
transduction and embryonic development (Zeng, et al., 2010). Proteins identified from 
the native gel –PAGE were actin proteins present in the construct sample and not in 
the empty vector control, RhoGEF exchange factor 33, Sodium dependent phosphate 
transporter 2, Outter row dynein assembly protein 16 and DOMO domain-containing 
protein FRRS1L (data not shown) were also detected in this analysis. All proteins 
identified as relevant were deemed so, on the basis that their theoretical molecular 
weight matched that of the observed molecular weight. However, validation studies 
are required in order to draw definitive conclusions. 
Since actin was identified with the highest degree of confidence in both C-terminus 
and full length mass spec analysis, to ascertain if they colocalise in vitro A431-C7 and -
Vect Ct cells  where stained for Dsg3, pERM and F-actin and analysed by confocal 
microscopy. As illustrated in Figure 5.12 all three proteins colocalise predominantly at 
the plasma membrane, in particular in Dsg3 overexpressing cells (arrows in Figure 
5.12A) as well as at membrane protrusion (Figure 5.12B). Interestingly the 
overexpression of Dsg3 appears to significantly alter the organisation of cortical actin 
at cell-cell junctions compared to the Vect Ct (Figure 5.12A). 
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Figure 5.12 Desmoglein 3 colocalise with Ezrin and Actin at cell-cell junctions and 
membrane protrusions. Confocal microscopy of A431-Vect Ct and –C7 cell lines fixed 
and stained with Phalloidin, Dsg3 (5H10) and pERM specific antibodies 24 h after 
seeding at 50-60% confluence on coverslips. Using confocal microscopy Z stacks of 3 
fields per coverslip were obtained.(A) A comparison of Vect Ct and -C7 cells 
colocalisation of pERM, F-actin and Dsg3. Colocalisation shown highlighted by white 
pixels. As illustrated colocalisation occurs at cell-cell junctions and membrane 
protrusions (white arrows). Scale bare 20μm. (B) Colocalisation of pERM, F-actin and 
Dsg3 at membrane protrusions in A431-C7 focused on membrane protrusions (white 
arrows). Scale bar 10μm. (C) Z stacks of C7 cells shown in (A) & (B) Colocalisation at 
regions of interest highlight with white arrow., scale bar 50µm  
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5.3 Discussion 
Using a range of technical approaches, this chapter sufficiently demonstrates that non-
junctional Dsg3 colocalises and associates with Ezrin, predominantly in membrane 
protrusions concentrated at the basolateral plasma membrane. Presented here is also 
evidence that Dsg3 forms a multi-protein complex with proteins that not only facilitate 
complex formation i.e. through anchoring proteins, but also with those essential to the 
regulation of actin dynamics i.e. RhoGEF-like proteins. 
The precise function of non-junctional Dsg3 is still unknown. Previous reports provide 
in vitro evidence of an association between non-junctional Dsg3 and intracellular signal 
proteins including Src (Tsang, et al., 2012). This study confirms that there are two pools 
of Dsg3 in epithelial cells, consistent with the observations by other research groups 
(Aoyama and Kitajima, 1999, Baron, et al., 2012, Yamamoto, et al., 2007), and also 
shows that non-junctional Dsg3 colocalises and possibly forms a complex with Ezrin. 
Several lines of evidence supports this notion: 1) colocalisation of Dsg3 and Ezrin was 
demonstrated by fluorescent microscopy, PLA and FRET analyses (Figure 5.1-5.6); 2) 
complex formation between Dsg3 and Ezrin was reproducibly demonstrated by co-IP in 
A431-Vect control cells and a variety of cloned cell lines to show a Dsg3-dose-
dependent association (Figure 5.7 and 5.9); 3) colocalisation is particularly abundant at 
membrane protrusions. Taken together these observations suggest that non-junctional 
Dsg3 possess functions beyond serving a prerequisite pool of desmosome 
components, through its association with Ezrin in what appears to be specific sub-
cellular domains. 
An interesting observation was the ability of Dsg3 to form a complex with Ezrin and to 
a lesser extent Radixin. Interestingly, Ezrin and Radixin both contain a proline rich 
region, also known as Proline Rich Motif 1 (PRM1) which is absent in Moesin. All 
proteins that associate with profilin/profilactin (profilin–G-actin complex) have been 
found to contain the PRM1 motif (Kang, et al., 1997, Purich and Southwick, 1997, 
Watanabe, et al., 1997). Theoretically, the PRM1 of Ezrin and Radixin would facilitate 
profilin/profilactin binding which would in turn enable actin filament elongation. 
However, it is not yet known if such an interaction occurs in vivo. If proven, the 
Dsg3:Ezrin:Profilin/Profilactin complex could play an essential role in the Dsg3-
depdendent regulation of the actin cytoskeleton.  
154 | P a g e  
It is possible that the PRM1 facilitates the association of Dsg3 with Ezrin and Radixin 
and also explain why Moesin is unable to do so. However, while Ezrin and Radixin 
appear to have the potential to from complexes with Dsg3. Their cellular localisation 
will ultimately determine if they will associate and/or form a molecular complex. 
Staining profiles revealed that while Ezrin and Radixin may both have the potential to 
associate with Dsg3, Ezrin but not Radixin share a similar cellular distribution to Dsg3 
(Figure 5.8). It is important to note that the staining profiles of Radixin and Moesin 
may be mis-interpreted by the unexpectedly high level of nuclear staining, this is most 
likely non-specific, due to the known cellular localisation of Ezrin Radixin and Moesin 
as cytoplasmic (inactive state) and membrane associated (active state) (Hirao, et al., 
1996, Takeuchi, et al., 1994). Examination of the images in Figure 5.7 show that all 
ERM proteins exhibit plasma membrane association with Ezrin the most predominate, 
followed by Radixin and Moesin which exhibits the least membrane localisation in 
A431-D3 cells. 
In light of a recent study carried out be Fang et al., which observed the increased 
cytoplasmic colocalisation of Dsg3 in SqCC compared to normal squamous cell 
epithelia which where it adopts a plasma membrane localisation (Fang, et al., 2014). It 
is possible that through an association with Radixin, Dsg3 could adopt a cytoplasm 
localisation, rather than the plasma membrane localisation through Ezrin association 
(Fang, et al., 2014). In support Intercellular colocalisation between Dsg3 and F-actin 
has been reported in HaCat cells (Tsang, et al., 2012) 
Difficulty in attaining conclusive evidence regarding Ezrin ability to immunoprecipitates 
with Dsg3, in Dsg3 specific co-immunoprecipitation assay, made for an interesting 
observation. It is possible that binding of 5H10 antibody to the extracellular region of 
Dsg3 promotes a confirmational change preventing complex formation and Ezrin 
interaction, this idea is supported by encouraging evidence of complex formation in 
Myc Tag mediated pull-down. Alternatively it could be attributed to the dynamic 
nature of the interaction or the interaction occurring between relatively small subset 
of Ezrin and Dsg3 which may require a more sensitive technique for detection. This 
may also explain failure to detect Ezrin on Dsg3 pull downs assessed by mass 
spectrometry. 
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The cytoplasmic localisation of truncated Dsg3 is most likely attributed to the absence 
of the transmembrane domain that would ordinarily facilitate its incorporation into the 
plasma membrane. It would be fair to speculate that the altered cellular localisation 
would affect the spectra of proteins the truncated C-terminus protein would interact 
with. Consequently, the profile of proteins indentified may not fully reflect the protein 
interactions in vivo. In light of this, mass spectrometry analysis was performed on 
proteins isolated using full length Dsg3. Interestingly, both actin proteins and RhoGEF-
like proteins were identified with the highest degree of certainty in both full length and 
truncated pull-down. It is likely that these molecules are core components of the Dsg3 
complex and facilitate interaction between Dsg3 and Ezrin. In support the 
colocalisation of actin with Dsg3 have been previously reported at the plasma 
membrane and cytoplasm (Tsang, et al., 2012) and that Ezrin principally functions 
through its association with actin (Algrain, et al., 1993, Turunen, et al., 1994). 
Encouragingly, an interaction between Ezrin and RhoGEF protein, Dbl, has been 
previously reported in the literature (Lee, et al., 2004, Prag, et al., 2007) to promote 
directional cell migration in a mechanism involving the downstream activation of Rho 
GTPases RhoA and Cdc42. These reports support the proposed interaction of Dgs3 with 
Ezrin and Rho GEF protein(s) as a mechanism to promote cell migration. The presence 
of AKAP, in the full length Dsg3 immuneprecipitates was a particularly interesting 
finding due to its orchestrative function, targeting cellular effectors to specific cellular 
domains including PKA and PKC (Faux, et al., 1999, Klauck, et al., 1996, Rossi, et al., 
1999). If the association between Dsg3 and scaffold proteins is proven, they could 
potentially facilitate Dsg3-dependent signalling and the recruitment of PKC to facilitate 
Ezrin phosphorylation. Interestingly, it has been reported that Ezrin itself can function 
as an AKAP selectively binding to the type II regulatory subunit of PKA (Dransfield, et 
al., 1997). Additionally, AKAPs have also been implicated in orchestrating transduction 
complexes at the actin cytoskeleton to promote/regulate actin dynamics (Diviani and 
Scott, 2001, Scott, 2003, Westphal, et al., 2000). While the other proteins identified in 
complex with Dsg3 support the proposal of Dsg3-dependent signalling and actin 
regulation capabilities, in order to draw definitive conclusions additional studies would 
need to be carried out to validate and substantiate such claims. 
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The identification of actin and RhoGEF-like proteins in both Dsg3 C-terminus and full 
length pull downs and its absence in control sample is an encouraging result, 
supporting previous reports that Dsg3 regulates actin organisation and dynamics 
(Tsang, et al., 2012). Such an event has been suggested by independent researchers 
focusing on PV pathogenesis demonstrate that PVIgG binding of Dsg3 provokes actin 
re-organisation (Gliem, et al., 2010). Together, the data presented here and previous 
chapters suggest that Dsg3 may act as a regulator of the actin cytoskeleton to promote 
actin based cellular processes including cell migration and invasion, through an 
association with the actin cytoskeleton and the recruitment of actin regulators to 
specific sub-cellular domains. 
Ezrin was not detected in either the C-term and full length pull downs. This may be 
attributed to the transient nature of the interaction between Dsg3 and Ezrin and/or 
the less than adequate optimisation of the steps taken during the isolation Dsg3 
complexes. A combination of the both explanations appears plausible with the latter 
supported by our inability to identify the bait protein, Dsg3. Another consideration is 
the identification of Keratin associated proteins such as Filaggrin-2 identified in the C-
term Pull down and Plectin, Identified in the full length pull down. It cannot be ignored 
or ruled out that their presence may be attributed to potential contamination of the 
samples by human skin and hair, which is possible as these pull downs were carried 
out on the bench. In future pull down assay carried out asepctically. 
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5.4 Future work 
The proximity Ligation assay is a good tool for the qauntitation of protein-protein 
interactions in situ. However, in future the incorporation of a counter stain such as F-
actin would allow for the exact cellular localisation of the interactions to be 
determined. While attempts were made to achieve this, further optimisation was 
required to determine the best time to incorporate phalloidin Alexa Flour 488 to attain 
successful F-actin staining.  
The positive control for the PLA does not appear to yield an expected frequency of 
interactions, given that all exogenous Dsg3 expressed in A431-D3 has a mycTag, I 
would expect an interaction frequency in excess of the levels detected in the A431-C2 
cell for example. I believe that is attributed to the mycTag antibody that was used 
provided by BD bioscience which lacked sensitivity. This was replaced later during this 
study by a MycTag antibody provided by cell signalling which exhibited a much higher 
level of sensitivity. To confirm that this is the reason for the low positive Ct interaction 
frequency and experiment comparing the two mycTag antibodies will need to be 
conducted. 
To develop the mass spectrometry aspect of the study, further protocols optimisation 
to ensure the detection of the ‘bait’ protein, in this case Dsg3, would increase the 
validity of future findings. Like-wise the development of the FRET using Dsg3 and Ezrin 
tagged proteins with a FRET pair such as CFP and YFP, or conjugated primary 
antibodies rather than primary and secondary antibody conjugates would greatly 
increase the sensitivity of the assay. Additionally the affect of actin disruption on FRET 
between Dsg3 and Ezrin could be implemented to establish that actin is essential to 
their association.  
Regarding the inability to confirm the ability of Ezrin to co-immunoprecipitate with 
Dsg3, several things could be adjusted using an antibody which targets other epitopes 
of Dsg3. Alternatively Co-IP could be carried out on membrane enriched cellular 
fractions to increase the sensitivity of the assay. Furthermore, the interaction can be 
analysed using a different approach such as the Co-transfection of Dsg3 and Ezrin 
cDNA into Cos-1 cells followed by Co-immunoprecipitation analysis. 
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An interesting aspect of future investigation would be to further substantiate nature of 
the Dsg3 and Ezrin interaction. For example, to establish if they interact directly or 
indirectly the yeast 2-hybrid system could be used. If found to be direct, the point of 
interaction could be further elucidated using a series of blocking peptides. If indirect, 
the identification of critical binding partners could be confirmed using siRNA the 
consequences of which could be accessed through the examination colocalisation or 
FRET between Dsg3 and Ezrin. 
 













It has been shown that Dsg3 is capable of regulating the actin cytoskeleton (Tsang, et 
al., 2012), cell morphology and motility (Chapter 4). Chapter 5 provides evidence of a 
close association and interaction between Dsg3 and Ezrin. Such a close interaction 
posed the question, whether Dsg3 is in fact functionally regulating Ezrin activity, to 
modulate the actin cytoskeleton. 
The ability of Dsg3 to act as a membrane receptor, mediating signal transduction has 
been evidenced in pathogenesis studies of PV. Treatment of keratinocytes with Dsg3 
auto-antibodies (PVIgGs) have revealed the signalling roles of Dsg3, including its own 
rapid phosphorylation (Aoyama and Kitajima, 1999), activation of plakoglobin (Pg), PKC, 
p38 MAPK, heat shock protein p27, Src, Rho A and c-Myc etc. (Berkowitz, et al., 2005, 
Kawasaki, et al., 2006, Osada, et al., 1997, Waschke, et al., 2006, Williamson, et al., 
2006). In addition to the initiation of signalling cascades concurrent cellular events 
such as an increase in intracellular calcium concentrations (Kitajima, et al., 1999) and 
actin reorganisation (Gliem, et al., 2010) have been observed. However, the precise 
role of Dsg3 in regulating these intracellular events and mechanisms involved remains 
elusive. 
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Ezrin, as described in Chapter 1, is a membrane cytoskeleton linker protein and plays a 
role in regulating actin dynamics and the organisation of specialised membrane 
domains. Ezrin overexpression and phosphorylation at the tyrosine residue 477 and 
threonine 567 have been shown to be associated with cell migration (Crepaldi, et al., 
1997, Donatello, et al., 2012, Lee, et al., 2004, Prag, et al., 2007), cancer progression, 
metastasis and poor patient prognosis in cancers including breast, pancreas and head 
and neck squamous cell carcinoma (Chen, et al., 2011, Elliott, et al., 2005, Huang, et al., 
2011, Ma and Jiang, 2013, Mak, et al., 2012, Meng, et al., 2010, Saito, et al., 2013, 
Zhong, et al., 2012). Various kinases, including PKCα (Ng, et al., 2001), PKCθ 
(Pietromonaco, et al., 1998), Rho-, Cdc42-binding and Nck-interaction kinase 
(Baumgartner, et al., 2006, Matsui, et al., 1998, Nakamura, et al., 2000) have been 
shown to directly phosphorylate ERM family proteins. Among them, PKC has been 
reported to be activated in response to both PVIgG and Ca
2+
 switch (Kitajima, et al., 
1999). Furthermore, PKC has also been implicated to participate in actin dynamics 
(Brandt, et al., 2002), cell motility (Ng, et al., 1999, Xiao and Liu, 2013) and is known to 
be deregulated in numerous cancer cell lines with its aberrant activation promoting 
invasiveness while its inhibition perturbed cell invasion (Gopalakrishna and Barsky, 
1988, Isakov, et al., 1991, Korczak, et al., 1989, Schwartz, et al., 1990, Takenaga and 
Takahashi, 1986).  
Sharing a common feature, in the regulation of actin-based cellular events, the 
implication of Ezrin as an effector of Dsg3 through PKC would undoubtedly furnish 
Dsg3 with the means of regulating cell morphology, migration and invasion. The data 
presented in pervious chapters characterises the physical relationship between Dsg3 
and Ezrin, however, the relationship between Dsg3 and Ezrin activity remains 
undefined. It is possible that Dsg3, acting as a scaffolding protein, targets Ezrin to 
specific membrane domains through its recruitment, where Dsg3 elicits Ezrin 
activation. This chapter focuses on the work undertaken to examine this potential 
mechanism which proposes that Dsg3 and Ezrin are functionally linked. 
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Figure 6.1. Differential Dsg3 expression and ERM protein phosphorylation in sub-confluent 
and confluent culture. Western blot of total cell lysates of A431-Vect Ct (V), D3, C7 and C11 
that were seeded to achieve confluent and sub-confluent density (A). (B) Quantitaion of 2 
experiments comparing confluence and sub-confluent culture conditions. Both western blots 
were normalised against α tubulin and relative Vect control level set at 1 arbitrary unit.  
6.2 Results  
6.2.1 Overexpression of Dsg3 increases the phosphorylation of Ezrin at Threonine 
567. 
It has been shown that the phosphorylation of Ezrin at conserved C-terminal threonine 
residue 567 (Thr567) confers activation and is implicated in tumour cell migration, 
invasion and metastasis (Ng, et al., 2001). In the search for biomarkers in cancers, 
other independent studies have discovered that Dsg3 is up-regulated in squamous cell 
carcinoma in various organs of the body, particularly in lung and the lymph node with 
metastases in head and neck cancer (Patel, et al., 2013). To characterise the 
relationship between Dsg3 and Ezrin activity the level of Ezrin phosphorylation at  
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Figure 6.2 Overexpression of Dsg3 enhances ERM protein phosphorylation assessed by 
fluorescence microscopy analysis. A431 cell lines were seeded on coverslips at 50-60% 
confluence 24 h before fixation and immunostained for the indicated proteins Colocalisation in 
merged channels is highlight by the yellow/orange pixels. Four fields for each cell line were 
acquired. Illustrated are representative images for each cell line. n= 5, Scale bar20 µm.  
Thr567 with respect to Dsg3 expression was examined. For this purpose, a rabbit 
polyclonal antibody that detects phosphorylated Ezrin, Radixin and Moesin at 
Threonine 567, 564 or 558, respectively [Phospho-Ezrin (Thr567)/Radixin 
(Thr564)/Moesin (Thr558), denoted as ‘pERM’], was employed.  
In order to establish the cellular conditions that would promote Dsg3-dependent 
phosphorylation of ERM proteins, Dsg3 expression and ERM protein phosphorylation 
were examined in both confluent and sub-confluent cultures. Here, total cell lysates 
from A431-Vect Ct, -D3, -C7 and -C11 cells, seeded to achieve confluent and sub-  
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Figure 6.3 Colocalisation between Dsg3 and pERM are equally significant in A431-Vect Ct and 
A431-D3 cells. A431 cell lines were prepared and processed as previously described. Using the 
ImageJ colocalisation analysis plug-in, Pearson’s correlation Coefficients (Rr), Mander’s Overlap 
Coefficients (R) and Intensity Correlation Quotient (ICQ) were determined for Dsg3 and pERM 
staining. Two independent experiments were performed and data were representative 
(coefficient mean value ± SD) (A). (B) Representative images of A431-Vect Ct and –D3 cells 
show colocalisation between both exogenous and endogenous Dsg3 with pERM (white arrows). 
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Figure 6.4. Overexpression of Desmoglein 3 enhances the ERM protein phosphorylation 
assess by Western blot. Western blot of total cell lysates of A431 cell lines seeded at 50-60% 
density for 24 h showed increased Dsg3 expression correlated with elevated levels of pERM. 
Band density of blots were determined using ImageJ gel analysis tool normalised against 
GAPDH. (n=7, *p< 0.05).  
confluent culture 24 h prior, were extracted followed by Western blot analysis. As 
illustrated in Figure 6.1, culture confluence had an apparent effect on both Dsg3 
expression and ERM protein phosphorylation. In confluent culture Dsg3 expression and 
ERM phosphorylation were suppressed and exhibited little sample variation. In sub-
confluent culture however, the cells exhibited differential Dsg3 expression and Dsg3-
dependent ERM protein phosphorylation. In support, fluorescent microscopy was 
performed on A431 cell lines labelled with Dsg3 and pERM specific antibodies. As 
shown in Figure 6.2, a significant increase in pERM staining was observed in cell lines 
with high Dsg3 expression, A431-D3 and -C7 (p<0.01), compared to the Vect Ct, 
suggesting a dose-dependent correlation between Dsg3 expression and the 
phosphorylation of ERM proteins (p<0.01, Figure 6.2). An assessment of percentage 
colocalisation using ImageJ in these cell lines demonstrated a significant increase in the 
colocalisation between Dsg3 and pERM (>5-fold) in A431-D3 and -C7 cells compared to 
-Vect Ct (p<0.001, Figure 6.2). To confirm the colocalisation exhibited in Vect Ct and D3 
cell were equally significant, Pearson, Manders and ICQ coefficients as described in 
Chapter 5, were performed using ImageJ and showed that Dsg3:pERM staining was 
dependent, synchronous and colocalised in both Dsg3 low (A431-Vect Ct) and Dsg3 
high (A431-D3) expressing cells (Figure 6.3). In further support, Western blot analysis 
showed consistently a significant increase in ERM protein phosphorylation in Dsg3 
overexpressing cells compared to Vect Ct and C11 cells with a clear dose-dependent  
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Figure 6.5 Ezrin is the predominate ERM protein hyper-phosphorylated in response to Dsg3 
overexpression. A431-C7 cell lines were seeded 24 h prior to treatment with either Ezrin, 
Moesin specific or Scrambled Ct siRNA. A further 24 h after siRNA treatments. (A) Quantitation 
from 3 independent experiments. Blot densitometry: normalised against αTubulin and relative 
Scrambled control level set at 1 arbitrary unit (B) Illustrates a representative Western blot of 
total cell lysates was carried out with the indicated antibodies (Exp n=3, *P < 0.05, ***P < 
0.001).  
correlation with respect to Dsg3 (a representative of seven independent experiments 
is shown in Figure 6.4).  
6.2.2 Ezrin is the predominant ERM protein in A431 cells. 
The use of pERM antibody as a means of assessing Ezrin phosphorylation is limited due 
to the inability of distinguish between phospho-Ezrin (Thr567), phospho-Radixin 
(Thr564) and phospho-Moesin (Thr558). To determine which of the ERM protein 
predominantly attributes to Dsg3-dependent increases ERM phosphorylation, a 
knockdown experiment for the individual ERM proteins was carried out. Here, silencing 
was restricted to Ezrin and Moesin, the predominant ERM proteins in A431 cells 
(Yonemura and Tsukita, 1999). In this analysis, A431-D3 cells, prepared a day prior, 
were transiently transfected with Ezrin Moesin specific and scrambled Ct siRNAs. Cells 
were re-seeded 24 hrs after transfection followed by lysate extraction and Western 
blot analysis. Figure 6.5 shows that cells transfected with scrambled siRNA exhibited 
typical double bands of pERM in A431 cells, with the upper band being attributed to 
Ezrin and Radixin (~80 kDa) and the lower band attributed to Moesin (~75 kDa). 
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Figure 6.6 Desmoglein 3 silencing reduces CD44:F-actin and Ezrin:F-actin colocalisation. 
A431-D3 cell lines were seeded 24 h prior to treatment with either Dsg3 specific or Scram Ct 
siRNA. Cells were re-seeded 24 h after transfection on coverslips followed by fixation and 
immunostaining for the indicated proteins 24 h later. At least 3 fields per coverslip were 
acquired with a confocal microscope and analysed using ImageJ to determine the percentage 
colocalisation between the labelled proteins as shown in bar charts on the right. (n=2, *P< 0.05, 
**P< 0.01).  
band density (~75%) compared to control and also that of the Moesin knockdown (~10% 
reduction), implying that Dsg3-dependent increases in ERM protein phosphorylation is 
predominately attributed to Ezrin phosphorylation. Additionally,  
6.2.3 Knockdown of Dsg3 reduces Ezrin activity. 
To address the question whether Dsg3 knockdown attenuates ERM phosphorylation, 
Western blot and immunofluorescence analyses were performed on A431-D3 cell 
transiently transfected with Dsg3-specific and Scrambled siRNA as described above. No 
detectable reduction in ERM protein phosphorylation was evident following Dsg3 
silencing (Figure 6.7).  
As discussed in Chapter 1, upon activation, Ezrin functions as a regulated linker 































































167 | P a g e  
with the integral membrane proteins, such as 
CD44 and the actin cytoskeleton. In light of 
this the effect of Dsg3 silencing on Ezrin 
function was examined by accessing the 
colocalisation of CD44 with F-actin and Ezrin 
with F-actin. Illustrated in Figure 6.6 are 
representative colocalisation images of A431-
D3 cells treated with Dsg3-specfic and 
 
Figure 6.7. Desmoglein 3 knockdown appears to have no significant affect on ERM protein 
phosphorylation. Western blot analysis of Dsg3 knockdown and scrambled Ct A431-D3 cells 
prepared as previously described revels. Illustrated are representative mages of A431-Vect Ct 
and A431-D3 cells and A431-D3 cells subjected to either Scrambled Ct or Dsg3 specific siRNA 
(n > 3) 
scrambled siRNA 48h prior to immunostaining stained for CD44:F-actin and Ezrin:F-
actin. Colocalisation analysis of these images using ImageJ renders overlapping pixels 
in white. As shown the knockdown of Dsg3 significantly reduces the level of 
colocalisation between of F-actin:Ezrin and F-actin:CD44 by ~2-fold compared to the 
scrambled control, suggesting that Dsg3 function regulates Ezrin activity at the plasma 
membrane. 
6.2.4 Desmoglein 3-dependent ERM phosphorylation could be abrogated by 
inhibiting a variety of signal molecules. 
In order to elucidate the possible signalling mechanism(s) involved in Dsg3-mediated 
Ezrin activation/regulation, a pharmacological based study was performed to examine 
the effect of specific molecular inhibition on Dsg3-dependent ERM protein 
phosphorylation. In preparation, A431-C7 cells were seeded and allowed to adhere 
before being serum starved overnight. The following day cells were treated with a 
variety of pharmacological inhibitors that target various signal molecules including 
isoform-specific PKC inhibitors Bisindolymaleimide I HCl, Gӧ 6976 and Rö 31-7549. 
Bisindolymaleimide I HCl (BIM) is a potent broad spectrum competitive inhibitor for 
the ATP-binding site of PKC, highly selective for classical isoforms  
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Figure 6.8 Desmoglein 3–dependent ERM protein phosphorylation is inhibited by PKC, RhoA 
and p38 inhibition. A431-C7 cells were seeded at 50-60% confluence and allowed to adhere 
for 4-6 h before serum starved overnight. Cells were then treated with various inhibitors or 
vehicle control in media supplemented with 10% serum for ~4 h.(A) Western blot of total cell 
lysates. Quantitation of relative Dsg3 expression (B) and ERM protein phosphorylation (C) 
were shown in the bar charts showing relative band density, normalised against GAPDH (n=4, 
*P<0.05).  
particularly PKCα and PKCβ1 with no effect on calcium independent isoforms (Martiny-
Baron, et al., 1993) and Rö 31-7549 selectively inhibits all classical isoforms as well as 
novel PKCε which requires DAG but not Ca
2+ 
for activation (Wilkinson, et al., 1993). 
Other inhibitors employed include those targeting Src, ROCK, Rac1 and MAPK p38, all 
of which have been implicated in Dsg3 signalling and ERM protein activation (Auvinen, 
et al., 2007, Hébert, et al., 2008, Kawasaki, et al., 2006, Menager, et al., 1999, Tsang, et 
al., 2012, Tsang, et al., 2010). The inhibitor solvent, DMSO, was used as a vehicle 
control in these analyses. Cells were incubated with an inhibitor diluted in normal 
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Figure 6.9 Abrogation of ERM protein phosphorylation by PKC inhibition occurs in a Dsg3-
dose dependent manner. Western blotting of total cell lysates of the cell lines indicated 
seeded at sub-confluence and allowed to adhere for 4-6 h before serum starvation overnight. 
Cells were then treated with inhibitors or vehicle control (DMSO) diluted in media 
supplemented with 10% serum at concentration and time points indicated. (A) A higher 
concentration of BIM was required to bring ERM phosphorylation levels of A431-D3 and -C7, 
(Red box) Similar to those of the Vect Ct and low expression cell population -C11 (Blue boxes). 
(B) When exposed to fixed concentration of BIM, cells overexpressing Dsg3 (A431-D3 and –C7) 
maintain a higher level of ERM protein phosphorylation than those of the Vect Ct and low 
expression cells, C11. (A) n=3, (B) n=3). 
followed by cell lysate extraction. Lysates were then analysed by Western blot for Dsg3 
and pERM. As illustrated in Figure 6.8 the inhibition of PKC, RhoA, ROCK, Rac1 and p38 
resulted in a significant reduction in Dsg3-dependent ERM phosphorylation. 
Interestingly, the inhibition of p38 MAPK also resulted in a significant reduction in Dsg3 
expression, implying a negative feedback loop suppressing Dsg3 expression 
downstream of p38. Together, these results suggest that PKC, Rac1, RhoA and p38 
signalling pathways play a role, in concert, in facilitating Dsg3-dependent Ezrin 
phosphorylation in A431 cells  
6.2.5 Desmoglein 3-dependent ERM phosphorylation is abrogated by PKC inhibition. 
PKCs are the characterised serine/threonine kinases that directly regulate ERM 
phosphorylation (Ng, et al., 2001, Pietromonaco, et al., 1998, Wald, et al., 2008) and 
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al., 1999). To further investigate whether Dsg3-mediated Ezrin activation was PKC-
dependent, dose-response and time-course assays were performed using A431 cells 
treated with the broad spectrum PKC inhibitor, BIM. In preparation for the dose-
response assay, A431-Vect Ct, -D3, -C7 and -C11 were seeded for ~4 h and serum 
starved overnight. The following day cells were treated with BIM at a series of 
increasing concentrations (0.5, 5, 10, 20, 40 μM) or DMSO vehicle control diluted in 
normal growth media for 4 h. Following treatment cell lysates were extracted and 
analysed by Western blot for Dsg3 and pERM. As illustrated clearly in Figure 6.9A, a 
higher concentration of BIM (red box) was required to bring the levels of ERM protein 
phosphorylation down to that of Vect control or C11 cells treated with less 
concentration of the drug (blue boxes). This suggests that Dsg3-dependent ERM 
phosphorylation involves PKC and that PKC activity is modulated by Dsg3. Similar 
results were shown in a time-course study where A431-Vect Ct, -D3, C7 and –C11 cells, 
prepared in the same way, were treated with a fixed concentration of BIM (5µm) with 
cell lysates extracted after 0.5 and 1 h incubations. Lysates extracted at time point zero 
served as a control. As illustrated in Figure 6.9B, an observable slight increase in ERM 
protein phosphorylation at 0 h time point was evident in A431-D3 and -C7 cells 
compared to Vect Ct and C11 cells. A significant reduction of pERM was seen in all cell 
lines treated with inhibitor for both 0.5 h and 1 h incubation periods. On closer 
inspection, the degree of inhibition of ERM phosphorylation was not occurring at the 
same degree amidst different cell lines, with the level of ERM phosphorylation 
inhibition observed in A431-D3 and -C7 cells comparatively less than that of the Vect 
Ct and C11 cells (Figure 6.8B). This results show that cells with high Dsg3 expression 
retained higher levels of pERM than those with low Dsg3 expression, suggesting a 
positive correlation between Dsg3 expression and PKC activity, with Dsg3 sequestering 
PKC to phosphorylate (activate) ERM proteins in a dose dependent fashion. Together, 
these results suggest that Dsg3-mediated Ezrin phosphorylation is mediated through 
PKC. 
It has been shown that PKC isoforms localise in different sub-cellular compartments 
indicative of isoform specific function (Kiley and Parker, 1995). To examine the cellular 
localisation of PKC with respect to Dsg3, immunostaining of A431-Vect Ct and -D3 cells 
was performed using Dsg3 and pan-phospho-PKC (pPKC) antibodies. The results  
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Figure 6.10 Dsg3 colocalises with PKC at the plasma membrane in a dose dependent mannerr. 
A431-Vect Ct and D3 lines seeded at 50-60% density were fixed and immunostained for the 
indicated proteins 24 h after seeding. Here pPKC denotes pan-phospho-PKC. Image analysis 
was carried out using ImgaeJ to determine relative integrated density (B), percentage 
colocalisation (B) and various colocalisation coefficients (Rr=Pearson’s correlation coefficient, 
R=Mander’s Overlap coefficient, ICQ=Intensity Correlation Quotient in the table) (C). (A) 
Representative images of A431-Vect Ct and –D3 cells colocalisation images show only 
colocalisation pixels (Orange) (n=2, **P<0.01, ***P< 0.001). Scale bar, 30µm.  
predominately at the plasma membrane, with a significant increase in percentage 
colocalisation in A431-D3 compared to Vect Ct (Figure 6.10). Further analysis of the 
colocalisation in both cell lines using Manders, Peasons and ICQ coefficients showed 
that the colocalisation in both Vect Ct and –D3 cells is of equal significance (Figure 6.10 
Table). Currently there are 15 characterised PKC isoforms which can be classified into 3 
groups, i.e. conventional, novel and atypical. Conventional isoforms include α (alpha), 
β (beta), γ (gamma) that require DAG (Diacylglycerol), Ca
2+
 and phospholipids for their 
activation. Novel isoforms comprise δ (delta), ε (eplison), η (eta), and θ (theta) that 
require DAG but not Ca
2+
 for their activation and Atypical isoforms including ι (iota), ζ 
(zeta) and PKN (serine/threonine protein kinase) that require neither DAG nor Ca
2+ 
for 
their activation. In order to determine which group of PKCs was engaged in Dsg3 
mediated Ezrin phosphorylation (activation), an experiment with various PKC inhibitors 
was performed in A431-C7 cells either in the presence or absence of calcium. The 
calcium chelating agent, EGTA, has been reported to have the similar effect to that of 
pharmacological inhibition of PKC (Hui, et al., 2006). Assuming that classical isoforms 
ofPKC were involved, depletion of extracellular calcium should reduce ERM protein 
phosphorylation. To test this hypothesis three PKC inhibitors were employed, the 
broad spectrum PKC inhibitor BIM (Toullec, et al., 1991), Gӧ 6976 for classical isoforms 
(Martiny-Baron, et al., 1993) and Rö 31-7549 a broad spectrum PKC inhibitor with a 
preference to classical isoforms, particularly PKC alpha (Wilkinson, et al., 1993). As 
illustrated in Figure 6.10, the addition of calcium caused a significant increase in Dsg3 
expression, as expected. In relation to ERM phosphorylation, calcium switching 
appeared to have little or no apparent effect on the level of phosphorylation. The 
inhibition of PKC did not appear to have any effect on Dsg3 expression in the presence 
or absence of calcium (Figure 6.11). However, only in the absence of calcium did all 
three inhibitors bring about a significant reduction in ERM protein phosphorylation  
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Figure 6.11 Inhibition of dependent ERM protein phosphorylation by PKC inhibition is 
enhanced by extracellular calcium depletion. Western blot analysis of total cell lysates of 
A431-C7 cells, in the presence and absence of calcium, treated with various PKC inhibitors. (A) 
Schematic for experimental time line, briefly cells were seeded at sub-confluence for 4 hrs and 
then serum starved overnight. Media was then replaced with calcium-free media for 2 h 
before addition of either media with Ca
++
 and inhibitor or Ca
++
 -free media together with 
inhibitors. (B) Western blots of Dsg3 and pERM, a representative of three independent 
experiments. GAPDH was used as a loading control here. (C) Quantitation of relative band 
density from 3 independent experiments illustrated in A & B. n=3,normalised against GAPDH 
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compared to the DMSO controls. On close inspection, only the inhibition of ERM 
protein phosphorylation by Rö 31-7549 was significantly enhanced in the absence of 
calcium (Figure 6.10) suggesting an additive effect. Collectively, this suggest classical 
PKCs are involved in Dsg3-dependent Ezrin phosphorylation (activation). However, 
further investigation would be required to draw definitive conclusions. 
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6.3 Discussion 
This chapter presents data suggesting that Dsg3 acts as an upstream regulator of PKC 
to induce Ezrin activation at the plasma membrane. The membrane localisation of the 
Dsg3:Ezrin complex presented in chapter 5 together with the data presented here with 
regard to the colocalisation between Dsg3 and PKC suggests the likelihood of a 
regulatory complex of Dsg3:pPKC:Ezrin at the plasma membrane.  
Regarding Dsg3 in the regulation of Ezrin phosphorylation, the gain- and loss-of-
function experiments presented inconsistent results. While the gain-of-function 
analysis showed reproducibly a significant correlation between Dsg3 expression and 
ERM protein phosphorylation, Dsg3 silencing failed to show the suppression of ERM 
phosphorylation. This inconsistency could be attributed to constitutive activation of 
Ezrin in cells overexpressing Dsg3. However, using fluorescent microscopy Dsg3 
knockdown appeared to significantly suppress Ezrin activity by inhibiting its function as 
a membrane cytoskeleton linker. Together, this suggests that Dsg3 may not directly 
regulate Ezrin activation but rather indirectly through a mechanism involving the 
recruitment of Ezrin to the plasma membrane where it is phosphorylated by other 
protein(s). It is also possible that a compensation mechanism by other desmosomal 
cadherin(s) is at play as a degree of functional redundancy has been reported in other 
studies (Brennan, et al., 2010, Mahoney, et al., 1999, Pan, et al., 2011). Alternatively 
other mechanisms of ERM activation may be responsible for the sustained ERM 
protein phosphorylation in cells with Dsg3 silencing.  
The data presented provides strong evident of Dsg3s ability to regulate Ezrin activity 
and I believe that this is achieved through a mechanism involving the recruitment of 
Ezrin to the plasma membrane where it is activated by PKC. In support, reports have 
showed induced PKC activation in response to PVIgG binding to Dsg3 in human 
keratinocytes (Kawasaki, et al., 2006, Kitajima, et al., 1999), In addition to the 
recruitment of, PKCα and to a lesser extent PKCδ, η and ζ from the cytosol to the 
cytoskeleton (Osada, et al., 1997). Furthermore, I have demonstrated that Dsg3-
dependent ERM phosphorylation is significantly suppressed by the inhibition of PKC as 
well as RhoA and p38MAPK, both of which have also been reported in Dsg3 specific 
signalling events (Berkowitz, et al., 2005, Waschke, et al., 2006), suggesting that these 
molecules act in concert as downstream effectors of Dsg3. On closer inspection using 
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dose- and time-dependent inhibition experiments, which identified a correlation 
between PKC and Dsg3-dependent ERM phosphorylation, suggests that Dsg3 is 
sequestering PKC at the plasma membrane where it phosphorylates (activate) Ezrin. 
This is supported by observations using fluorescence microscopy which demonstrated 
colocalisation of Dsg3 and PKC at the plasma membrane which was significantly higher 
in Dsg3 overexpressing cells compared to the Vect Ct. With regards to the specific role 
of RhoA, Rac1 and p38MAPK, further studies are required to elucidate their 
contribution to the phosphorylation of Ezrin in this system. 
Taking into consideration that PKCα has been implicated in Ezrin activation and 
localisation (Stapleton, et al., 2002) and Dsg3-dependent signal transduction (Kitajima, 
et al., 1999) the data presented here provide strong evidence of a mechanism by 
which Dsg3 regulates the PKC/Ezrin pathway that in turn influences actin dynamics 
associated cell motility. Furthermore, the data implicate the classical PKC isoforms in 
the activation of this pathway. PKCs in general have been implicated in regulating cell 
adhesion, motility and invasion, with increased activity of PKCα in stimulating cell 
motility and invasion (Sun and Rotenberg, 1999), novel PKCη involved in cell adhesion 
(Chun, et al., 1996) and spreading (Berrier, et al., 2000). PKCθ has been shown to 
regulate migration in endothelial cells (Tang, et al., 1997) while atypical isoforms have 
been implicated in the organisation of the actin cytoskeleton (Laudanna, et al., 1998, 
Uberall, et al., 1999). To determine which isoforms(s) of PKC are specifically involved in 
the Dsg3:PKC:Ezrin pathway, additional study is necessary. 
How Dsg3 is able to facilitate complex formation with other non-desmosomal proteins 
is not known. The Mass Spec data presented in Chapter 5 identifies A-kinase anchor 
protein (AKAP) in the Dsg3 complex. AKAP, a scaffold protein, has been shown to 
interact with PKC, thus theoretically AKAP could facilitate the recruitment of PKC to the 
Dsg3:Ezrin complex. The ability of Dsg3 to be phosphorylated has been demonstrated 
previously (Aoyama and Kitajima, 1999, Kawasaki, et al., 2006), however, the exact 
mechanism by which this occurs remains unknown but the data presented suggests 
that this event could facilitate the formation of the Dsg3:Ezrin:PKC complex. 
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6.4 Future Work 
To ascertain with certainty which PKC isoform is acting downstream of Dsg3, I propose 
firstly, the use of DAG inhibition in conjunction with calcium depletion using both 
intracellular and extracellular calcium chelators, for example BAPTAAM and EGTA 
respectively. I would expect classical isoforms to be inhibited by both DAG inhibition 
and calcium depletion while novel isoforms would still function in the absence of 
calcium but not with DAG inhibition. Finally atypical isoforms would not be affected by 
DAG or Calcium depletion. Once one or more of the isoforms groups have been 
excluded, isoform specific antibodies could be applied to identify candidates that 
colocalise with Dsg3 and Ezrin. This could then be validated with the use of isoform 
specific siRNA or antisense oligonucleotide mediated silencing to provide a more 
definitive identification. On speculation PKCα is the most likely candidate as it is not 
only shown to activate Ezrin but also to be activated downstream of Dsg3.  
What would also be of value, is to knockdown Dsg3 and examine its effect on PKC sub-
cellular localisation, phosphorylation and activity compared to the Vect Ct. I would 
expect that knockdown would inhibit the translocation of PKC to the plasma 
membrane where it could potentially form a complex with Dsg3:Ezrin to facilitate Ezrin 
phosphorylation and subsequent activation. 
Thus far, with regard to PKC the use of pPKC antibodies was used as an indication of 
PKC activity. Fractionation of cell lysate to yield cytosolic and particulate factions 
followed by enzymatic determination of PKC activity would be a more accurate 
indication of PKC activity and this could be carried out in cell lines overexpressing Dsg3 
compared to the vector control and knockdown of Dsg3 compared to a Scrambled 
control to test the hypothesis that Dsg3 recruits PKC to the plasma membrane where it 
is utilised as a Dsg3 effector. 
Finally this study proposes that non-junctional Dsg3 exhibits extra-junctional functions. 
To determine which pool of Dsg3 colocalises with pPKC would further validate our 
proposal. I would expect to observe pPKC present in the Triton soluble fraction 
colocalising with non-junctional Dsg3. 
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As discussed in Chapter 1 the transcription factor AP-1 has been shown to function as a 
regulator of EMT and cancer progression (see section 1.4). It has been previously 
reported that the overexpression of Dsg3 reduces the levels of E-cadherin (Tsang, et al., 
2010), the loss of which being a hallmark of EMT with the dissolution of adheren 
junctions (Lamouille, et al., 2014).taken together with the observation reported here 
and previously that the overexpression of Dsg3 does not promote adhesion but rather 
promotes a migratory phenotype (Tsang, et al., 2010) suggesting that Dsg3 in some 
way promotes EMT.  
The overexpression of AP-1 components and increased activity of AP-1 up-regulate the 
expression of AP-1 target genes, many of which have been identified as having 
putative roles in tumour development and progression (Hu, et al., 1994, Kustikova, et 
al., 1998, Marconcini, et al., 1999). Furthermore, Ezrin is a known transcriptional target 
of AP-1 and has been demonstrated to promote cancer cell invasiveness through c-Fos 
(Jooss and Müller, 1995). I show that Dsg3 may be exerting its ability to regulate pro-
invasive and migratory actin based processes through the modulation of Ezrin activity 
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Thus it is likely that AP-1 is also involved in Dsg3 mediated signalling to promote cancer 
cell migration and invasion.  
This chapter outlines several lines of investigation in an effort to identify potential 
signalling events that may orchestrate Dsg3-mediated activation of Ezrin, cell migration 
and invasion.  
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7.2 Results 
7.2.1 Desmoglein 3 enhances the phosphorylation of numerous kinases. 
The initial exploration of other potential signalling mechanisms involved in Dsg3-
dependent signalling in A431 cells, a human phospho-kinase array (R&D systems) was 
performed to gain a global perspective on the effect of Dsg3 overexpression on a 46 
kinases. In this study, A431-Vect Ct and –D3 Cells were plated at sub-confluent density 
followed by cell lysate extraction 5 h after seeding. The array was carried out 
immediately according to the manufacturers specification (R&D systems). The dot 
blots generated from the array were analysed using ImageJ to determine the density of 
each duplicate which represented a phosphorylated kinase. Values for each duplicate 
were averaged and the background subtracted to generate an average value for each 
phospho-kinase. Finally, the Log2 ratio of D3:Vect Ct was calculated which allows for 
the identification of 2 fold variations in kinase phosphorylation in the Dsg3 
overexpressing cells with respect to the control. Treating both increases and decreases 
equally differential phosphorylation results in a ratio value of >1 or >-1 where a log2 
ratio of 1 or -1 representing a 2-fold increase or decrease, respectively. Figure 7.1A 
shows the result of the array. As illustrated, a wide range of kinases exhibited 
increased phosphorylation in A431-D3 cells relative to the Vect Ct. Among them, Pyk-2 
(red bar), STAT1-Y701 (yellow bar) and c-Jun-S63 (black bar) kinases were shown to 
exhibit a 2-fold increase in Dsg3 overexpressing cells. STAT1 is a member of the Signal 
Transducers and Activators of Transcription (STAT) family. Phosphorylation of tyrosine 
residue 701 induces dimerisation, nuclear translocation and DNA binding to regulate 
the transcription of Interferon stimulated genes (Ihle, et al., 1994). Pyk-2 is a non-
receptor tyrosine kinase that mediates signals from G-protein coupled receptors in the 
MAP Kinase pathway (Schlaepfer, et al., 1999). As described in the introduction, c-Jun 
is a bZIP protein and predominant component of the AP-1 transcription factor. 
Phosphorylation of c-Jun at serine residue 63 increases its transcriptional activation 
(Smeal, et al., 1994) and has also been implicated in cancer development by up 
regulating genes which promote proliferation, angiogenesis and to a lesser extent 
invasiveness of cancer (Eferl and Wagner, 2003). In summary, this array analysis 
indicates that various kinases are induced by Dsg3 overexpression and may participate 
in the regulation of Ezrin activation and cell migration and invasion. 
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Figure 7.1 The overexpression of Dsg3 enhances the phosphorylation of a variety of kinases. 
A431- Vect Ct and –D3 cell lines were seeded at 50-60% density. 5 h after plating cell lysates 
were collected and analysed by kinase array according to the manufacturer’s specification (B). 
(A) Illustrated the Log2 Ratio of D3 cells vs. Vect Ct. The threshold of -1 and 1 represent a 2-
fold decease or increase Highlighted in colured bars are kinases that exhibited a 2 fold increase, 
STAT (yellow), Pyk2 (red) and cJun (black). The trend of increased phosphorylation of STAT 
kinases is highlight by blue shading. (C) Western blot of lysates used as an input in array 
analysis.  
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Figure 7.2 The overexpression of Dsg3 does not affect total integrin expression. (A) Western 
blot of total cell lysates of four A431 cell lines with high or low Dsg3 expression. (B) Fold 
change in the integrin expression in A431-D3 cells. Blots normalised against GAPDH and 
relative Vect control level set at 1 arbitrary unit. Data were pooled from 4 independent 
experiments and showed that the overexpression of Dsg3 did not significantly affect integrin 
protein levels except for α2 which showed a marginal increase (1.5-fold). The threshold of 1 
indicates the Vector control expression for each protein (mean ± SD).  
7.2.2 Desmoglein 3 overexpression does not affect integrin expression. 
Pyk2 has been shown to be important to the integration of signals initiated by a 
diverse group of extracellular stimuli, including integrin binding (Schlaepfer, et al., 
1999). PYk2 has also been implicated in cell spreading and motility (Watson, et al., 
2001). Intgerins are heterodimeric adhesion receptors composed of an α and a β 
subunit that facilitate cell-extracellular matrix adhesion and also transmit signals vital 
to cell survival, proliferation and motility (Hynes, 2002). Integrins play a pivotal role in 
a range of physiological processes, including cell migration, wound healing and 
immune responses. Aberrant integrin signalling is involved in the development of 
various human diseases including cancer through their ability to influence cell  
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spreading (Flevaris, et al., 2007), cell motility (Holly, et al., 2000, Huttenlocher and 
Horwitz, 2011), invasiveness, growth and survival (Parise, et al., 2000). The 
observations from the phospho-kinase array (Figure 7.1) together with previous 
findings in cell spreading and migration suggests possible cross-talk between integrin 
and Dsg3 mediating signalling. To address the question whether Dsg3 is able to 
influence integrin expression, Western blot of total cell lysates from A431-Vect Ct, -D3, 
-C7 and -C11 cells was performed using a variety of integrin specific antibodies. For 
these experiments A431 cell lines were seeded at sub-confluence and allowed to 
propagate overnight prior to harvesting cell lysates. Three independent experiments 
were carried out comparing the effect of Dsg3 overexpression to the Vect Ct. As 
illustrated in Figure 7.2 the overexpression of Dsg3 appeared to have no significant 
effect on the expression of integrin α5, αV, α3, αL, β4, β3 or β1, while integrin α2 
showed a marginal increase compared to Vect Ct cells. 
7.2.3 Desmoglein 3 does not affect STAT protein phosphorylation. 
The array analysis revealed that the overexpression of Dsg3 promoted a 2-fold increase 
in the phosphorylation of STAT1 (Y701) and to a lesser extent the phosphorylation of 
STAT 4, 5a, 5b, 6 and 3 (bars highlight in Figure 7.1). The STAT protein family, of which 
there are 7 members, are transcription factors, which, upon JAK induced activation 
facilitate the transcription of the cytokine inducible genes. STAT1 facilitates the 
transcription of interferon-stimulated genes that are anti-proliferation, pro-apoptosis 
and immune surveillance (Bennett, et al., 1994, Bromberg, et al., 1996, Kaplan, et al., 
1998). In this regards, it is considered to be a tumour suppressor. However, 
inappropriate activation of STAT1 has also been observed in a variety of malignant cells 
including breast cancer, head and neck squamous carcinoma and leukemia (Gouilleux-
Gruart, et al., 1996, Weber-Nordt, et al., 1996), suggesting that STAT1, under specific 
conditions, may contribute to rather than inhibit malignant transformation (Haura, et 
al., 2005). STAT3, 5a/b and 6 have all been associated with cancer progression, 
enhancing invasiveness and a poor clinical outcome (Chen, et al., 2007, Dagvadorj, et 
al., 2010, Liao, et al., 2010, Merk, et al., 2011, Yu, et al., 2009).To validate the finding 
observed in the array and examine whether Dsg3 regulates STAT activity to promoting 
migration and invasion in Dsg3 overexpressing cells, Western blot analysis of total cell 
lysates from A431-D3 and -Vect Ct cells were performed. Blots were probed for  
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Figure 7.3 Overexpression of Dsg3 had no significant effect on the STAT phosphorylation. (A) 
Western blots of total lysates of A431-Vect Ct and D3 cell lines that were seeded at 50-60% 
density and harvested 5 h later. (B) Fold change in STAT phosphorylation in A431-D3 compared 
to vector control cells. Results were summarised from 3 independent experiments showing 
that overexpression of Dsg3 did not significantly affect the STAT phosphorylation. The 
threshold of 1 indicates the phosphorylation level of control cells. Blot densitometry: 
normalised against GAPDH and relative Vect control level set at 1 arbitrary unit (n= 3, mean ± 
SD).  
phosphorylated STAT1, 2, 3, 5, and 6 using the phospho-STAT antibody sampler kit 
(Cell Signalling Technology). The blots from 3 independent experiments were analysed 
using ImageJ to determine the band density and further in Excel to determine fold 
change with respect to the Vect Ct. As shown in Figure 7.3, the overexpression of Dsg3 
did not appear to have any significant effect on the phosphorylation of the STAT 
proteins analysed. 
7.2.4 Desmoglein 3 regulates c-Jun expression and phosphorylation of residues S63 
and S73. 
The phospho-kinase array also demonstrated an increase in c-Jun phosphorylation at 
serine residue S63 (pc-JunS63) in A431-D3 cells, implicating Dsg3 in the regulation of 
AP-1 activity. To substantiate this preliminary array finding, various methodologies 
including fluorescence microscopy and Western blot analyses were employed to 
investigate the effect of Dsg3 on c-Jun protein expression and phosphorylation at 
serine residues 63 (pc-JunS63) and 73 (pc-JunS73). Phosphorylation of both residues 
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Figure 7.4 Overexpression of Dsg3 promotes cJun expression and phosphorylation at Serine 
63 and 73 assessed by fluorescence microscopy analysis. Cells were seeded at 40-50% 
confluence and 24 h later cells were fixed with Methanol:Acetone at 1:1 and immunostained 
with the indicated antibodies. Three random fields were captured and images were analysed 
using ImageJ to determine the integrated density per cell. (A) The overexpression of Dsg3 
showed to significantly increase the phospho-cJun S63 and S73 staining compared to vector 
control cells. (B) Knockdown of Dsg3 in A431-D3 significantly reduced the total cJun staining 
(n=2. **P<0.01, *P<0.05). 
was performed on A431 cell lines that were seeded on coverslips 24 h prior to fixation 
and immunostaining. The acquired images were analysed using ImageJ to 
determinethe integrated density per cell for each protein target. As illustrated in 
Figure 7.4A, a significant increase in pc-JunS63 (~2-fold) and pc-JunS73 (~0.5 fold) was 
identified in A431-D3 cells compared to the Vect Ct (p<0.05). Knockdown of Dsg3 in 
A431-D3 cells showed an opposite effect with a marked reduction in total c-Jun protein 
expression (Figure 7.4B). To investigate the dose-dependent nature between Dsg3 and 
cJun, high and low Dsg3 expressing cells, A431-C7 and -C11 respectively, were included 
in Western blot analysed together with A431-Vect Ct and D3 cells. As illustrated in 
Figure 7.5 a clear dose-dependent correlation between Dsg3 expression and the 
phosphorylation of c-Jun-S63 and S73 was displayed. No significant relationship was 
observed between total cJun and Dsg3 expression in this analysis (Figure 7.5). Taken 
together, the data presented here suggests that Dsg3 regulates the c-Jun 
phosphorylation. 
It has been reported that the sub-cellular localisation of c-Jun correlates with 
transcriptional activity (Nateri, et al., 2004, Weiss, et al., 2003). To ascertain if 
modulation of Dsg3 affects the cellular localisation of c-Jun, fluorescence microscopy 
was performed on A431-D3 cells transfected with either scrambled control or Dsg3 
specific siRNA as described previously. Nuclear staining of c-Jun in both control and 
Dsg3 knockdown cells was quantitatively analysed using ImageJ to generate cross-
sectional nuclear staining profiles. The graphical presentation of the staining profiles 
shown in Figure 7.6 illustrated that compared to control cells, knockdown of Dsg3 in 
A431-D3 cells reduced the nuclear localisation of c-Jun, observed as a reduction in the 
integrated density (mean grey value) within the nucleus. Collectively, these studies 
suggest that Dsg3 regulates c-Jun phosphorylation (activation) at S63 and S73 which is 
essential for the dimerisation and AP-1 transcription activity in the nucleus. 






Figure 7.5 Overexpression of Dsg3 enhances the 
phosphorylation of cJun-S63 and S73 but not 
total cJun.  Western blotting analysis of A431 cell 
lines expressing high (D3, C7) and low (Myc tag Ct, 
C11) Dsg3. Total cell lysates were harvested 5 h 
after cell seeding at 40-50% confluence. An 
increased phosphorylation of cJun-S63 and S73 
was detectable in both D3 and C7 compared to 
MycTag Ct (expressing endogenous Dsg3) and C11 
cells, indicating a clear correlation between the 
phosphorylation of cJun-S63 and S73 and the 
level of Dsg3 expression. Dsg3 expression does 
not appear to affect total cJun expression ( n = 3). 
 
7.2.5 Desmoglein 3 promotes AP-1 transcriptional activity. 
Thus far, the data suggests that Dsg3 regulates the phosphorylation of c-Jun at S63 and 
S73, a prerequisite for transcriptional activity. To evaluate whether the increased cJun 
phosphorylation confers increased AP-1 activity in A431 cells, a Luciferase reporter 
assay was used. This assay works on the principle that the expression of target genes 
can be used as an assessment of transcriptional activity. Based on this principle, the 
Luciferase enzyme gene is inserted downstream of the AP-1 promoter resulting in the 
transcription of the Luciferase enzyme. The level of Luciferase transcription can be 
measured directly by the addition of the Luciferase enzyme substrate. In the presence 
of Luciferase enzyme the addition of substrate results in luminescence, the amount of 
which is directly proportional to the level of AP-1 transcriptional activity.  
The Luciferase reporter assay was performed using A431-parental cells which were co-
transfected with increasing concentrations (0, 0.25, 0.1 and 1 µg) of pBABE-hDsg3.myc, 
supplemented with pBABE-GFP to make the total concentration of cDNA constant (i.e. 
1 µg per well), together with either wild type AP-1:luciferase construct or vector 
control construct (1 µg per well) which served as a negative control. As illustrated in 
Figure 7.7A, the transient overexpression of Dsg3 in A431 cells at increasing 
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Figure 7.6 Knockdown of Dsg3 affected the nuclear localisation of cJun. A431-D3 cell lines 
treated with either Dsg3 specific or scrambled control siRNA at a final concentration of 50 nM 
for 48 h before fixation and immunostained with total cJun antibody. The immunofluorescence 
profiles across each nucleus of >60 cells were analysed in both scrambled Ct and knockdown 
cells and showed that knockdown of Dsg3 reduced cJun nuclear staining. Scale bar 40 μ.  
significant increase in luminescence. To further validate this finding, a knockdown 
study was performed in A431-D3 cells. Cells were transiently transfected with Dsg3 
specific or scrambled Ct siRNA. The following day, cells with or without Dsg3 
knockdown were subjected to transfection with either wild type AP-1 or 
vector:Luciferase construct. The Luciferase assay was performed a further 24 h later. 
As shown in Figure 7.7B, Dsg3 silencing in A431-D3 cells significantly reduced (~4-fold) 
Luciferase activity compared to the scrambled Ct. Collectively, these results indicate 
that Dsg3 regulates the AP-1 transcriptional activity in a dose-dependent manner. To 
ascertain that the Dsg3-dependent AP-1 activity was not restricted to A431 cells but 
rather a universal mechanism, the AP-1 response to the transient overexpression of 
Dsg3 was also analysed in MDCK and Cos-1 cell lines (courtesy of MSc student, Suzan 
Hama). Cos-1 and MDCK cells were subjected to co-transfection as described above 
and the luciferase activities were determined 48 h later. As shown in Figure 7.8, a 
significant increase (~4-fold) in luciferase activity was consistently observed in cells 
transfected with hDsg3.myc but not GFP control, indicating that Dsg3 is also able to 
regulate AP-1 transcriptional activity in other cell types. Taken together, these findings 
corroborate the above finding and strongly suggest that the Dsg3-depenedent 
regulation of cJun:AP-1 activity is not restricted to A431 cells but appears to be a 
universal mechanism. 
7.2.6 Desmoglein 3-dependent AP-1 activity is abrogated by JNK, PKC, p38 and Rac1 
inhibition. 
In an attempt to identify the downstream effectors of Dsg3 which leads to AP-1 
activation, the Luciferase assay was carried out in conjunction with various inhibitors 
that target a range of signalling pathways. In this case, 24 h after co-transfection, cells 
were re-seeded and allowed to adhere for 6 h. Media was then changed to serum free 
media, and cells were subjected to serum starvation overnight. The following day, 
inhibitors diluted in growth medium (DMEM supplemented with 10% serum) were 
added to cultures for 4 h before proceeding with the Luciferase assay (assayed 48 h   
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Figure 7.7 Overexpression of Dsg3 promotes AP-1 transcriptional activity. (A) Luciferase 
reporter assay demonstrates a significant increase in the AP-1 transcription activity in a dose-
dependent manner in A431 parental cells co-transfected with pBABE-hDsg3.myc and AP-
1:Luciferase construct (black bars) but not with pBABE-hDsg3.myc and Vector:Luciferase 
construct (grey bar). The total amount of cDNA was supplemented by pBABE-GFP (as stated) 
and 1ug of each construct was used so a total of 2ug of constructs were used in each well (n=3, 
***P < 0.001, **P < 0.01). (B) Silencing of Dsg3 in A431-D3 cell line significantly reduces the 
AP-1 transcriptional activity. Cells were treated with either Dsg3 or scrambled control siRNA at 
a concentration of 50nM for 24 h prior to transfection with 1ug AP-1:Luciferase construct 
(black bar) or Vector:Luciferase construct (grey bar). After further culture for 24 h cell lysates 
were harvested and assayed for Luciferase activity. The representative result is shown (n=3, 
**P < 0.01).  
after transfection). The concentrations of inhibitors used in this experiment are as 
described previously (Table 2.2). As indicated in Figure 7.9, the Dsg3-dependent 
activation of AP-1 appeared to be abrogated by inhibition of JNK, PKC, p38, Src and 
Rac-1, respectively (courtesy of a Master student Sazan Hama), suggesting their 








































































GFP cDNA (ug)                    1.0            0.75          0.5            0.0
**
191 | P a g e  
Figure 7.8 Dsg3 regulates the AP-1 transcriptional activity in Cos-1 and MDCK cells. Cos-1 and 
MDCK cell lines were co-transfected with either GFP or hDsg3.myc construct in conjunction 
with wild type AP-1:Luciferase construct. 48 h later, the Luciferase assay was carried out. As 
shown, the overexpression of Dsg3 resulted in increased Luciferase activity (n=3 per cell line, 
*** P< 0.001; courtesy of Suzan Hama).  
 
 
Figure 7.9 Inhibition of PKC, p38, Src and Rac-1 abrogated Dsg3-dependent activation of AP-1 
transcription. Cos-1 cells were co-transfected with either GFP or hDsg3.myc and WT AP-1 
targeting luciferase construct. Twenty-four h following transfection, cells were serum starved 
overnight. Forty-eight h after transfection, cells were treated with the indicated inhibitors 
diluted in DMEM plus 10% serum for 4 h. Total cell lysates were collected and assayed for 
luciferase activity (n=3) courtesy of Suzan Hama, Mean luciferase activity ± SD, all samples 
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7.3 Discussion 
In summary, the data presented in this chapter demonstrate a novel function of Dsg3 
as an upstream regulator of AP-1 transcriptional activity through the modulation of 
cJun phosphorylation.  
The ability of Dsg3 to act as a cell surface receptor for various intracellular signalling 
has been established through studies employing Dsg3 autoantibody which upon 
binding provokes the activation of p38 and PKC as downstream effectors of Dsg3-
dependent actin reorganisation (Kawasaki, et al., 2006). This finding is in agreement 
with the data presented in this study, that provides evidence that Dsg3 regulates c-
Jun:AP-1 activity through JNK, p38 and PKC. The activation of PKC by phorbol esters or 
diacylglycerol has been reported to induce at least two MAPK (mitogen-activated 
protein kinase) pathways, the ERK (extracellular signal-regulated kinase) pathway and 
JNK (c-Jun N-terminal kinases) pathway (Lang, et al., 2004), with the induction by PKC 
increasing AP-1 activity through the modulation of c-Jun, c-Fos and ATF2 (Boyle, et al., 
1991). 
A recent study by Chen et al (2013) has demonstrated that DSG3 silencing increased 
the translocation of plakoglobin (Pg) to the nucleus where it interacts with the TCF/LEF 
transcription factor and inhibits its transcriptional activity to suppress tumour growth 
and invasion (Chen, et al., 2013). Previous work by Dr Wan has shown that the 
overexpression of Dsg3 in A431 cells promotes an increase in tyrosine phosphorylation 
of β-catenin (Tsang, et al., 2010) In support Figure 7.1 illustrates an increase in β-
catenin phosphorylation although below the cut off threshold (2-fold). Tyrosine 
phosphorylation of β-catenin at residue 142 has been identified to increase its 
dissociation from the E-cadherin adhesion complex and enhance its association with 
the LEF/TCF cofactor, BCL9 as a result of increasing β-catenin transcriptional activity 
(Brembeck, et al., 2004). Additionally, increased β-catenin activity (2~fold) was 
detected in A431-D3 cells compared to the Vect Ct (unpublished data). It has also been 
reported that c-Jun interacts with TCF4 to form a tertiary complex containing c-Jun, 
TCF4 and β-catenin which was shown to interact with the c-Jun promoter thus 
conferring transcription activity, in a JNK-dependent manner, in intestinal 
tumourigenesis (Nateri, et al., 2005). Thus it is likely that the phosphorylation of β-
catenin in Dsg3 overexpressing cells also contributes to the activation of cJun. 
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Together, these reports are consistent with the proposal that Dsg3 acts as an upstream 
regulator of JNK/cJun pathway to promote cancer cell migration and invasion. 
The relationship, or lack of, between Dsg3 and total c-Jun proves to be of less 
significance compared to its phosphorylation suggesting that Dsg3 regulates the 
activity of c-Jun:AP-1 through post translational modification rather than by regulating 
its expression. Phosphorylation of c-Jun at N-terminal S63 and S73 mediated by JNK is 
considered to be the most important regulatory phospho-sites by increasing the 
transcriptional activation of AP-1 (Dérijard, et al., 1994) as both a c-Jun homodimer 
(Pulverer, et al., 1991, Smeal, et al., 1991) or heterodimer (Deng and Karin, 1994). The 
phosphorylation of these sites has also been implicated to reduce ubiquitination and 
subsequent degradation of c-Jun, thus increasing its stability (Musti, et al., 1997).  
As discussed in Chapter 1, AP-1 dimeric composition determines the genes that are 
regulated. The data presented thus far implicates c-Jun as a downstream effector of 
Dsg3. However, what remains unknown is whether the Dsg3 mediated AP-1 activity is 
facilitated by c-Jun homodimers or heterodimers. Both c-Jun homodimers and c-Jun:c-
on Fos heterodimers preferentially bind the TRE (Smeal, et al., 1989), however, the 
stability and DNA binding affinity of the heterodimer is significantly higher than that of 
homodimers (Rauscher, et al., 1988). As a result, when co-expressed the heterodimeric 
combination results in more efficient activation of AP-1 response genes (Chiu, et al., 
1988, Rauscher, et al., 1988, Smeal, et al., 1989). Based on this observation and that 
provided by Cavigelli et all who demonstrates that MAPKs, JNK and ERK are capable of 
activating Elk-1:TCF to induce c-Fos and ATF expression (Cavigelli, et al., 1995) one 
would speculate that Dsg3 regulates heterodimeric AP-1 rather than c-Jun 
homodimers. However, it remains undefined whether overexpression of Dsg3 acts also 
cFos. It is possible that activation of cFos also occurs in Dsg3 overexpressing cells that 
in turn contributing to the enhanced migratory phenotype of these cells.     
With regards to Integrin expression, the data presented in this Chapter suggests that 
Dsg3 overexpression has no significant effect on integrin protein expression. However, 
it cannot be ruled out that the integrin activity may vary in relation to the Dsg3 
expression which warrants further study. In addition, the culture condition and cell 
harvesting time point may not have been optimal to identify differential integrin 
profiles. Furthermore, the phosphorylation status of integrins could also be of 
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importance as it has been shown that the phosphorylation of β subunit of integrin 
regulates integrin activation.  
While this aspect of this study are still in its infancy, the data presented in this Chapter 
provides strong evidence that Dsg3 regulates c-Jun:AP-1 transcriptional activity to 
promote cancer cell migration and invasion, collectively, providing a valuable link 
between novel non-junction Dsg3 function and an established mechanism of c-Jun:AP-
1 activation in cancer development. 
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7.4 Future work  
The work carried out in this chapter provide the basis for additional studies to 
determine the downstream effectors of Dsg3 which lead to the activation of JNK and 
the dimeric composition of c-Jun:AP-1 which would ultimately uncover the AP-1 
specific transcriptional array of target genes induced by Dsg3 to promote migration 
and invasion. It would also be of interest to examine the effect of Dsg3 expression of 
cFos activity. 
To confirm that Dsg3-dependent activation of AP-1 activity infers migration and 
invasion, functional assays of stable Dsg3 cell lines (A431-D3 or C7) transfected with 
either c-Jun specific or Scrambled siRNA could be performed. I would expect to 
observe inhibited migration and invasion in c-Jun silenced cells compared to the 
Scrambled control and Vect Ct cells. 
Preliminary inhibitor study findings support PKC’s role as a downstream effector of 
Dsg3 in regulation of AP-1 activity but also implicates p38, rac1 and Src downstream of 
Dsg3 with their inhibition resulting in a significant reduction in AP-1 activity (Figure 7.9) 
as well as ezrin activation (Figure 6.7). Further to this study, the inhibition of Dsg3 and 
the effect on the activity, location and abundance of these proteins will validate their 
contribution to Dsg3 dependent signalling. Finally functional assays with respect to 
invasion with p38, Rac1 and Src silencing would further substantiate their roles as 
downstream effectors in Dsg3-dependent cell invasion. 
As discussed, phosphorylation of Integrins, particularly the β subunit is a regulatory 
event and one that has also been implicated in oncogenesis. It would be interesting to 
look at the phospho-status of β integrins in response to Dsg3 expression. I would 
expect to see an increase in phosphorylation, which would result in an increased 
affinity of DoK1 and subsequent reduction in Cell-Extracellular matrix adhesion as a 
means to promote migration and invasion (Tsang, et al., 2012). 
  






Chapter 8: Concluding Discussion 




8.1 Concluding Discussion 
The development and progression of malignancy is a highly complex multistage 
process (Woodhouse, et al., 1997), which alters a cell’s biology in its entirety to 
fundamentally affecting the way the cell interacts and responds to its surrounding 
microenvironment. The leading cause of cancer related fatalities, with > 90% of cancer 
deaths, is attributed to metastasis (Coghlin and Murray, 2010, Gupta and Massagué, 
2006, Steeg, 2006). What is becoming clear is the need to expand the development of 
anti-metastatic therapies, the progress of which is currently limited by our 
understanding of invasion and metastasis in cancer cell biology. The identification of 
metastatic biomarkers is most definitely the first step in the treatment of disseminated 
disease, however to successfully translate them into therapeutic targets requires 
greater comprehension of their roles in the molecular mechanisms of these processes. 
The aim of this study was to examine the role of Dsg3 in the regulation of cancer cell 
morphology, motility and invasion. The results provided in this thesis demonstrate a 
positive role of Dsg3 in cancer progression and metastasis in line with recent reports in 
the literature. As illustrated in Figure 8.1 my study shows: 1) the overexpression of 
Dsg3 promotes membrane protrusions and cell spreading and increases migration and 
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invasion; 2) non-junctional Dsg3 colocalises and forms a molecular complex with Ezrin 
predominantly at the basolateral domains of the plasma  
 
Figure 8.1. Desmoglein 3 regulates cancer cell migration and invasion through AP-1 and PKC-
dependent Ezrin activation. Illustrated is a schematic of the proposed mechanisms by which 
Dsg3 promotes cell migration and invasion in A431 cells. Dsg3 recruits Ezrin via actin to the 
plasma membrane where Ezrin is activated through a PKC-dependent mechanism. 
Furthermore, Dsg3 acts as an upstream regulator of cJun S63 and S73 phosphorylation to 
promote cJun:AP-1 transcriptional activity.  
membrane; 3) Dsg3 regulates Ezrin activity at the plasma membrane, likely in a PKC-
dependent manner; and finally, 4) Dsg3 also acts as an upstream regulator of cJun:AP-
1 transcriptional activity. In conclusion, my study suggests that Dsg3 promotes cancer 
invasion and metastasis through the mechanisms of PKC-dependent Ezrin and cJun:AP-
1 activation and may serve as a potential drug target for the treatment of cancer. 
Cell 
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Phenotype of Dsg3 overexpressing cells 
Genetic profiling of numerous cancers has identified the aberrant overexpression of 
Dsg3 which appears to correlate with disease progression and metastasis as discussed 
previously. I provide evidence that Dsg3 regulates cell morphology, migration and 
invasion. These observations are consistent with reports by Tsang et al who 
demonstrated enhanced membrane protrusions and cell migration in Dsg3 
overexpressing A431 cells (Tsang, et al., 2012). In support independent studies using 
animal models to examine the effect of differential expression of Dsgs in the epidermis 
(Elias, et al., 2001, Merritt, et al., 2002) showed that the specific expression patterns of 
Dsgs have a regulatory role in tissue morphogenesis and homeostasis. These studies 
demonstrated, through targeted mis-expression of Dsg3 in the epidermis, altered cell 
morphology, proliferation and differentiation. Furthermore a Dsg3 knockdown down 
study in head and neck cancer cell lines showed that upregulation of Dsg3 elicits 
increased migration and invasion both in vitro and in vivo (Chen, et al., 2007).  
The ability of Dsg3 to regulate actin based cellular processes was recently 
demonstrated in a study by Tsang et al, which showed that non-junctional Dsg3 
(Triton-soluble) co-immunoprecipitates with actin and regulates the activity of Rho 
GTPases, Rac1 and Cdc42, to modulate actin organisation and membrane dynamics 
(Tsang, et al., 2012). Furthermore, studies based on PV which employ the use of anti-
Dsg3 auto-antibodies also demonstrate Dsg3-dependent regulation of the actin 
cytoskeleton as a fundamental mechanism in the pathogenesis of the disease (Gliem, 
et al., 2010). Consistent with previous reports, my observations provide compelling 
evidence towards Dsg3 function in the regulation of cell morphology, migration and 
invasion. I believe that Dsg3 is capable of regulating actin indirectly through the 
modulation of Ezrin activity.  
Desmoglein 3 associates with and regulates Ezrin activity 
Ezrins ability to regulate actin based processes, including cell polarity (Zhu, et al., 2010), 
lamellipodia and filopodia formation (Baumgartner, et al., 2006, Gandy, et al., 2013), 
cell spreading (Mak, et al., 2012) and migration (Meng, et al., 2010, Ng, et al., 2001) 
has been well established in the literature. So too is the aberrant regulation of Ezrin in 
cancer with its altered expression, phosphorylation and sub-cellular localisation shown 
to correlate with enhanced migration, invasion and metastasis (Chen, et al., 2011, 
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Chuan, et al., 2006, Donatello, et al., 2012, Elliott, et al., 2005, Heiska, et al., 2011, Ma 
and Jiang, 2013, Meng, et al., 2010, Xie, et al., 2011). The specific mechanisms by 
which Ezrin confers this vast array of functions in health and disease are still being 
elucidated. However, as currently understood involves: the organisation of specialised 
membrane domains that bring ligands, receptors and effector molecules into close 
proximity (Lamb, et al., 1997, Saotome, et al., 2004, Zhu, et al., 2010); and secondly, 
the initiation of signalling pathways. The specific pathways that are activated by Ezrin 
and subsequent cellular response is dependent on which kinase facilitates its 
phosphorylation and the specific phosphorylation sites (Clucas and Valderrama, 2014). 
For example, phosphorylation of Ezrin Thr567 by PKCα promotes cell migration (Ng, et 
al., 2001), while phosphorylation by Akt is associated with NHE3 translocation and 
activation that leads to cytoplasmic localisation in intestinal epithelial cells (Shiue, et 
al., 2005) and phosphorylation by Rho-kinase confers Ezrin to function as an effector of 
RhoA (Clucas and Valderrama, 2014). Furthermore the EGFR-dependent 
phosphorylation of Ezrin at Try145 and Try353 promote cell proliferation and 
lamelliapodia formation (Gandy, et al., 2013, Krieg and Hunter, 1992), while 
phosphorylation of Try145 by Src promotes cell spreading (Mak, et al., 2012); Finally 
Ezrin’s functional array is also conferred by its vast and expanding repertoire of 
proteins that Ezrin can associate with through either directly binding to integral 
membrane proteins, including CD44, EGFR and ICAM1, or through membrane 
associated proteins such as scaffold proteins, EBP50 and PDZK1 which themselves have 
two and four PDZ domains, respectively, (LaLonde, et al., 2010, Morales, et al., 2004).  
Precisely how Ezrin participates in cancer cell migration and invasion is not fully 
understood, however the overexpression of Ezrin rather than its phosphorylation is the 
most common aberration reported in cancer. I did not observe an increase in Ezrin 
expression in response to Dsg3 overexpression but rather its hyper-phosphorylation 
and altered cellular localisation. I show increased phosphorylation of Ezrin Thr567 and 
its colocalisation with Dsg3 at basolateral domains of plasma membrane in A431 Dsg3 
overexpressing lines compared to control cells. The phosphorylation of Ezrin Thr567 is 
essential to activation (Fievet, et al., 2004, Matsui, et al., 1998) and associated with the 
establishment of cell polarity (Casaletto, et al., 2011, Zhou, et al., 2005, Zhu, et al., 
2010), filopodia and lamellipodia formation (Baumgartner, et al., 2006, Gandy, et al., 
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2013, Krieg and Hunter, 1992), changes in cell morphology (Belkina, et al., 2009) and 
migration (Ng, et al., 2001). In cancer, phosphorylation of Ezrin Thr567 has been 
implicated in tumour metastasis, with hyper-phosphorylation associated with 
metastasis of hepatocellular carcinoma (Chen, et al., 2011), osteosarcoma (Ren, et al., 
2009) and colorectal cancer (Leiphrakpam, et al., 2014). In all these studies, the 
increased phosphorylation of Ezrin T567 is seen to be accompanied by increased 
expression levels, which is contrary to what I observed in this study. This discrepancy 
could be attributed to increased turnover of Ezrin proteins or the dynamic regulation 
of Ezrin expression (Ren, et al., 2009) which may not be evident in endpoint Western 
blot and fluorescence microscopy analysis carried out in this study.  
Mislocalisation of ERM proteins is believed to interfere with complex formation and 
subsequent signalling pathways which could aid tumour progression (Arpin, et al., 
2011). Abnormal distribution of Ezrin has also been shown in invasive breast and lung 
cancer cells. In both cases, the re-localisation from apical regions to motile projections 
and cytoplasm were reported (Li, et al., 2012, Sarrió, et al., 2006). This non-polar 
(apical-basal axis) redistribution of Ezrin in invasive cancer cells suggests that its 
function in cancer mechanics is not only modulated by its activation but also by its 
temporal and spatial localisation. With this in mind, it seems plausible that Dsg3 
regulates the activity of Ezrin by facilitating its activation through PKC and targeting 
Ezrin to specific cellular domains by recruiting Ezrin to the basolateral domain the of 
plasma membrane to alter cell polarity and promote the formation of locomotion and 
invasive membrane structures. This proposal is in part supported by a recent study by 
Tsang et al that demonstrated the ability of Dsg3 to regulate cell polarity in normal 
epithelial cells (Tsang, et al., 2012). Another study showed increased localisation of 
phosphorylated Ezrin T567 at the plasma membrane of invadapodia of invasive breast 
tumour cells with the phosphorylation of Ezrin inducing invadapodia-dependent ECM 





exchanger type 1) (Antelmi, et al., 2013).  
To further support Dsg3 ability to regulate actin based processes through Ezrin, I show 
reproducibly that Dsg3 not only colocalises but also forms a molecular complex with 
Ezrin, at the plasma membrane. I have provided evidence by Mass spectrometry that 
this is most likely a muti-protein complex that includes scaffold proteins as well as 
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regulators of actin such as ankyrin and RhoGEF proteins. The presence of these 
proteins would theoretically support not only multi-protein complex formation but 
also facilitate the regulation of actin dynamics and Dsg3-depndent Ezrin 
phosphorylation. Taken together, my findings suggest that Dsg3 promotes cancer cell 
migration and invasion through functionally interacting with Ezrin, among others, at 
the plasma membrane.  
Desmoglein 3 regulates the AP-1 activity 
AP-1 is regarded as central to the regulation of the multigenic invasion programme 
required for transformation, development and progression of cancer (Dong, et al., 
1997, Malliri, et al., 1998, Saez, et al., 1995, Young, et al., 1999, Yuspa, 1998). The 
aberrant regulation of AP-1 results in the inappropriate expression of genes that 
promote or suppress tumour development (Eferl and Wagner, 2003). With respect to 
the pro-oncogenic role of AP-1, the target gene repertoire which confers proliferation, 
inhibition of apoptosis, invasiveness and angiogenesis is extensive (Eferl and Wagner, 
2003). With respect to migration and invasion, the regulation of the actin cytoskeleton 
is paramount and AP-1 target genes which confer these activities include Mts-1, CD44, 
stromelysin 1, Ezrin and uPAR (Hennigan, et al., 1994, Jooss and Müller, 1995, Lamb, et 
al., 1997, Lamb, et al., 1997) which are all implicated in cytoskeletal organisation, cell 
motility and remodelling of the extracellular matrix. In support, studies have shown 
that AP-1 is required for the activation of Rho-GTPases, localisation of CD44 and Ezrin 
to membrane ruffles, cytoskeleton rearrangement, motility and invasion in A431 cells 
(Malliri, et al., 1998, Stapleton, et al., 2002). Collectively, the findings from these 
reports are consistent with the phenotype that we have observed in Dsg3 
overexpressing A431 cells and the involvement of AP-1 activation. I have shown that 
Dsg3 acts as an upstream regulator of AP-1 transcriptional activity through a 
mechanism of cJun phosphorylation that attributes, at least in part, to enhanced cell 
migration and invasion.  
Plakoglobin (Pg) interacts directly with the cytoplasmic tail of Dsg3 (Chen, et al., 2013, 
Garrod, et al., 2002, Green and Gaudry, 2000, Yin and Green, 2004). A recent study by 
Chen et al. presented evidence that Dsg3 silencing facilitates cancer cell growth and 
invasion through the DSG3-Pg-TCF/LEF-Myc/Cyclin D1/MMP signalling pathway (Chen, 
et al., 2013). The TCF/LEF transcription factors have also been implicated as 
202 | P a g e  
downstream effectors of Dsg3 in the pathogenesis of PV (Lo Muzio, et al., 2002, 
Mignogna, et al., 2001, Sharma, et al., 2007, Williamson, et al., 2006). Pg is closely 
related to β-catenin, an established regulator of the canonical Wnt/wingless signalling 
pathway (Huelsken and Birchmeier, 2001, Zhurinsky, et al., 2000). Plakoglobin is 
capable of associating and possibly competing with the same binding partners as β-
catenin. Hence, through this competition Dsg3 is capable of modulating the Wnt 
signalling pathway through Pg (Gat, et al., 1998, Teulière, et al., 2004). Although 
studies have yielded some conflicting observations they do suggest that binding of 
auto-antibodies to Dsg3 induces intracellular signalling, including the altered 
localisation of Pg from desmosomes to modulate the transcription of TCF/LEF target 
genes, as well as the AP-1 target genes, including uPAR, c-Myc that may have 
implications in PV acantholysis (Caldelari, et al., 2001, Garcia-Gras, et al., 2006, 
Mignogna, et al., 2001, Seishima, et al., 1997, Williamson, et al., 2007, Williamson, et 
al., 2006). Findings from both PV and cancer specific studies are in agreement with the 
hypothesis that Dsg3 acts as an upstream regulator of AP-1 since the TCF/LEF 
transcription factors have also been reported to bind to the AP-1 promoter in a JNK-
dependent manor (Nateri, et al., 2005) or directly interact with and activate cJun in 
cancer cells (Rivat, et al., 2003). 
With respect to the Dsg3-dependent activation of cJun:AP-1, I provide evidence that, in 
addition to JNK and p38 MAPKs, PKC, ROCK, Src and Rac1 are possibly involved since 
inhibition of these signalling molecules resulted in abrogated Dsg3-dependent AP-1 
activity as well as Ezrin activation. The involvement of PKC, ROCK, Src and Rac1 in the 
activation of AP-1 has been previously demonstrated in T lymphocytes (Baier-Bitterlich, 
et al., 1996, Funakoshi-Tago, et al., 2003, Kaminuma, et al., 2001).However, further 
study is necessary in order to elucidate the involvement of these molecules in Dsg3-
dependent processes. 
Ezrin has been identified as a transcriptional target of cFos:AP-1 activation (Jooss and 
Müller, 1995). I did not report an increase in Ezrin expression suggesting that Dsg3 may 
regulate cJun homodimers or heterodimers with other bZIP proteins such as ATF family 
transcription factors.  
The role of cJun in the progression of cancer through the AP-1 invasion programme is 
somewhat conflicting since cJun has been shown to preferentially regulate genes 
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associated with proliferation as well as apoptosis while cFos is shown to preferentially 
modulate genes associated with angiogenesis and invasion of tumour cells (Eferl and 
Wagner, 2003). However, some of cJun target genes have established roles in the 
tumour invasion including MMP1/2/3/9 (Whitmarsh and Davis, 2000), Ezrin and CD44 
(Katabami, et al., 2005) which confer invasiveness; uPAR (van Dam and Castellazzi, 
2001) and VEGF (Schreiber, et al., 1999) involved in angiogenesis. Studies by Smith et 
al., show that the overexpression of cJun promotes cell spreading, loss of cell polarity 
and increased motility and invasiveness with increased expression of MMP-9 in the 
breast cancer cell line, MCF-7 (Bos, et al., 1999, Smith, et al., 1999). Bos el al. also 
observed increased cell spreading, motility and invasion in chick embryo fibroblasts 
overexpressing cJun (Bos, et al., 1999), with the disruption of cJun reported to inhibit 
cell migration and invasiveness in mouse embryo fibroblasts (Jiao, et al., 2008) as well 
as in oral squamous cell carcinoma cell lines (Lu, et al., 2012). Together, these findings 
are consistent with the phenotype of A431 cells with Dsg3 overexpression implicating 
Dsg3-dependent activation of cJun:AP-1 in the regulation of cell migration and invasion. 
What remains undefined in the studies by Smith et al. and Bos et al. is the composition 
of the cJun:AP-1 dimer, which raises the possibility that migration and invasion could 
be elicited by cJun heterodimers with Fos, Maf and ATF proteins rather than cJun 
homodimers. It has been shown that cJun:cFos are more stable and have a higher 
affinity for the AP-1 response element, TRE, than cJun homodimers (Allegretto, et al., 
1990). cJun can also form heterodimers with CREB/ATF proteins to bind the CRE 
response element. The dimeric partner of cJun have a significant effect on the cJun 
phenotype. For example, cJun:Fos confers anchorage-dependent cell growth while 
cJun:ATF confers growth-factor dependent cell growth with only a combination of 
these heterodimers resulting in a fully transformed phenotype (van Dam, et al., 1998). 
Taking into consideration the number of variables that attribute to the regulation of 
AP-1 activity, it would be almost impossible to predict the cJun:AP-1 composition and 
subsequent target gene repertoire in Dsg3 overexpressing cell lines. As a result further 
study aimed at defining cJun:AP-1 composition and its target gene repertoire in A431-
D3 cell could enable conclusions to be drawn. However, since the cJun:cFos 
heterodimers have been shown to be required for cell invasion both in vivo (Saez, et al., 
1995, Young, et al., 1999) and in vitro (Hennigan, et al., 1994, Lamb, et al., 1997, Malliri, 
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et al., 1998), I would speculate that  the cooperative function by c-Jun and c-Fos likely 
plays a role in accelerated migration and invasion of the Dsg3 overexpressing cells. 
Desmoglein 3 regulates cell morphology, migration and invasion through AP-1 and 
PKC-dependent Ezrin activation 
The likelihood of a positive role of Dsg3 in cancer has been documented in several 
studies based on gene screening for potential biomarkers in cancers, identifying the 
upregulation of Dsg3, the pemphigus vulgaris antigen (PVA) in a variety of cancers 
including those of the skin, lung, prostate and head and neck (Fukuoka, et al., 2007, 
Hiraki, et al., 1996, Kurzen, et al., 2003, Patel, et al., 2013, Trojan, et al., 2005, Trojan, 
et al., 2005). Furthermore, the overexpression of Dsg3 has also been shown to 
correlate with the clinical stage of cancers suggesting its potential use as a therapeutic 
target in treating cancer and preventing tumour progression and metastasis (Chen, et 
al., 2007). Collectively, the phenotype of Dsg3 overexpressing cells, includes hyper-
proliferation (Merritt, et al., 2002), increased membrane protrusions (Tsang, et al., 
2010), loss of cell polarity (Tsang, et al., 2012), abnormal differentiation (Merritt, et al., 
2002), increased motility and invasion (Chen, et al., 2013, Tsang, et al., 2012) are all 
consistent with observations in this study. The correlation between these phenotypes 
and level of Dsg3 overexpression together with its identification as a potential 
biomarker in the detection of lymph node metastasis in head and neck squamous cell 
carcinoma (Patel, et al., 2013) affirms its potential as a metastatic determinant and a 
valid target for anti-metastatic therapy(Chen, et al., 2007). This proposal is supported 
by two recently released patent publications in which Dsg3 has been used as a 
biomarker in cancer diagnosis and also a therapeutic target. However, the translational 
research regarding the role of Dsg3 as a potential target is lacking and warrants further 
in-depth investigations  
To date, the only mechanistic study regarding the role of Dsg3 in cancer was 
conducted by Chen et al., as mentioned above, this study based on RNAi knockdown of 
Dsg3 provides in vitro and in vivo evidence of the positive role of Dsg3 in cell invasion 
and the genetic metastatic programme in head and neck cancer. My reports are 
consistent with these findings with respect to both Dsg3 phenotype and mechanistic 
implications. With respect to Dsg3-dependent mechanisms, cross-talk between 
TCF/LEF and AP-1 pathways has been previously reported (Rivat, et al., 2003, 
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Saadeddin, et al., 2009) with both JNK and p38 capable of activating TCF transcription 
factors (Eferl and Wagner, 2003). Additionally the promoter of MMP-7, as highlighted 
in the study by Chen et al., has a TATA box and binding site for both TCFs and AP-1 (Le 
Floch, et al., 2005, Pacheco, et al., 2002, Rivat, et al., 2003). This also implicates Pg in 
the Dsg3-dependent signalling axis, by demonstrating that the levels of Dsg3 
expression directly affect Pg cellular localisation and subsequent interactions with TCF 
in the nucleus to suppress TCF/LEF transcriptional activity (Chen, et al., 2013). This 
study is, in part, consistent with a study by Tsang el al which demonstrated that Dsg3 
co-Immunoprecipitates with Pg in a Dsg3-dose-dependent manner (Tsang, et al., 2010) 
to possibly sequester Pg to the plasma membrane, preventing its translocation to the 
nucleus, where it would interact and suppress TCF/LEF transcriptional activity. 
Nevertheless, this hypothesis warrants further investigation in A431-D3 cell before 
drawing a conclusion. 
Interestingly, the basal localisation of Ezrin in epithelial cells has been reported to be 
aberrant as Ezrin adopts an apical localisation in polarised epithelial cells. Therefore, 
the basolateral localisation observed in this study suggests a loss of cell polarity which 
is consistent with the Dsg3 phenotype. Loss of cell polarity, coupled with the enhanced 
cell spreading, and enhanced migratory and invasive characteristics, is indicative of 
epithelial to mesenchymal transition (EMT), a process essential to cancer progression 
and metastasis (Tsai, et al., 2012), supporting further the proposal that Dsg3 is acting 
as a metastatic determinant . 
My data suggest that Dsg3 regulates cell morphology, migration and invasion through 
AP-1-dependent transcriptional regulation of genes of the migration and invasion 
programme. For the successful translation of genetic programmes into a cellular 
phenotype, signalling pathways need to be modified to implement these processes. 
My results indicate that Dsg3 may facilitate this translation through the modulation of 
AP-1 target gene products. For example, I show that Dsg3 may recruit Ezrin to the 
basolateral membrane in order to co-ordinate the formation of locomotory and 
invasive membrane structures. I also show that silencing of Dsg3 inhibits the 
colocalisation of Ezrin with CD44 and F-actin at the plasma membrane. The Ly24, 
lymphocyte homing receptor, CD44, is another gene product of cJun:AP-1 and is shown 
to be required for AP-1-dependent invasion (Lamb, et al., 1997). Upon activation, Ezrin 
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acts as a molecular linker between CD44 and the actin cytoskeleton (Hirao, et al., 1996, 
Tsukita, et al., 1994, Yonemura, et al., 1998). CD44 is a transmembrane cell adhesion 
molecule which functions in process including cell homing, adhesion, angiogenesis, cell 
proliferation and migration (Martin, et al., 2003). Interestingly, variant isoforms of 
CD44 have been shown to be expressed exclusively in malignant cells and tumour-
derived cell lines and CD44 expression has been shown to correlate with metastatic 
behaviour and poor prognosis in cancers including head and neck (Gotoda, et al., 2000), 
pancreatic (Gansauge, et al., 1995, Gotoda, et al., 1998) and lung cancers (Miyoshi, et 
al., 1997, Tran, et al., 1997). Furthermore, the interactions of CD44 and Ezrin has been 
proven to promote cancer cell migration and invasion (Donatello, et al., 2012).  
I have identified several signalling molecules that are likely to be involved in the Dsg3-
dependent activation of Ezrin and cJun:AP-1 which, when inhibited, abrogated Dsg3-
dependent Ezrin activation and AP-1 transcriptional activity. In normal physiological 
conditions, the serine/threonine kinase PKC acts as an effective regulator in 
desmosome assembly with evidence that PKC activation by TPA induces the formation 
of desmosomes even in the presence of low calcium (Kitajima, et al., 1999). PKC has 
also been identified as downstream effector of Dsg3-dependent signalling with its 
activation and translocation to cortical actin reported in response to binding of Dsg3 
autoantibodies in cultured keratinocytes (Osada, et al., 1997). In accord, Sanchez-
carpintero et al demonstrated that the inhibition of PKC, PLC and calmodulin inhibit 
Dsg3-autoantibody-induced acantholysis in vivo (Sánchez-Carpintero, et al., 2004). In 
cancer, both in vitro and in vivo models show that PKCα and β isoforms exhibit 
increased activity associated with increased cell motility and invasion with their 
inhibition suppressing this phenotype (Engers, et al., 2000, Koivunen, et al., 2004, 
Masur, et al., 2001, Zhang, et al., 2004). Further, studies also suggest that PKCα-
dependent invasion may occur through inhibition of adheren and desmosomal 
junctions (Koivunen, et al., 2004, Masur, et al., 2001). PKC is associated with and 
activates Ezrin (Ng, et al., 2001, Wald, et al., 2008), with the phosphorylation of Ezrin 
induced by PKCα resulting in enhanced cell migration and invasion (Ng, et al., 2001). In 
support of this observation Wald et al demonstrated that the atypical PKC isoform, iota, 
is essential to the activation and normal distribution of Ezrin at the early stages of 
intestinal epithelial cell differentiation (Wald, et al., 2008) and the colocalisation of 
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Ezrin with CD44 (Stapleton, et al., 2002). Furthermore, PKC is known to regulate AP-1 
activity through its ability to activate its upstream regulators JNK and p38 MAPKs 
(Efimova and Eckert, 2000, Efimova, et al., 1998, Ghaffari-Tabrizi, et al., 1999, Reifel-
Miller, et al., 1996, Sokolova, et al., 2013). These observations together with my results, 
support the potential role of PKC in Dsg3-dependent regulation of Ezrin and cJun:AP-1 
activation. 
Src, a non-receptor tyrosine kinase, is a member of the Src family kinases. Src is 
activated following stimulation of membrane receptors and integral to the 
maintenance of normal cell homeostasis through the regulation of functions including 
proliferation, adhesion, cell shape change, actin cytoskeleton and migration (Thomas 
and Brugge, 1997, Yeatman, 2004). Overexpression or hyper-activation of Src is 
associated with a variety of carcinomas, including colorectal, breast, head and neck 
and lung (Shor, et al., 2007, Summy and Gallick, 2003). While its transforming ability is 
unlikely (Biscardi, et al., 1999) its role in tumour progression and metastasis is well 
established, with increased Src activity associated with hyperproliferation, migration, 
invasion and metastasis (Guarino, 2010, Irby and Yeatman, 2000). Recent studies by 
Tsang et al. showed that overexpression of Dsg3 in A431 cells causes a significant 
increase in Src activation contributing to filopodia formation and cell migration (Tsang, 
et al., 2012, Tsang, et al., 2010). I report that Src activation also contributes to Dsg3-
dependent cJun:AP-1 activation since its inhibition suppressed Dsg3-dependent 
cJun:AP-1 transcription most likely occurs through the regulation of AP-1 MAPK 
pathway as Src has been identified as upstream of p38, JNK and ERK to promote the 
transcription of target genes of the migration and invasion programme (Guarino, 2010). 
I also demonstrate that the overexpression of Dsg3 increases the phosphorylation of 
various Src family kinases, compared to Vect Ct (Figure 7.1). Src functions at the 
plasma membrane to facilitate cell migration, invasion and actin reorganisation 
(Guarino, 2010) and could plays a key role in aiding Dsg3-dependent migration and 
invasion not only on a transcriptional level via Src signalling but also through the 
regulation of locomotory and invasive machinery at the leading edge through the 
association of Src with integrin, paxillin and Rho GTPases (Guarino, 2010). 
RhoA has been shown to play a positive role in the regulation of desmosomal adhesion 
with the treatment of keratinocyte cultures with Dsg3-autoandtibodies resulting in its 
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inactivation in a p38-dependent manner (Waschke, et al., 2006). RhoA is capable of 
activating the ERM family proteins (Yonemura, et al., 2002) as well as co-localising with 
cortical actin and Ezrin at membrane ruffles and lamellipodia of spreading and 
migrating endothelial cells (Menager, et al., 1999). RhoA can also function downstream 
of Ezrin, in a positive feedback loop, to regulate the organisation of the actin 
cytoskeleton (Hatzoglou, et al., 2007). Studies by Spindler et al. suggest the 
involvement of Rho GTPases as part of the pathological mechanism of PV, with 
reductions in their activity causing loss of cell adhesion, with RhoA having the most 
protective effect in cell adhesion (Spindler and Waschke, 2011). In line with this finding, 
I have shown that inhibition of RhoA results in significant inhibition of Dsg3-dependent 
Ezrin activation, suggesting that RhoA participates in the Dsg3/Ezrin signalling axis. Like 
RhoA, Rac1 is another small GTPase that has been implicated in numerous cellular 
processes including cell-cell adhesion, actin based motility and epithelial 
differentiation. Inhibition of Rac1 also showed a significant suppression of the Dsg3-
dependent cJun-AP-1 transcriptional activity and Ezrin phosphorylation. In support, 
Dsg3 has recently been reported to regulate Rac1/Cdc42 activity to promote actin 
organisation and dynamics (Tsang, et al., 2012). 
Taken together my study is consistent with the notion that Dsg3 acts as a potent 
regulator of various signalling pathways that function in concert to modulate actin 
based cellular events in cancer.  
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8.2 Conclusion 
 
Figure 8.2 Proposed mechanism of Dsg3-dependent regulation of PKC-dependent activation 
of Ezrin and cJun:AP-1. Pathways highlighted in red are supported by the findings presented in 
this thesis. Pathways heighted in Green are established mechanisms published in the literature. 
As shown, the downstream effectors of Dsg3 include RhoA, Rac1, PKC and Src that facilitate 
the activation of Ezrin and cJun:AP-1 activity.  
Figure 8.2 summarises the major findings described in this thesis with regard to Dsg3 in 
the regulation of intracellular signalling (red) and in relation to the established 
pathways (green), highlighting the proposed function of Dsg3 as a cell surface 
regulator of cell morphology, migration and invasion through the regulation of 
cJun:AP-1 and PKC-dependent Ezrin activation. This proposal is consistent with and 
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capabilities of Dsg3 and those that have identified Dsg3 to be unregulated in cancer. 
This study however, goes further to elucidate the molecular mechanisms by which 
Dsg3 promotes cancer cell migration and invasion. I have shown that Dsg3 possibly 
achieves this through regulating the transcription of genes of the migration and 
invasion programme through cJun:AP-1. Furthermore, I show that Dsg3 may fulfil an 
orchestrative function in promoting cell migration and invasion through a complex 
with a cohort of membrane associated proteins including Ezrin that in turn facilitates 
the formation of locomotory and invasive structures. In conclusion, this study 
intrinsically links a recently patented biomarker of lymph node metastasis, Dsg3, to 
cJun:AP-1 and Ezrin, both of which have been individually implicated in cancer 
progression and metastasis.  
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8.3 Future perspective 
The identification of increased Dsg3 expression and increased expression and/or 
activation of Ezrin in cancer progression and metastasis are important events which 
assist in distinguishing the differences between normal, non-metastatic and metastatic 
malignant cells. However, to translate these observations into tangible anti-metastatic 
therapeutic targets requires a greater understanding into how these aberrations in 
protein expression and activation alter cell network biology, how and why they are 
overexpressed and hyperphosphorylated. Such an understanding of metastatic 
determinates, or molecules associated with metastasis will aid our understanding of 
refractory metastases and acquired drug resistance mechanisms which currently 
threatens the success and longevity of current therapies such as those targeting HER2 
in breast cancer, BRAF in melanoma and ALK in lung cancers which is evident in drug 
resistance that often occurs in metastatic relapse. The treatment of metastatic disease 
is thought to be complicated by differential expression and/or activity of oncogenes 
and/or the influence of the secondary site microenvironment (Wan, et al., 2013).  
Though a novel gain-of-function approach detailed examination of the effect of Dsg3 
overexpression on the cellular proteome and phenotype has demostrated Dsg3s ability 
to regulate gene transcription through AP-1 and participate in the organisation of 
specialised regulatory protein complexes involving the actin regulator, Ezrin. Through 
this novel perspective, our understanding, as to how the Dsg3 is able to promote 
cancer progression and metastasis, is expanded and supports the proposal of Dsg3 as a 
potential therapeutic target (Chen, et al., 2007).  
To further develop the presented finding towards translational application. The 
validation of the major findings i.e. the phenotype, hyper-phosphorylation of Ezrin and 
enhanced AP-1 activity associated with Dsg3 overexpression, will be essential. This 
could be achieved through the analysis of Primary cancer cells which exhibit increased 
Dsg3 expression. it would be interesting and necessary to expand this study in primary 
cells derived from SCC as well as those from the metastatic sites and to compare their 
gene expression and proteomic profile with respect to Dsg3. A recent study based on 
oesophageal SCC has shown that in addition to strong correlation between Dsg3 
expression and histological grade, the cytoplasmic distribution of Dsg3 in the absence 
of lymph node metastases predicts worse overall survival than those with membrane-
212 | P a g e  
cytoplasmic staining (Fang, et al., 2014).Thus, an increased protein solubility of Dsg3 
might be a predictive factor of malignancy and prognosis that merits further 
confirmation. Importantly, the clinical implication of the work presented here will be 
dependent on replication of major findings in vivo. 
Dgs3 is a transmembrane protein which associates with other desmosomal cadherins 
to confer cell-cell adhesion. The non-junctional pool of Dsg3 is membrane associated 
but not incorporated into desmosomes(Jennings, et al., 2011). It would be interesting 
to see if in malignant tissue overexpressing Dsg3 whether the increase is that of the 
Triton soluble or insoluble pool. Based on this study and that of other carried out by Dr 
Wan et al., I would expect to see an increase in the soluble non-junctional pool of 
Dsg3.  
Another aspect that would be interesting to examine would be the effect the 
microenvironment has on Dsg3 dependent signalling mechanisms, specifically if Dsg3 
signalling and associated phenotype is influenced by changes in the microenvironment 
which may suggest that Dsg3 is functioning as a mechano-sensor. A preliminary study 
on this proposal in SCC is currently underway in this laboratory  
Finally the development of this project to incorporate in vitro and in vivo live cell 
imaging to examine the localisation of Dsg3, Ezrin and other proteins of interest with 
respect to cellular events in real time and space would be invaluable. Such a model, 
enlisting techniques such as intra-vital imaging with FRET and FLIM would allow us to 
look at recruitment, interactions and phosphorylation status in great detail in addition 
to the localisation and sequent of these events. Interactions with microenvironment 
could also be examined, particularly its effect on cellular behaviour. 
In conclusion, this thesis provides important insights into the possible mechanisms by 
which Dsg3 promotes cancer cell migration, invasion and metastasis affirming Dsg3’s 
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